var title_f26_34_27168="Ossicular disruption";
var content_f26_34_27168=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57714&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57714&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ossicular disruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intra-operative transcanal view of a traumatic ossicular disruption at the incudo-stapedial joint. (Stapes is not readily visualized in this image.)",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Adele Karen Evans, MD, FAAP and Steven D Handler MD, MBE.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_34_27168=[""].join("\n");
var outline_f26_34_27168=null;
var title_f26_34_27169="Contarinis condition CT";
var content_f26_34_27169=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55527&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55527&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Contarini's condition",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 305px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient with a right sided transudate from left ventricular failure and with a left sided empyema that is loculated, adjacent to a focus of pneumonia with air bronchograms in the subjacent lung. This is also called Contarini's condition and refers to bilateral pleural effusions of differing etiologies.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_34_27169=[""].join("\n");
var outline_f26_34_27169=null;
var title_f26_34_27170="Patient information: Congenital hypothyroidism (The Basics)";
var content_f26_34_27170=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17218\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/43/15024\">",
"         Thyroid and parathyroid glands",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?37/1/37907\">",
"         Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/54/3938\">",
"         Patient information: Hypothyroidism (underactive thyroid) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?3/6/3172\">",
"         Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/54/15203\">",
"         Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Congenital hypothyroidism (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/congenital-hypothyroidism-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H8447283\">",
"      <span class=\"h1\">",
"       What is congenital hypothyroidism?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Congenital hypothyroidism is a condition that causes the body to have too little thyroid hormone. Babies can be born with it. The term &ldquo;congenital&rdquo; means a condition a person is born with.",
"     </p>",
"     <p>",
"      There is a gland in the neck called the thyroid gland. It makes thyroid hormone. This hormone controls how the body uses and stores energy (",
"      <a class=\"graphic graphic_figure graphicRef66834 \" href=\"UTD.htm?14/43/15024\">",
"       figure 1",
"      </a>",
"      ). &ldquo;Hypothyroidism&rdquo; is the term doctors and nurses use when a person does not make enough thyroid hormone. People sometimes confuse this condition with HYPERthyroidism, which is when a person makes too much thyroid hormone.",
"     </p>",
"     <p>",
"      Congenital hypothyroidism is a serious condition because it can cause life-long learning problems if it is not treated.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8447298\">",
"      <span class=\"h1\">",
"       What are the symptoms of congenital hypothyroidism?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most babies with this condition have no symptoms. If they do, the symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Being less active than other babies",
"       </li>",
"       <li>",
"        Slow movements &nbsp; &nbsp;",
"       </li>",
"       <li>",
"        Hoarse-sounding cry &nbsp;",
"       </li>",
"       <li>",
"        Problems with eating",
"       </li>",
"       <li>",
"        Constipation (not having enough bowel movements)",
"       </li>",
"       <li>",
"        Unusual appearance &ndash; Such as a large tongue, bulging around the belly button, or large soft spots on the head",
"       </li>",
"       <li>",
"        Muscles that are less firm or strong than those of other babies",
"       </li>",
"       <li>",
"        Dry skin",
"       </li>",
"       <li>",
"        Being very cold",
"       </li>",
"       <li>",
"        Jaundice &ndash; A condition that makes the skin or the white part of the eye turn yellow. But most jaundice in newborn babies is not caused by hypothyroidism.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If your baby has any of the symptoms listed above, talk to the baby&rsquo;s doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8447313\">",
"      <span class=\"h1\">",
"       Is there a test for congenital hypothyroidism?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Today, most newborn babies in the United States and many other countries have a blood test to check for congenital hypothyroidism. The test is done as part of the routine newborn screening tests.",
"     </p>",
"     <p>",
"      If the results of this test are abnormal, doctors might do other tests. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Urine tests",
"       </li>",
"       <li>",
"        Ultrasound &ndash; This test uses sound waves to create a picture of the inside of the body.",
"       </li>",
"       <li>",
"        Thyroid scan &ndash; For this test, the baby gets a pill or a shot with a small amount of a radioactive substance. Then a camera or scanner creates a picture of the thyroid gland.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8447328\">",
"      <span class=\"h1\">",
"       How is congenital hypothyroidism treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Congenital hypothyroidism is treated by giving a thyroid hormone pill every day. Crush the pill into powder or very small pieces, mix it with breast milk, formula, or water, and feed it to the baby. If you are not sure how to do this, ask the doctor or nurse for help.",
"     </p>",
"     <p>",
"      Important instructions to follow:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Do NOT use soy formula or soy milk with the pill.",
"       </li>",
"       <li>",
"        Do NOT change the dose or give more medicine without asking the doctor. Giving too much thyroid hormone can cause heart problems and giving too little can cause learning problems.",
"       </li>",
"       <li>",
"        Give the pill every day.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Children with congenital hypothyroidism need regular checkups. They also need blood tests to check hormone levels. Ask the doctor or nurse how often to get checkups and tests, and go to the child&rsquo;s appointments on time. The child needs to see a doctor or nurse regularly to make sure he or she is getting the right amount of thyroid hormone. Not giving the right amount of thyroid hormone can cause serious life-long problems.",
"     </p>",
"     <p>",
"      Some children grow out of congenital hypothyroidism. The doctor will do a blood test to check for this. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8447342\">",
"      <span class=\"h1\">",
"       Can congenital hypothyroid be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Not usually. But the learning problems it causes can be prevented by:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Checking to make sure the baby is tested for congenital hypothyroidism right after birth. This is done as part of the newborn screening tests in the United States and many other countries. &nbsp;",
"       </li>",
"       <li>",
"        Giving thyroid hormone for as long as the doctor recommends. Many people with congenital hypothyroidism need to take thyroid hormone for life.",
"       </li>",
"       <li>",
"        Making sure the child with congenital hypothyroidism gets regular checkups and blood tests to see if he or she is getting the right amount of thyroid hormone.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have hypothyroidism (underactive thyroid) and want to get pregnant, talk to your doctor, nurse, or midwife. He or she can measure your thyroid hormone levels with a blood test. Having normal thyroid hormone levels can help you have a healthy baby.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8447357\">",
"      <span class=\"h1\">",
"       What will my child&rsquo;s life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most babies with congenital hypothyroidism live normal lives if the condition is found and treated soon after they are born.",
"     </p>",
"     <p>",
"      Getting enough thyroid hormone is especially important in babies and young children. The thyroid hormone helps the brain develop. If a child&rsquo;s brain does not get enough thyroid hormone, he or she can have learning problems. This causes life-long problems with thinking, learning, and doing daily activities.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8447372\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/54/3938?source=see_link\">",
"       Patient information: Hypothyroidism (underactive thyroid) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/1/37907?source=see_link\">",
"       Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15203?source=see_link\">",
"       Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=see_link\">",
"       Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?26/34/27170?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17218 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-458F631DC3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_34_27170=[""].join("\n");
var outline_f26_34_27170=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8447283\">",
"      What is congenital hypothyroidism?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8447298\">",
"      What are the symptoms of congenital hypothyroidism?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8447313\">",
"      Is there a test for congenital hypothyroidism?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8447328\">",
"      How is congenital hypothyroidism treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8447342\">",
"      Can congenital hypothyroid be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8447357\">",
"      What will my child&rsquo;s life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8447372\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17218\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/43/15024\">",
"      Thyroid and parathyroid glands",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/1/37907?source=related_link\">",
"      Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15203?source=related_link\">",
"      Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/54/3938?source=related_link\">",
"      Patient information: Hypothyroidism (underactive thyroid) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_34_27171="Vitamin B2 (riboflavin): Patient drug information";
var content_f26_34_27171=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Vitamin B2 (riboflavin): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/15/17651?source=see_link\">",
"     see \"Vitamin B2 (riboflavin): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/18/44322?source=see_link\">",
"     see \"Vitamin B2 (riboflavin): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F218108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ribo-100 [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help growth and good health.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691526",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat riboflavin deficiency.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702868",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to riboflavin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697942",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of body fluids to orange.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12054 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-F9050627AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_34_27171=[""].join("\n");
var outline_f26_34_27171=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218108\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015188\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015187\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015192\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015193\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015195\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015190\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015191\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015196\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015197\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/15/17651?source=related_link\">",
"      Vitamin B2 (riboflavin): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/18/44322?source=related_link\">",
"      Vitamin B2 (riboflavin): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_34_27172="Anatomy wrist dorsal";
var content_f26_34_27172=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 497px\">",
"   <div class=\"ttl\">",
"    Anatomy of the dorsal aspect of the wrist",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 477px; height: 580px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    One useful landmark for dorsal palpation is Lister's tubercle which lies in approximately the middle of the distal radius, aligned with the middle metacarpal (blue arrow). Between these bony landmarks lie the lunate and capitate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_34_27172=[""].join("\n");
var outline_f26_34_27172=null;
var title_f26_34_27173="Tiotropium: Drug information";
var content_f26_34_27173=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tiotropium: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/7/36981?source=see_link\">",
"    see \"Tiotropium: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F228272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Spiriva&reg; HandiHaler&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F228273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Spiriva&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F228290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticholinergic Agent;",
"     </li>",
"     <li>",
"      Anticholinergic Agent, Long-Acting",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F228275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      COPD:",
"     </b>",
"     Oral inhalation: Contents of 1 capsule (18 mcg) inhaled once daily using HandiHaler&reg; device.",
"     <b>",
"      Note:",
"     </b>",
"     To ensure drug delivery the contents of each capsule should be inhaled twice.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F228276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F228277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Plasma concentrations may increase in renal impairment. Use caution in moderate-to-severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;50 mL/minute); although no dosage adjustment is required, monitor closely.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F228252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Spiriva&reg; HandiHaler&reg;: 18 mcg/capsule (5s, 30s, 90s) [contains lactose]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F14191295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Spiriva&reg;: 18 mcg/capsule (10s) [contains lactose]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F4806258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F228255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer once daily at the same time each day. Remove capsule from foil blister immediately before use. Capsule should not be swallowed. Place capsule in the capsule-chamber in the base of the HandiHaler&reg; Inhaler. Must only use the HandiHaler&reg; Inhaler. Close mouthpiece until a click is heard, leaving dustcap open. Exhale fully. Do not exhale into inhaler. Tilt head slightly back and inhale (rapidly, steadily and deeply); the capsule vibration may be heard within the device. Hold breath as long as possible. If any powder remains in capsule, exhale and inhale again. Repeat until capsule is empty. Throw away empty capsule; do not leave in inhaler. Do not use a spacer with the HandiHaler&reg; Inhaler. Do not use HandiHaler&reg; device for other medications. Always keep capsules and inhaler dry.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Delivery of dose: Instruct patient to place mouthpiece gently between teeth, closing lips around inhaler. Instruct patient to inhale deeply and hold breath for 5-10 seconds. The amount of drug delivered is small, and the individual will not sense the medication as it is inhaled. Remove mouthpiece prior to exhalation. Patient should not breathe out through the mouthpiece.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F228254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maintenance treatment of bronchospasm associated with COPD (including bronchitis and emphysema); reduction of COPD exacerbations",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F228296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Spiriva&reg; may be confused with Inspra&trade;, Serevent&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tiotropium may be confused with ipratropium",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Spiriva&reg; capsules for inhalation are for administration via HandiHaler&reg; device and are",
"       <b>",
"        not",
"       </b>",
"       for oral use",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F228288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (5% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract infection (41%), pharyngitis (9% to 13%), sinusitis (7% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (1% to 7%), edema (dependent, 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (6%), insomnia (4%), depression (1% to 4%), dysphonia (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypercholesterolemia (1% to 3%), hyperglycemia (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (6%), abdominal pain (5%), constipation (4% to 5%), vomiting (4%), gastroesophageal reflux (1% to 3%), stomatitis (including ulcerative; 1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (4%), myalgia (4%), arthritis (&ge;3%), leg pain (1% to 3%), paresthesia (1% to 3%), skeletal pain (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Cataract (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis (6%), epistaxis (4%), cough (&ge;3%), laryngitis (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (4%), moniliasis (4%), flu-like syndrome (&ge;3%), allergic reaction (1% to 3%), herpes zoster (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Angioedema; application site irritation (glossitis, mouth ulceration, pharyngolaryngeal pain); atrial fibrillation, blurred vision, candidiasis (oral), dizziness, dehydration, dry skin, dysphagia, gingivitis, glaucoma, hoarseness, hypersensitivity reactions, ileus (paralytic), intestinal obstruction, intraocular pressure increased, joint swelling, palpitation, paradoxical bronchospasm, pruritus, pupil dilation (if powder comes in contact with eyes), skin infection, skin ulcer, supraventricular tachycardia, tachycardia, throat irritation, urinary difficulty, urinary retention, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F228258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tiotropium or ipratropium, or any component of the formulation (contains lactose)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F228242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospasm: Rarely, paradoxical bronchospasm may occur with use of inhaled bronchodilating agents; discontinue use  and consider other therapy if bronchospasm occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Immediate hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm) have been reported. Discontinue immediately if signs/symptoms occur. Use with caution in patients with a history of hypersensitivity to atropine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Tiotropium may worsen symptoms of narrow-angle glaucoma; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Tiotropium may worsen symptoms of myasthenia gravis; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/bladder neck obstruction: Tiotropium may worsen the symptoms of prostatic hyperplasia and/or bladder neck obstruction; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with moderate-to-severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;50 mL/minute); monitor closely for anticholinergic adverse events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactose: Capsule for oral inhalation contains lactose; use with caution in patients with severe milk protein allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate administration: Not indicated for the initial (rescue) treatment of acute episodes of bronchospasm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: The contents of Spiriva&reg; capsules are for inhalation only via the HandiHaler&reg; device. Capsules should not be swallowed;  there have been reports of incorrect administration (swallowing of the capsules).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Avoid ocular contact: Avoid inadvertent instillation of powder into the eyes; may dilate pupils and/or cause blurred vision.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F228284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F228246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the anticholinergic effect of Tiotropium.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ketotifen (Ophthalmic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F228248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F228259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events (fetal loss, decreased birth weights, delayed sexual maturation) were observed in some animal studies. There are no adequate and well-controlled studies in pregnant women. Use only when expected benefit to mother outweighs potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F228281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F17917867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if tiotropium is excreted in breast milk. The manufacturer recommends that caution be exercised when administering tiotropium to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Spiriva HandiHaler Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     18 mcg (30): $312.17",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F228250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     , peak flow (or other pulmonary function studies)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F228260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Favint (NZ);",
"     </li>",
"     <li>",
"      Spiriva (AE, AR, AT, AU, BE, BG, BH, BO, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EG, ES, FI, FR, GB, GR, GT, HK, HN, ID, IE, IL, IQ, IR, IT, JO, KP, KW, LB, LY, MX, MY, NI, NL, NO, NZ, OM, PA, PE, PH, PL, PR, PT, PY, QA, RU, SA, SE, SG, SV, SY, TH, TR, TW, UY, VE, YE);",
"     </li>",
"     <li>",
"      Spiriva Respimat (ID, KP, MY, SG);",
"     </li>",
"     <li>",
"      Teromar (CO);",
"     </li>",
"     <li>",
"      Tiova Rotacaps (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F228241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitively and reversibly inhibits the action of acetylcholine at type 3 muscarinic (M",
"     <sub>",
"      3",
"     </sub>",
"     ) receptors in bronchial smooth muscle causing bronchodilation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F228257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Poorly absorbed from GI tract, systemic absorption may occur from lung",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 32 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 72%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic (minimal), via CYP2D6 and CYP3A4",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Following inhalation, 19.5%; oral solution: 2% to 3%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 5-6 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 5 minutes (following inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (14% of an inhaled dose); feces (primarily nonabsorbed drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Adams SG, Anzueto A, Briggs DD Jr, et al, &ldquo;Tiotropium in COPD Patients Not Previously Receiving Maintenance Respiratory Medications,&rdquo;",
"      <i>",
"       Respir Med",
"      </i>",
"      , 2006, 100(9):1495-503.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/34/27173/abstract-text/16698259/pubmed\" id=\"16698259\" target=\"_blank\">",
"        16698259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gross NJ, &ldquo;Tiotropium Bromide,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2004, 126(6):1946-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/34/27173/abstract-text/15596697/pubmed\" id=\"15596697\" target=\"_blank\">",
"        15596697",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hvizdos KM and Goa KL, &ldquo;Tiotropium Bromide,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2002 62(8):1195-203.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/34/27173/abstract-text/12010082/pubmed\" id=\"12010082\" target=\"_blank\">",
"        12010082",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maltais F, Hamilton A, Marciniuk D, et al, &ldquo;Improvements in Symptom-Limited Exercise Performance Over 8 H With Once-Daily Tiotropium in Patients With COPD,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      ,  2005, 128(3):1168-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/34/27173/abstract-text/16162703/pubmed\" id=\"16162703\" target=\"_blank\">",
"        16162703",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Niewoehner DE, Rice K, Cote C, et al, &ldquo;Prevention of Exacerbations of Chronic Obstructive Pulmonary Disease With Tiotropium, a Once-Daily Inhaled Anticholinergic Bronchodilator: A Randomized Trial,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2005, 143(5):317-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/34/27173/abstract-text/16144890/pubmed\" id=\"16144890\" target=\"_blank\">",
"        16144890",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodrigo GJ and Nannini LJ, &ldquo;Tiotropium for the Treatment of Stable Chronic Obstructive Pulmonary Disease: A Systematic Review With Meta-Analysis,&rdquo;",
"      <i>",
"       Pulm Pharmacol Ther",
"      </i>",
"      , 2007, 20(5):495-502.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/34/27173/abstract-text/16621638/pubmed\" id=\"16621638\" target=\"_blank\">",
"        16621638",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10300 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8E53C3882F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_34_27173=[""].join("\n");
var outline_f26_34_27173=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228272\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228273\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228290\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228275\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228276\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228277\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228252\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14191295\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4806258\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228255\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228254\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228296\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228288\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228258\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228242\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228284\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228246\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228248\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228259\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228281\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F17917867\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422284\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228250\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228260\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228241\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228257\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10300\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10300|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/7/36981?source=related_link\">",
"      Tiotropium: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_34_27174="Pathophysiology of the trigeminal autonomic cephalalgias";
var content_f26_34_27174=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology of the trigeminal autonomic cephalalgias",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/34/27174/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/34/27174/contributors\">",
"     Arne May, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/34/27174/contributors\">",
"     Anna S Cohen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/34/27174/contributors\">",
"     Peter J Goadsby, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/34/27174/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/34/27174/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/34/27174/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/34/27174/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/34/27174/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 17, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The trigeminal autonomic cephalalgias (TACs) are a group of primary headache disorders characterized by unilateral trigeminal distribution pain that occurs in association with prominent ipsilateral cranial autonomic features [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The TACs include cluster headache, paroxysmal hemicrania, short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT), and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite their common elements, the TACs differ in attack duration and frequency, as well as the response to therapy (",
"    <a class=\"graphic graphic_table graphicRef65541 \" href=\"UTD.htm?41/12/42188\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cluster headache has the longest attack duration (minutes to hours) and relatively low attack frequency (up to eight a day)",
"     </li>",
"     <li>",
"      Paroxysmal hemicrania has intermediate duration (minutes) and intermediate attack frequency (up to 40 a day)",
"     </li>",
"     <li>",
"      SUNCT has the shortest attack duration (seconds to minutes) and the highest attack frequency (up to 200 a day)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review the pathophysiology of the TACs. Clinical aspects of these disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14327?source=see_link\">",
"     \"Cluster headache: Epidemiology, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3898?source=see_link\">",
"     \"Cluster headache: Acute and preventive treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25545?source=see_link\">",
"     \"Paroxysmal hemicrania: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9112?source=see_link\">",
"     \"Paroxysmal hemicrania: Treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28648?source=see_link\">",
"     \"SUNCT and SUNA headache syndromes: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2264?source=see_link\">",
"     \"SUNCT and SUNA headache syndromes: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGIC MODELS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of the trigeminal autonomic cephalalgias &ndash; cluster headache, paroxysmal hemicrania, and short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) &ndash; is complex and remains incompletely understood. Any pathophysiologic construct for trigeminal autonomic cephalalgias must account for the two major features that are common to the syndromes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Trigeminal distribution pain",
"     </li>",
"     <li>",
"      Ipsilateral cranial autonomic features",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the underlying pathophysiology should account for the differentiation of the syndromes, including the episodic (circadian) pattern of attacks seen in cluster headache [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The excruciatingly severe unilateral pain is likely to be mediated by activation of the first (ophthalmic or V1) division of the trigeminal nerve, while the autonomic symptoms, such as lacrimation, are due to activation of the cranial parasympathetic outflow from cranial nerve VII [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/5\">",
"     5",
"    </a>",
"    ]. The sympathetic paralysis (miosis and ptosis) may be caused by a (neuropraxic) injury of postganglionic fibers in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Vascular theory",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vascular theory holds that the clinical symptoms of cluster headache are caused by neurogenic inflammation of the walls of the cavernous sinus, which is the only peripheral anatomic location where a single pathology could involve trigeminal C-fibers and sympathetic fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/8\">",
"     8",
"    </a>",
"    ]. This inflammation is postulated to obliterate venous outflow and thus injure the traversing sympathetic fibers of the intracranial internal carotid artery and its branches [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/8,9\">",
"     8,9",
"    </a>",
"    ], thus explaining the unilateral pain and ipsilateral damage of sympathetic outflow.",
"   </p>",
"   <p>",
"    The acceptance of the vascular theory has been substantially reduced by recognition that neurovascular phenomena related to the trigeminal autonomic reflex and some central impulse generator or \"oscillator\" &ndash; thought to be in the hypothalamic region &ndash; seem to be more important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Trigeminal autonomic reflex",
"    </span>",
"    &nbsp;&mdash;&nbsp;The trigeminal autonomic reflex encapsulates the notion that stimulation of trigeminal afferents can result in cranial autonomic outflow.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pain-producing innervation of the cranium projects through branches of the trigeminal and upper cervical nerves to the trigeminocervical complex in the caudal brainstem and upper cervical spinal cord. From there, nociceptive pathways project to higher centers.",
"     </li>",
"     <li>",
"      The ipsilateral autonomic features of the trigeminal autonomic cephalalgias suggest cranial parasympathetic activation (lacrimation, rhinorrhea, nasal congestion, and eyelid edema) and sympathetic hypofunction (ptosis and miosis). These cranial autonomic symptoms are thought to result, in part, from activation of the trigeminal autonomic reflex [",
"      <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/1,10,11\">",
"       1,10,11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is considerable experimental animal literature showing that stimulation of trigeminal afferents can result in cranial autonomic outflow [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/10\">",
"     10",
"    </a>",
"    ]. Some degree of cranial autonomic symptomatology is a normal physiologic response to cranial nociceptive input [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In addition, electrical stimulation in the brainstem at the level of the superior salivatory nucleus, which is the origin of cells for the cranial parasympathetic autonomic vasodilator pathway, results in both neuronal trigeminovascular and cranial autonomic responses [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cranial autonomic symptoms are also recognized in other forms of head pain, including experimental head pain with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    injection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/9\">",
"     9",
"    </a>",
"    ] and other headache syndromes such as migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The main distinction between the trigeminal autonomic cephalalgias and other headache syndromes is, next to the shortness of attacks, the degree of cranial autonomic activation and its often prominent lateralization [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The cranial autonomic symptoms may be prominent in the trigeminal autonomic cephalalgias due to a central disinhibition of the trigeminal-autonomic reflex.",
"   </p>",
"   <p>",
"    In chronic cluster headache, the headache and autonomic symptoms may be generated entirely through central mechanisms, as an activation of the trigeminal autonomic reflex is not necessary (any more) to display the full clinical picture [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hypothalamic activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The posterior hypothalamic region plays an important role in the pathophysiology of the trigeminal autonomic cephalalgias [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/19\">",
"     19",
"    </a>",
"    ]. A number of characteristic cluster headache features, including the relapsing-remitting course [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/20\">",
"     20",
"    </a>",
"    ], seasonal variation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/20\">",
"     20",
"    </a>",
"    ], and the clockwise regularity of single attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/21\">",
"     21",
"    </a>",
"    ], imply involvement of a biologic clock, namely the hypothalamus, in the origin of the illness [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/22-24\">",
"     22-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Significantly lowered levels of plasma testosterone in men with cluster headache during cluster periods provided the first evidence of such an involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/25\">",
"     25",
"    </a>",
"    ]. Further support was provided by the finding of a reduced response to thyrotropin-releasing hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/26\">",
"     26",
"    </a>",
"    ] and by a range of other circadian irregularities in patients with cluster headache. As an example, melatonin is a marker of the circadian system, and one study found that patients with cluster headache during cluster periods demonstrated a blunted nocturnal peak in melatonin level and a complete loss of a circadian rhythm [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following observations from experimental animal studies also support the role of the hypothalamus in pain modulation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are direct hypothalamic-trigeminal connections [",
"      <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The hypothalamus is involved in anti-nociceptive and autonomic responses [",
"      <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/30-32\">",
"       30-32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The hypothalamus is activated during acute cluster headache when intracranial pain structures are activated [",
"      <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/33\">",
"       33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The hypothalamic neuropeptides orexin A and B can elicit pro-nociceptive and anti-nociceptive effects in the trigeminal system [",
"      <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/34\">",
"       34",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In humans, posterior hypothalamic activation has been observed by the use of functional neuroimaging during attacks of trigeminal autonomic cephalalgias, as discussed in the next section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Activation patterns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given that many of the basic features of cluster headache are shared by paroxysmal hemicrania and short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT), the question arises whether a shared pathophysiologic basis exists, which may find its expression in similar cerebral activation patterns. In addition, the pattern of brain activation needs to be considered so that the distinct clinical phenotypes of the different syndromes can be understood.",
"   </p>",
"   <p>",
"    Supporting evidence is emerging from functional imaging studies. Positron emission tomography (PET) studies in cluster headache [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/35,36\">",
"     35,36",
"    </a>",
"    ] and paroxysmal hemicrania [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/37\">",
"     37",
"    </a>",
"    ] and functional MRI studies in SUNCT syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/38-40\">",
"     38-40",
"    </a>",
"    ] have demonstrated that all of these headache syndromes share an activation of the posterior hypothalamic gray area. The hypothalamic involvement in the pain process appears to occur in a permissive or triggering manner rather than simply as a response to pain mediated by the trigeminal nociceptive pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Functional imaging data suggest that primary headache syndromes can be distinguished on a neuroanatomic basis by areas of activation specific to the clinical presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. In contrast to hypothalamic activation in the TACs, most studies in episodic and chronic migraine have not observed hypothalamic activation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/44-48\">",
"     44-48",
"    </a>",
"    ], although there are exceptions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/49\">",
"     49",
"    </a>",
"    ]. In addition, hypothalamic activation does not accompany experimental trigeminal distribution head pain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. These findings have led to the successful introduction of a therapeutic target for cluster headache and the other trigeminal autonomic cephalalgias using deep brain stimulation of the posterior hypothalamic gray matter [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27174/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     OUTSTANDING ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several issues that remain unresolved in the understanding of the pathophysiology of the trigeminal autonomic cephalalgias.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      What is the nature of the hypothalamic abnormality?",
"     </li>",
"     <li>",
"      Why do cluster headache, paroxysmal hemicrania, and short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) have such different phenotypes and treatment responses if the defining abnormality of the trigeminal autonomic cephalalgias is hypothalamic derangement?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The hypothalamus is a complex structure with various nuclei and widespread projections to numerous central structures. It is possible that the specific substructures, neurons or biochemical pathways involved in these primary headache syndromes vary, thereby explaining both the different phenotypes and treatment responses.",
"   </p>",
"   <p>",
"    Further studies are needed to seek the anatomic or functional basis of these variations. Advances in the pathophysiologic understanding of the trigeminal autonomic cephalalgias are likely to lead to better treatments for these devastatingly painful syndromes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pathogenesis of the trigeminal autonomic cephalalgias (cluster headache, paroxysmal hemicrania, and SUNCT) is complex and remains incompletely understood. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiologic models'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The vascular theory holds that the autonomic symptoms of cluster headache are caused by neurogenic inflammation of the walls of the cavernous sinus. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Vascular theory'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most widely accepted theory is that the trigeminal autonomic cephalalgias are due to an abnormality in the hypothalamus leading to hypothalamic activation with secondary activation of the trigeminal autonomic reflex, probably via a trigeminal-hypothalamic pathway. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Trigeminal autonomic reflex'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Hypothalamic activation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/1\">",
"      Goadsby PJ, Lipton RB. A review of paroxysmal hemicranias, SUNCT syndrome and other short-lasting headaches with autonomic feature, including new cases. Brain 1997; 120 ( Pt 1):193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/2\">",
"      Goadsby PJ. Trigeminal autonomic cephalalgias. Pathophysiology and classification. Rev Neurol (Paris) 2005; 161:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/3\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/4\">",
"      Goadsby PJ. Pathophysiology of cluster headache: a trigeminal autonomic cephalgia. Lancet Neurol 2002; 1:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/5\">",
"      Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain 1994; 117 ( Pt 3):427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/6\">",
"      Drummond PD. Mechanisms of autonomic disturbance in the face during and between attacks of cluster headache. Cephalalgia 2006; 26:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/7\">",
"      Fanciullacci M, Pietrini U, Gatto G, et al. Latent dysautonomic pupillary lateralization in cluster headache. A pupillometric study. Cephalalgia 1982; 2:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/8\">",
"      Hardebo JE. Activation of pain fibers to the internal carotid artery intracranially may cause the pain and local signs of reduced sympathetic and enhanced parasympathetic activity in cluster headache. Headache 1991; 31:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/9\">",
"      May A, B&uuml;chel C, Bahra A, et al. Intracranial vessels in trigeminal transmitted pain: A PET study. Neuroimage 1999; 9:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/10\">",
"      May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab 1999; 19:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/11\">",
"      Akerman S, Holland PR, Summ O, et al. A translational in vivo model of trigeminal autonomic cephalalgias: therapeutic characterization. Brain 2012; 135:3664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/12\">",
"      May A, B&uuml;chel C, Turner R, Goadsby PJ. Magnetic resonance angiography in facial and other pain: neurovascular mechanisms of trigeminal sensation. J Cereb Blood Flow Metab 2001; 21:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/13\">",
"      Frese A, Evers S, May A. Autonomic activation in experimental trigeminal pain. Cephalalgia 2003; 23:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/14\">",
"      Benoliel R, Sharav Y. Trigeminal neuralgia with lacrimation or SUNCT syndrome? Cephalalgia 1998; 18:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/15\">",
"      Barbanti P, Fabbrini G, Pesare M, et al. Unilateral cranial autonomic symptoms in migraine. Cephalalgia 2002; 22:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/16\">",
"      Goadsby PJ, Matharu MS, Boes CJ. SUNCT syndrome or trigeminal neuralgia with lacrimation. Cephalalgia 2001; 21:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/17\">",
"      Goadsby PJ. Trigeminal autonomic cephalalgias: fancy term or constructive change to the IHS classification? J Neurol Neurosurg Psychiatry 2005; 76:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/18\">",
"      Matharu MS, Goadsby PJ. Persistence of attacks of cluster headache after trigeminal nerve root section. Brain 2002; 125:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/19\">",
"      Leone M, Bussone G. Pathophysiology of trigeminal autonomic cephalalgias. Lancet Neurol 2009; 8:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/20\">",
"      KUNKLE EC, PFEIFFER JB Jr, WILHOIT WM, HAMRICK LW Jr. Recurrent brief headache in cluster pattern. Trans Am Neurol Assoc 1952; 56:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/21\">",
"      Ekbom K. Nitrolglycerin as a provocative agent in cluster headache. Arch Neurol 1968; 19:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/22\">",
"      Ekbom K. Patterns of cluster headache with a note on the relations to angina pectoris and peptic ulcer. Acta Neurol Scand 1970; 46:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/23\">",
"      Kudrow L. The cyclic relationship of natural illumination to cluster period frequency. Cephalalgia 1987; 7 Suppl 6:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/24\">",
"      Strittmatter M, Hamann GF, Grauer M, et al. Altered activity of the sympathetic nervous system and changes in the balance of hypophyseal, pituitary and adrenal hormones in patients with cluster headache. Neuroreport 1996; 7:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/25\">",
"      Nelson RF. Testosterone levels in cluster and non-cluster migrainous headache patients. Headache 1978; 18:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/26\">",
"      Leone M, Patruno G, Vescovi A, Bussone G. Neuroendocrine dysfunction in cluster headache. Cephalalgia 1990; 10:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/27\">",
"      Waldenlind E, Gustafsson SA, Ekbom K, Wetterberg L. Circadian secretion of cortisol and melatonin in cluster headache during active cluster periods and remission. J Neurol Neurosurg Psychiatry 1987; 50:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/28\">",
"      Malick A, Burstein R. Cells of origin of the trigeminohypothalamic tract in the rat. J Comp Neurol 1998; 400:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/29\">",
"      Malick A, Strassman RM, Burstein R. Trigeminohypothalamic and reticulohypothalamic tract neurons in the upper cervical spinal cord and caudal medulla of the rat. J Neurophysiol 2000; 84:2078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/30\">",
"      Wang Q, Mao LM, Han JS. Naloxone-reversible analgesia produced by microstimulation of the arcuate nucleus of the hypothalamus in pentobarbital-anesthetized rats. Exp Brain Res 1990; 80:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/31\">",
"      Dafny N, Dong WQ, Prieto-Gomez C, et al. Lateral hypothalamus: site involved in pain modulation. Neuroscience 1996; 70:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/32\">",
"      Lumb BM, Lovick TA. The rostral hypothalamus: an area for the integration of autonomic and sensory responsiveness. J Neurophysiol 1993; 70:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/33\">",
"      Benjamin L, Levy MJ, Lasalandra MP, et al. Hypothalamic activation after stimulation of the superior sagittal sinus in the cat: a Fos study. Neurobiol Dis 2004; 16:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/34\">",
"      Bartsch T, Levy MJ, Knight YE, Goadsby PJ. Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area. Pain 2004; 109:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/35\">",
"      May A, Bahra A, B&uuml;chel C, et al. Hypothalamic activation in cluster headache attacks. Lancet 1998; 352:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/36\">",
"      Sprenger T, Boecker H, Tolle TR, et al. Specific hypothalamic activation during a spontaneous cluster headache attack. Neurology 2004; 62:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/37\">",
"      Matharu MS, Cohen AS, Frackowiak RS, Goadsby PJ. Posterior hypothalamic activation in paroxysmal hemicrania. Ann Neurol 2006; 59:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/38\">",
"      Sprenger T, Valet M, Platzer S, et al. SUNCT: bilateral hypothalamic activation during headache attacks and resolving of symptoms after trigeminal decompression. Pain 2005; 113:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/39\">",
"      May A, Bahra A, B&uuml;chel C, et al. Functional magnetic resonance imaging in spontaneous attacks of SUNCT: short-lasting neuralgiform headache with conjunctival injection and tearing. Ann Neurol 1999; 46:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/40\">",
"      Cohen, AS, Matharu, MS, Kalisch, R, et al. Functional MRI in SUNCT shows differential hypothalamic activation with increasing pain [abstract]. Cephalalgia 2004; 24:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/41\">",
"      May A. The role of imaging in the pathophysiology and diagnosis of headache. Curr Opin Neurol 2005; 18:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/42\">",
"      May A. A review of diagnostic and functional imaging in headache. J Headache Pain 2006; 7:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/43\">",
"      May A. Functional anatomy of headache. Neurol Sci 2006; 27 Suppl 2:S103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/44\">",
"      Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995; 1:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/45\">",
"      Bahra A, Matharu MS, Buchel C, et al. Brainstem activation specific to migraine headache. Lancet 2001; 357:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/46\">",
"      Afridi SK, Giffin NJ, Kaube H, et al. A positron emission tomographic study in spontaneous migraine. Arch Neurol 2005; 62:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/47\">",
"      Matharu MS, Bartsch T, Ward N, et al. Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain 2004; 127:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/48\">",
"      Afridi SK, Matharu MS, Lee L, et al. A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain 2005; 128:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/49\">",
"      Denuelle M, Fabre N, Payoux P, et al. Hypothalamic activation in spontaneous migraine attacks. Headache 2007; 47:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/50\">",
"      May A, Kaube H, B&uuml;chel C, et al. Experimental cranial pain elicited by capsaicin: a PET study. Pain 1998; 74:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27174/abstract/51\">",
"      Kupers RC, Svensson P, Jensen TS. Central representation of muscle pain and mechanical hyperesthesia in the orofacial region: a positron emission tomography study. Pain 2004; 108:284.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3339 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-2ED33AB258-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_34_27174=[""].join("\n");
var outline_f26_34_27174=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGIC MODELS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Vascular theory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Trigeminal autonomic reflex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hypothalamic activation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Activation patterns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      OUTSTANDING ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/3339\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/3339|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/12/42188\" title=\"table 1\">",
"      Clinical features trigeminal autonomic cephalalgias",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3898?source=related_link\">",
"      Cluster headache: Acute and preventive treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14327?source=related_link\">",
"      Cluster headache: Epidemiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25545?source=related_link\">",
"      Paroxysmal hemicrania: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9112?source=related_link\">",
"      Paroxysmal hemicrania: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28648?source=related_link\">",
"      SUNCT and SUNA headache syndromes: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2264?source=related_link\">",
"      SUNCT and SUNA headache syndromes: Treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_34_27175="Unipolar depression in adults: Augmentation of antidepressants with thyroid hormone";
var content_f26_34_27175=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Unipolar depression in adults: Augmentation of antidepressants with thyroid hormone",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/34/27175/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/34/27175/contributors\">",
"     Michael Gitlin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/34/27175/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/34/27175/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/34/27175/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/34/27175/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/34/27175/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H27577764\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid hormone can be used in two different ways to treat unipolar major depression. Most commonly, thyroid hormone is used as augmentation for patients who respond insufficiently to antidepressant monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In addition, thyroid hormone can be started simultaneously with a tricyclic at the beginning of pharmacotherapy to accelerate response compared with tricyclic antidepressant monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. However, a faster response to treatment does not increase the number of patients who respond by the end of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/6\">",
"     6",
"    </a>",
"    ]. Thyroid hormone is generally administered as triiodothyronine (T3). &nbsp;",
"   </p>",
"   <p>",
"    Interest in treating major depression with thyroid hormone initially arose in part because of overlap in the symptoms of major depression and hypothyroidism, including dysphoria, psychomotor retardation, cognitive impairment, fatigue, and weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Although diminished thyroid function is present in some cases of major depression, adjunctive T3 may be effective for depressed patients who are euthyroid [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of thyroid hormone in treating major depression is reviewed here. Treatment resistant depression is discussed separately, as is the initial treatment of depression and treatment of hypothyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"     \"Treatment of resistant depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link\">",
"     \"Treatment of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27577771\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for treating nonpsychotic, unipolar major depression with triiodothyronine (T3) include [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Augmenting response &ndash; T3 is added to ongoing antidepressant monotherapy because the patient has not responded adequately; this is the most common indication.",
"     </li>",
"     <li>",
"      Accelerating response &ndash; T3 plus a tricyclic antidepressant are started simultaneously at the beginning of treatment to provide a more rapid response compared with tricyclic monotherapy. However, a faster response to treatment does not enhance response, ie, does not increase the number of patients who respond by the end of treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no evidence that T3 monotherapy is efficacious for treating major depression in the absence of hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/7,10\">",
"     7,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25560550\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;T3 is contraindicated in patients with adrenal insufficiency, unstable angina, or recent myocardial infarction or compromised cardiovascular function, because increasing the metabolic rate in these conditions can be unsafe. In addition, T3 should be used cautiously in elderly patients to avoid cardiac complications, and in patients with diabetes mellitus to avoid aggravating diabetic symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment of hypothyroidism\", section on 'Older patients or those with coronary heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1937670\">",
"    <span class=\"h1\">",
"     GOAL OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of treating unipolar major depression is remission, which is defined as resolution of depressive symptoms, or improvement to the point that only one or two symptoms of mild intensity persist. For patients who do not achieve remission, a reasonable goal is response, which is defined as stabilization of the patient&rsquo;s safety and substantial improvement in the number, intensity, and frequency of symptoms. Standardized rating scales such as the self-report Patient Health Questionnaire &ndash; Nine Item (",
"    <a class=\"graphic graphic_table graphicRef59307 \" href=\"UTD.htm?14/12/14541\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/11\">",
"     11",
"    </a>",
"    ] can be used to quantify response, but this is not standard clinical practice. Use of scales in treating depression is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4745?source=see_link\">",
"     \"Using scales to monitor symptoms and treatment of depression (measurement based care)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25558861\">",
"    <span class=\"h1\">",
"     AUGMENTING RESPONSE TO ONGOING ANTIDEPRESSANT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with nonpsychotic, unipolar major depression, triiodothyronine (T3) is used most frequently to augment response to existing antidepressant treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Adjunctive treatment is often necessary because remission with antidepressant monotherapy occurs in only 28 to 47 percent of patients, even with an optimal trial [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. It is commonly thought that an adjuvant may be more effective for patients who initially have a partial response to antidepressant monotherapy, compared with patients who do not respond at all, but this is not established [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/15\">",
"     15",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Practice guidelines for treating unipolar major depression from the American Psychiatric Association, Canadian Network for Mood and Anxiety Treatments, and World Federation of Societies of Biological Psychiatry suggest adjunctive thyroid hormone as one of several options for patients who do not respond to antidepressant monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. However, the United Kingdom National Institute for Clinical Excellence guideline suggests that clinicians should not routinely augment an antidepressant with thyroid hormone because there is inconsistent evidence of effectiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25559300\">",
"    <span class=\"h2\">",
"     Evidence of efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with major depression who have not responded adequately to antidepressant monotherapy, there is low quality evidence supporting adjunctive T3 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of four, heterogeneous randomized trials (95 depressed patients unresponsive to a tricyclic) compared adjunctive T3 to either adjunctive placebo or thyroxine (T4) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/17\">",
"       17",
"      </a>",
"      ]. Although the clinical benefit of T3 was moderately large, and response (improvement from baseline on the depression rating scale &ge; 50 percent) occurred in 53 percent more patients who received T3, the difference in the frequency of response between T3 and the control condition was not statistically significant (relative response 1.53, 95% CI 0.70-3.35). &nbsp;",
"     </li>",
"     <li>",
"      An open-label, randomized trial examined adjunctive T3 as part of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study of unipolar major depression [",
"      <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/18\">",
"       18",
"      </a>",
"      ]. In 73 patients who prospectively failed two trials of antidepressant monotherapy and subsequently received a third trial with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      plus T3, 25 percent remitted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4644767\">",
"    <span class=\"h2\">",
"     Compared with other adjunctive treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with unipolar major depression, adjunctive T3 has been compared only with adjunctive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    . Two randomized trials found that the two drugs were comparable in efficacy; in one of the trials, tolerability was significantly better with T3 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Additional information about these two trials is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/50/17192?source=see_link&amp;anchor=H2757334#H2757334\">",
"     \"Unipolar depression in adults: Treatment with lithium\", section on 'Triiodothyronine (T3)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adjunctive medications other than T3 are available for patients who do not respond to antidepressant monotherapy. The options include augmentation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , a second-generation antipsychotic, and a second antidepressant; these are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/50/17192?source=see_link&amp;anchor=H11208494#H11208494\">",
"     \"Unipolar depression in adults: Treatment with lithium\", section on 'Adjunctive treatment with lithium for acute depression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31993?source=see_link&amp;anchor=H21954769#H21954769\">",
"     \"Unipolar depression in adults: Treatment with second-generation antipsychotics\", section on 'Adjunctive treatment for nonpsychotic depression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of resistant depression in adults\", section on 'Another antidepressant'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2011945\">",
"    <span class=\"h2\">",
"     Pretreatment evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial assessment of patients with unipolar major depression includes a psychiatric and general medical history, mental status and physical examination, and focused laboratory tests. Prior to prescribing T3, clinicians should screen for thyroid disease by obtaining a baseline serum thyrotropin (TSH) concentration if not previously done:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      If the TSH is normal, thyroid disease is unlikely &nbsp;",
"     </li>",
"     <li>",
"      If the TSH is elevated, a serum free thyroxine (T4) concentration should be obtained to determine the degree of hypothyroidism &nbsp;",
"     </li>",
"     <li>",
"      If the TSH concentration is low, a serum free T4 and a total T3 concentration should be obtained to determine the degree of hyperthyroidism, and T3 should not be prescribed &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A baseline electrocardiogram is not routinely required. However, a pre-existing cardiac condition warrants a consult from the patient&rsquo;s internist or cardiologist.",
"   </p>",
"   <p>",
"    Additional information about diagnosing hypothyroidism and hyperthyroidism is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link\">",
"     \"Diagnosis of and screening for hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26520?source=see_link\">",
"     \"Diagnosis of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25559990\">",
"    <span class=\"h2\">",
"     Choice of thyroid hormone",
"    </span>",
"    &nbsp;&mdash;&nbsp;T3 is generally preferred over T4 for augmenting an antidepressant in unipolar major depression. Although both thyroid hormones are biologically active, T3 appears to be superior to T4 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/20\">",
"     20",
"    </a>",
"    ], and T3 has been more widely studied [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized trial compared T3 (37.5 mcg per day) with T4 (150 mcg per day) as adjunctive treatment in 38 patients with unipolar major depression who did not respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"     imipramine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/20\">",
"     20",
"    </a>",
"    ]. After three weeks of treatment, response (improvement from baseline on the depression rating scale &ge; 50 percent) occurred in significantly more patients who received adjunctive T3 compared with adjunctive T4 (53 versus 19 percent).",
"   </p>",
"   <p>",
"    Additional information about T3 and T4 is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33320?source=see_link\">",
"     \"Thyroid hormone synthesis and physiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25559997\">",
"    <span class=\"h2\">",
"     Dose and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;We generally start T3 at 25 mcg per day for one to two weeks, and if there is little or no improvement, increase the dose to 50 mcg per day; this is consistent with practice guidelines from the American Psychiatric Association and Canadian Network for Mood and Anxiety Treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. For frail, elderly patients, the initial dose is 12.5 mcg per day; if there is little or no improvement after one to two weeks, the dose is increased each week by 12.5 mcg per day, to no more than 50 mcg per day.",
"   </p>",
"   <p>",
"    Studies have generally utilized daily doses of 20 to 50 mcg per day. In some studies, a lower daily dose (20 to 25 mcg) was increased after one to two weeks to the higher dose (40 to 50 mcg), whereas other studies started T3 at the higher dose [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/17\">",
"     17",
"    </a>",
"    ]. However, there is no evidence that 50 mcg per day is more effective than 25 mcg. One eight week, randomized trial compared adjunctive T3 25 mcg per day with 50 mcg per day in 56 patients with major depression and found no significant difference in response [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    T3 is generally taken in the morning and can be taken without regard to meals because food does not alter absorption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25560004\">",
"    <span class=\"h2\">",
"     Length of an adequate trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that clinicians prescribe adjunctive T3 for at least four to six weeks before deciding whether it is helpful. Although remission may occur within one week, it may require months of treatment. In an open-label randomized trial, 73 patients with unipolar major depression were treated with adjunctive T3 for up to 14 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/18\">",
"     18",
"    </a>",
"    ]. Among the 18 patients who remitted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Five remitted after 2 weeks of treatment",
"     </li>",
"     <li>",
"      Three after 3 to 4 weeks",
"     </li>",
"     <li>",
"      Four after 5 to 6 weeks",
"     </li>",
"     <li>",
"      One after 7 to 9 weeks",
"     </li>",
"     <li>",
"      None after 10 to 12 weeks",
"     </li>",
"     <li>",
"      Five after 13 to 14 weeks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other controlled studies of T3 have lasted between one to five weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4644937\">",
"    <span class=\"h2\">",
"     Predictors of response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although individual studies have found predictors of response to adjunctive T3, no single consistent predictor has been identified. Biological predictors have typically included baseline thyroid indices, including lower serum T3 or higher TSH concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/23\">",
"     23",
"    </a>",
"    ]. However, many studies required normal baseline thyroid indices as an inclusion criterion, and it is thus unclear whether patients with subclinical hypothyroidism, defined as a normal serum free T4 concentration in the presence of an elevated serum TSH concentration, might preferentially respond to adjunctive T3. Treatment resistance to multiple antidepressant trials or depressive chronicity may predict a poorer response [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/4\">",
"     4",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25560018\">",
"    <span class=\"h2\">",
"     Safety issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;T3 is contraindicated in certain medical conditions; this is discussed elsewhere in the topic. (See",
"    <a class=\"local\" href=\"#H25560550\">",
"     'Contraindications'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25560032\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjunctive T3 at 25 to 50 mcg per day for one to two months is usually well tolerated and has a benign side effect profile compared with other adjunctive medications used in refractory depression (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , second-generation antipsychotic, or a second antidepressant) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/24\">",
"     24",
"    </a>",
"    ]. In nearly all randomized trials, there were no significant differences in adverse effects between T3 and placebo as augmentation with a tricyclic, SSRI, or other type of antidepressant [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/4,17\">",
"     4,17",
"    </a>",
"    ]. In addition, none of the studies reported a major health complication. Nevertheless, adverse effects consistent with hyperthyroidism may occur, including tremor, palpitations, heat intolerance, sweating, anxiety, increased frequency of bowel movements, shortness of breath, and exacerbation of cardiac arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/4,24\">",
"     4,24",
"    </a>",
"    ]. In addition, hyperthyroidism that emerges during long-term treatment may lead to bone demineralization, osteoporosis, and an increased risk of fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4165?source=see_link\">",
"     \"Exogenous hyperthyroidism\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H259472385\">",
"     'Long-term treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25560039\">",
"    <span class=\"h3\">",
"     Laboratory monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following a normal baseline TSH concentration, no other laboratory monitoring during a four to six week trial of adjunctive T3 is necessary. However, if T3 is continued longer, a serum TSH concentration should be checked after the first one to three months of treatment and then every six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25560046\">",
"    <span class=\"h3\">",
"     Drug-drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific interactions between T3 and other medications may be determined using the drug interactions tool (Lexi-Interact Online) included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on Drug interactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259472385\">",
"    <span class=\"h2\">",
"     Long-term treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance treatment has not been studied in depressed patients who respond to augmentation of an antidepressant with T3. Based upon maintenance trials with antidepressant monotherapy, we suggest that patients who respond to adjunctive T3 continue to receive the T3-antidepressant combination for at least one year [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/1\">",
"     1",
"    </a>",
"    ]. Long-term side effects with adjunctive T3 are unlikely, given the low doses prescribed (25 to 50 mcg per day). However, mild hyperthyroidism may occur and is more likely in patients treated with 50 mcg per day; the potential risks of long-term hyperthyroidism include bone demineralization, osteoporosis, and an increased risk of fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/24\">",
"     24",
"    </a>",
"    ]. Clinicians should monitor serum TSH concentrations every six months and decrease the T3 dose if the TSH concentration falls below the lower range of normal. Hyperthyroidism is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4165?source=see_link\">",
"     \"Exogenous hyperthyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=see_link\">",
"     \"Overview of the clinical manifestations of hyperthyroidism in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25559222\">",
"    <span class=\"h1\">",
"     ACCELERATING RESPONSE TO AN ANTIDEPRESSANT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid hormone started simultaneously with a tricyclic antidepressant (on the same day that the antidepressant is started or within three to five days) may provide a more rapid response compared with tricyclic monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/4\">",
"     4",
"    </a>",
"    ]. However, a faster response to treatment does not increase the number of patients who respond by the end of treatment. Thyroid hormone is generally administered as triiodothyronine (T3); the choice of thyroid hormone is discussed separately. (See",
"    <a class=\"local\" href=\"#H25559990\">",
"     'Choice of thyroid hormone'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The efficacy of using T3 to accelerate response seems to depend upon the antidepressant class that is used; T3 accelerates response to tricyclics but not selective serotonin reuptake inhibitors (SSRIs):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of six randomized trials (125 depressed patients) compared T3 (typically 25 mcg per day) plus a tricyclic antidepressant (typically",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"       imipramine",
"      </a>",
"      150 mg per day) at the start of treatment with placebo plus a tricyclic [",
"      <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/5\">",
"       5",
"      </a>",
"      ]. A significantly faster response of approximately 9 to 11 days occurred with concomitant T3 than placebo.",
"     </li>",
"     <li>",
"      A meta-analysis of four randomized trials (444 patients with unipolar major depression) compared T3 (25 or 50 mcg per day) plus an SSRI with placebo plus an SSRI, and found no significant difference in how quickly response occurred [",
"      <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both meta-analyses found that T3 was well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Other safety issues regarding T3 as a treatment for depression are discussed elsewhere in the topic. (See",
"    <a class=\"local\" href=\"#H25560018\">",
"     'Safety issues'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The length of an adequate trial of T3 used as an accelerator is commensurate with the duration of an antidepressant trial, which is generally four to eight weeks. Other aspects of prescribing T3 are discussed elsewhere in the topic. (See",
"    <a class=\"local\" href=\"#H2011945\">",
"     'Pretreatment evaluation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H25559997\">",
"     'Dose and administration'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H25560018\">",
"     'Safety issues'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4678006\">",
"    <span class=\"h1\">",
"     ENHANCING RESPONSE TO AN ANTIDEPRESSANT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with antidepressant monotherapy, thyroid hormone plus an antidepressant at the beginning of treatment does not increase the probability of response or remission. A meta-analysis of four randomized trials (444 patients with unipolar major depression) compared T3 plus a selective serotonin reuptake inhibitor (SSRI) with placebo plus an SSRI and found no evidence that T3 enhanced the effect of an SSRI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/6\">",
"     6",
"    </a>",
"    ]. A subsequent eight-week trial compared triiodothyronine (T3; 50 mcg per day) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    (50 to 200 mg per day) with placebo plus sertraline in 153 patients with major depression; response and remission were comparable for the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27175/abstract/25\">",
"     25",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27577869\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common indication for treating nonpsychotic, unipolar major depression with triiodothyronine (T3) is augmentation, ie, T3 is added to ongoing antidepressant monotherapy because the patient has not responded adequately. In addition, T3 plus a tricyclic antidepressant can be started simultaneously at the beginning of treatment to accelerate (provide a more rapid) response compared with tricyclic monotherapy. However, a faster response to treatment does not increase the number of patients who respond by the end of treatment. (See",
"      <a class=\"local\" href=\"#H27577771\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      T3 is contraindicated in patients with adrenal insufficiency, unstable angina, or recent myocardial infarction or compromised cardiovascular function. In addition, T3 should be used cautiously in elderly patients to avoid cardiac complications, and in patients with diabetes mellitus to avoid aggravating diabetic symptoms. (See",
"      <a class=\"local\" href=\"#H25560550\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial assessment of patients with unipolar major depression includes a psychiatric and general medical history, mental status and physical examination, and focused laboratory tests. Prior to prescribing T3, clinicians should screen for thyroid disease by obtaining a baseline serum thyrotropin (TSH) concentration. A baseline electrocardiogram is not routinely required. However, a pre-existing cardiac condition warrants a consult from the patient&rsquo;s internist or cardiologist. (See",
"      <a class=\"local\" href=\"#H2011945\">",
"       'Pretreatment evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      T3 is generally preferred over T4 either for augmenting an antidepressant in unipolar major depression, or accelerating response. The initial dose of T3 is typically 25 mcg per day for one to two weeks, and if there is little or no improvement, the dose is increased to 50 mcg per day. We suggest that clinicians prescribe adjunctive T3 for at least four to six weeks before deciding whether it is helpful. (See",
"      <a class=\"local\" href=\"#H25559990\">",
"       'Choice of thyroid hormone'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25559997\">",
"       'Dose and administration'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25560004\">",
"       'Length of an adequate trial'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adjunctive T3 at 25 to 50 mcg per day is usually well-tolerated. However, adverse effects consistent with hyperthyroidism may occur, including tremor, palpitations, heat intolerance, sweating, anxiety, increased frequency of bowel movements, shortness of breath, and exacerbation of cardiac arrhythmia. In addition, hyperthyroidism that emerges during long-term treatment may lead to bone demineralization, osteoporosis, and an increased risk of fracture. (See",
"      <a class=\"local\" href=\"#H25560032\">",
"       'Side effects'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H259472385\">",
"       'Long-term treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4165?source=see_link\">",
"       \"Exogenous hyperthyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest that patients who respond to adjunctive T3 continue to receive the T3-antidepressant combination for at least one year. Clinicians should monitor serum TSH concentrations every six months and decrease the T3 dose if the TSH concentration falls below the lower range of normal. (See",
"      <a class=\"local\" href=\"#H259472385\">",
"       'Long-term treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25560039\">",
"       'Laboratory monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Practice Guideline for the Treatment of Patients With Major Depressive Disorder,",
"Third Edition, 2010 file://www.psych.org/MainMenu/PsychiatricPractice/PracticeGuidelines_1.aspx (Accessed on January 27, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27175/abstract/2\">",
"      Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009; 117 Suppl 1:S26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27175/abstract/3\">",
"      Bauer M, Bschor T, Pfennig A, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry 2007; 8:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27175/abstract/4\">",
"      Cooper-Kazaz R, Lerer B. Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors. Int J Neuropsychopharmacol 2008; 11:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27175/abstract/5\">",
"      Altshuler LL, Bauer M, Frye MA, et al. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry 2001; 158:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27175/abstract/6\">",
"      Papakostas GI, Cooper-Kazaz R, Appelhof BC, et al. Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies. Int Clin Psychopharmacol 2009; 24:19.",
"     </a>",
"    </li>",
"    <li>",
"     Prange, AJ Jr, Wilson, et al. Hormonal alterations of imipramine response: A review. In: Hormones, Behavior, and Psychopathology, Sachar, EJ (Eds), Raven Press, New York 1976. p.41.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27175/abstract/8\">",
"      Preskorn SH. Treatment options for the patient who does not respond well to initial antidepressant therapy. J Psychiatr Pract 2009; 15:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27175/abstract/9\">",
"      DeBattista C. Augmentation and combination strategies for depression. J Psychopharmacol 2006; 20:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27175/abstract/10\">",
"      Joffe RT. Refractory depression: treatment strategies, with particular reference to the thyroid axis. J Psychiatry Neurosci 1997; 22:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27175/abstract/11\">",
"      Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27175/abstract/12\">",
"      Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27175/abstract/13\">",
"      Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005; 66:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27175/abstract/14\">",
"      Thase ME, Nierenberg AA, Vrijland P, et al. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Int Clin Psychopharmacol 2010; 25:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27175/abstract/15\">",
"      Hirschfeld RM, Montgomery SA, Aguglia E, et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry 2002; 63:826.",
"     </a>",
"    </li>",
"    <li>",
"     Depression: The Treatment and Management of Depression in Adults (Updated Version). ",
"National Clinical Practice Guideline 90. National Institute for Health &amp;",
"Clinical Excellence file://guidance.nice.org.uk/CG90/Guidance/pdf/English (Accessed on January 27, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27175/abstract/17\">",
"      Aronson R, Offman HJ, Joffe RT, Naylor CD. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry 1996; 53:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27175/abstract/18\">",
"      Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006; 163:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27175/abstract/19\">",
"      Joffe RT, Singer W, Levitt AJ, MacDonald C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993; 50:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27175/abstract/20\">",
"      Joffe RT, Singer W. A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Res 1990; 32:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27175/abstract/21\">",
"      Rosenthal LJ, Goldner WS, O'Reardon JP. T3 augmentation in major depressive disorder: safety considerations. Am J Psychiatry 2011; 168:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27175/abstract/22\">",
"      Appelhof BC, Brouwer JP, van Dyck R, et al. Triiodothyronine addition to paroxetine in the treatment of major depressive disorder. J Clin Endocrinol Metab 2004; 89:6271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27175/abstract/23\">",
"      Cooper-Kazaz R, Apter JT, Cohen R, et al. Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 2007; 64:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27175/abstract/24\">",
"      Shelton RC, Osuntokun O, Heinloth AN, Corya SA. Therapeutic options for treatment-resistant depression. CNS Drugs 2010; 24:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27175/abstract/25\">",
"      Garlow SJ, Dunlop BW, Ninan PT, Nemeroff CB. The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder. J Psychiatr Res 2012; 46:1406.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15722 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-817E36F31F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_34_27175=[""].join("\n");
var outline_f26_34_27175=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27577869\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27577764\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27577771\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25560550\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1937670\">",
"      GOAL OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25558861\">",
"      AUGMENTING RESPONSE TO ONGOING ANTIDEPRESSANT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25559300\">",
"      Evidence of efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4644767\">",
"      Compared with other adjunctive treatments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2011945\">",
"      Pretreatment evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25559990\">",
"      Choice of thyroid hormone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25559997\">",
"      Dose and administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25560004\">",
"      Length of an adequate trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4644937\">",
"      Predictors of response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25560018\">",
"      Safety issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25560032\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25560039\">",
"      - Laboratory monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25560046\">",
"      - Drug-drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H259472385\">",
"      Long-term treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25559222\">",
"      ACCELERATING RESPONSE TO AN ANTIDEPRESSANT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4678006\">",
"      ENHANCING RESPONSE TO AN ANTIDEPRESSANT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27577869\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/15722\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/15722|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/12/14541\" title=\"table 1\">",
"      PHQ-9 questionnaire",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26520?source=related_link\">",
"      Diagnosis of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4165?source=related_link\">",
"      Exogenous hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=related_link\">",
"      Overview of the clinical manifestations of hyperthyroidism in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33320?source=related_link\">",
"      Thyroid hormone synthesis and physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=related_link\">",
"      Treatment of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=related_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/50/17192?source=related_link\">",
"      Unipolar depression in adults: Treatment with lithium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31993?source=related_link\">",
"      Unipolar depression in adults: Treatment with second-generation antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4745?source=related_link\">",
"      Using scales to monitor symptoms and treatment of depression (measurement based care)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_34_27176="Robot-assisted laparoscopy";
var content_f26_34_27176=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Robot-assisted laparoscopy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/34/27176/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/34/27176/contributors\">",
"     Marie Fidela R Paraiso, MD, FACOG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/34/27176/contributors\">",
"     Tommaso Falcone, MD, FRCSC, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/34/27176/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/34/27176/contributors\">",
"     William J Mann, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/34/27176/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/34/27176/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/34/27176/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A surgical robot is a computer-controlled device that can be programmed to aid the positioning and manipulation of surgical instruments. Surgical robotics is typically used in laparoscopy rather than open surgical approaches. Since the 1980s, surgical robots have been developed to address the limitations of laparoscopy, including two-dimensional visualization, incomplete articulation of instruments, and ergonomic limitations. The goal of robot-assisted laparoscopic surgery is to help surgeons improve patient care by converting procedures that would have otherwise been performed by laparotomy into minimally invasive procedures. Robot-assisted laparoscopic surgery has all of the advantages of minimally invasive surgery include less postoperative pain, smaller and possibly more cosmetically appealing incisions, shorter hospital stay, shorter recovery time, and faster return to work.",
"   </p>",
"   <p>",
"    In its initial phase, robotic procedures were performed almost exclusively by surgeons with advanced laparoscopic skills. However, since the da Vinci&reg; robot (one type of robotic surgical platform) was approved by the United States Food and Drug Administration (FDA) for use in gynecologic surgery, there has been rapid adoption of robot-assisted laparoscopic procedures in gynecology by surgeons of all skill levels. Based upon data published in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/1\">",
"     1",
"    </a>",
"    ], there were more than 645 da Vinci&reg; systems in use worldwide and, since then, there continued to be an exponential rise in the use of these surgical systems. Barriers to the adoption of robotics in surgery include the expense, training requirements for physicians and nurses, and lack of high quality data. Similar to conventional laparoscopy, robot-assisted laparoscopy has been widely adopted prior to emergence of data supporting efficacy and safety.",
"   </p>",
"   <p>",
"    The role of robot-assisted laparoscopy in gynecologic surgery will be reviewed here. Related topics are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      General principles of conventional laparoscopic surgery (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31770?source=see_link\">",
"       \"Abdominal access techniques used in laparoscopic surgery\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Single port laparoscopy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9029?source=see_link\">",
"       \"Laparoendoscopic single-site (single port) surgery\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical robots can serve several functions, including [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Passive &mdash; Robotic movements are set preoperatively or act to guide the surgeon to a surgical target. Types of passive robots are:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Autonomous &mdash; Robot performs a sequence of movements which are programmed preoperatively (eg, Probot).",
"     </li>",
"     <li>",
"      Supervisory &mdash; Robot serves as a navigational aid or a precise positioning system (usually using preoperative imaging studies) to direct the surgeon to a lesion or other surgical target (eg, Minerva). Intraoperative ultrasound may be used to guide a surgeon to a tumor within an organ such as the liver or kidney.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Active &mdash; Surgeon directs the robot intraoperatively to move the surgical instruments (eg, AESOP&reg;, da Vinci&reg;). This is also referred to as a",
"      <span class=\"nowrap\">",
"       master/slave",
"      </span>",
"      manipulator. Terms used to describe active robots include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Immersive &mdash; The surgeon is using the robot as a tool, but is deeply engaged in the operative field as if he or she were actually right at the operative field. This is made possible by high quality imaging, magnification of the three-dimensional (3D) laparoscope, and use of a direct line of sight to position the instruments that the surgeon&rsquo;s hands are controlling.",
"     </li>",
"     <li>",
"      Haptics &mdash; The lack of haptics (ie, tactile feedback) is a limitation of robotic surgery. The surgeon cannot actually feel the resistance of the tissue as the instrument meets or manipulates the tissue, but accommodates for this by using visual cues and knowledge of anatomy and surgical planes based upon previous surgical experience and study of anatomy. &nbsp;",
"     </li>",
"     <li>",
"      Teleoperated or telerobotic &mdash; The robot is manipulated by input devices under the surgeon's control remote from the operating table.",
"     </li>",
"     <li>",
"      Telepresence surgery &mdash;",
"      <span class=\"nowrap\">",
"       Teleoperated/telerobotic",
"      </span>",
"      surgery in which the surgeon is located outside of the operating room (eg, in another city or country).",
"     </li>",
"     <li>",
"      Telementoring &mdash; Transmission of audio and video information from a robotic set-up to a remote site, thereby allowing an expert surgeon to guide a novice through a procedure.",
"     </li>",
"     <li>",
"      Telestration &mdash; For use in telementoring, a surgical mentor can draw on the operating surgeon's video display.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HISTORY OF SURGICAL ROBOTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical robotics were first used in 1985 in neurosurgery; applications soon followed in urology and orthopedics. Major milestones in the development of robotics are listed below [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First robotic surgery (1985) &mdash; The PUMA 560 was used to orient a needle for a brain biopsy under computerized tomography guidance [",
"      <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Robotic surgery extended to urology (1988, Probot), orthopedics (1992, Robodoc&reg;), and gynecology (1998, Zeus) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/2,4\">",
"       2,4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Robotic laparoscopic camera holder introduced (1994). The Automated Endoscopic System for Optimal Positioning (AESOP&reg;) was the first robotic device approved by the United States Food and Drug Administration (FDA) for use in intraabdominal surgery; AESOP&reg; would later be included in an integrated robotic surgical system, however, this system is no longer available (2001, Zeus) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/3\">",
"       3",
"      </a>",
"      ]. A surgically controlled robot called the ViKY&reg; has been introduced. It is voice activated and is used to control the laparoscope for single port procedures [",
"      <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Robotic telepresence technology became commercially available (the surgeon is at a remote site, yet has the feel of being in the operating room) (2000, da Vinci&reg;). The system was developed by the Stanford Research Institute and National Aeronautics and Space Administration [",
"      <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/3\">",
"       3",
"      </a>",
"      ]. The prototype was originally designed for use by the military to provide immediate operative care on the battle field from a remote surgical station.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ROBOTIC VERSUS OTHER SURGICAL APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional laparoscopy has led to notable improvements in surgery, however, optics and instrumentation are limited and advanced surgical training (specifically in laparoscopic suturing and knot-tying, ureterolysis, and dissection of and within the retroperitoneal space) is required to perform complex procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, poor ergonomics can lead to fatigue or joint strain in the surgeon [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/6\">",
"     6",
"    </a>",
"    ]. Robot-assisted laparoscopy has features which overcome the difficulties of conventional laparoscopy and may also introduce new surgical options (eg, remotely performed surgery). However, cost is higher and operative time (including time for robotic set-up and disassembly) is typically longer, particularly when a surgeon is learning the technique. Surgeon fatigue is minimized by use of a console at which the surgeon may sit comfortably.",
"   </p>",
"   <p>",
"    Conventional and robotic laparoscopy share similar advantages over laparotomy, including decreased morbidity, rapid recovery, and improved aesthetics of incisions. However, both of these minimally invasive routes have introduced trocar injuries, insufflation related problems, and trocar-site abdominal wall hematomas when compared with laparotomy. As with conventional laparoscopy, there is an increased risk of bladder and ureteral injury with robot-assisted laparoscopy compared to open surgery.",
"   </p>",
"   <p>",
"    Delayed thermal injuries are also increased compared to laparotomy because of increased use of electrosurgical instruments in conventional and robot-assisted laparoscopy procedures. Increased incidence of vaginal cuff dehiscence has also been reported with robot-assisted and conventional laparoscopic hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. This has been attributed to the use of monopolar energy to perform the colpotomy incision, running suture compared to interrupted stitches, and risk of lateral spread of thermal energy and subsequent inadequate closure due to inadequate purchase of tissue during suturing of the vaginal cuff. Many surgeons advocate barbed suture to facilitate vaginal cuff closure, while others favor closing the vagina from below as in routine vaginal hysterectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41990?source=see_link\">",
"     \"Vaginal cuff dehiscence after hysterectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unique complications that may occur with robot-assisted laparoscopic surgery include mechanical breakdown of the robotic equipment, use of excessive pressure on various tissues due to lack of tactile feedback, erroneous activation of a control (stepping on the monopolar foot pedal when the bipolar instrument is desired) or errant movement or positioning of a robotic arm.",
"   </p>",
"   <p>",
"    For benign gynecologic disease, there is no high quality evidence that robot-assisted laparoscopy is superior to laparotomy or conventional laparoscopy. The American Association of Gynecologic Laparoscopists (AAGL) states that robot-assisted laparoscopy should not replace conventional laparoscopic or vaginal procedures for benign gynecologic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/9\">",
"     9",
"    </a>",
"    ]. A systematic review found no evidence of improvement in effectiveness or safety with robotic surgery based upon two small randomized trials, one of which was published as an abstract and did not include details of study methodology [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/10\">",
"     10",
"    </a>",
"    ]. Another meta-analysis that included 22 observational studies, mostly retrospective, compared robotic surgery with other approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/11\">",
"     11",
"    </a>",
"    ]. Robotic surgery compared with open surgery was associated with significant decreases in blood loss and length of hospital stay. Compared with conventional laparoscopy, the only significant difference for robotic surgery was a decrease in blood loss and fewer conversions to open surgery for endometrial cancer staging.",
"   </p>",
"   <p>",
"    Use of robot-assisted laparoscopy for specific procedures is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/48/8970?source=see_link&amp;anchor=H1198933#H1198933\">",
"     \"Laparoscopic myomectomy and other laparoscopic treatments for uterine leiomyomas (fibroids)\", section on 'Robot-assisted laparoscopy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12393?source=see_link&amp;anchor=H10499406#H10499406\">",
"     \"Oophorectomy and ovarian cystectomy\", section on 'Use of robotic or single port laparoscopy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18810?source=see_link&amp;anchor=H17#H17\">",
"     \"Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment\", section on 'Robot-assisted or single port laparoscopy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19001?source=see_link&amp;anchor=H37208931#H37208931\">",
"     \"Operative management of achalasia: Laparoscopic and open Heller myotomy\", section on 'Robotic surgery'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/39/5749?source=see_link\">",
"     \"Laparoscopic/robotic-assisted radical cystectomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/22/14698?source=see_link&amp;anchor=H24766120#H24766120\">",
"     \"Laparoscopic approach to hysterectomy\", section on 'Robot-assisted laparoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Advantages of robotic surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major advantages of robot-assisted over conventional laparoscopy are [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Superior visualization &mdash; Three-dimensional (3D) versus two-dimensional (2D) imaging of the operative field.",
"     </li>",
"     <li>",
"      Mechanical improvements &mdash; A fulcrum effect is created when rigid conventional instruments pass through the incision, thereby leading to inversion of movement from the surgeon's hand to the working end of the instrument [",
"      <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/13\">",
"       13",
"      </a>",
"      ]. When an instrument is introduced into a trocar, the abdominal wall is the fulcrum. When a surgeon&rsquo;s hand moves in one direction, the instrument moves in the opposite direction. If a patient is obese, there is more torque placed on an instrument and the rigid smaller caliber instruments, such as laparoscopes, may fracture. Robotic instruments are less likely to break, thus, many surgeons prefer robot-assisted laparoscopy in obese patients. This is because all robotic instruments are 8 mm wide and attached to the robotic arms, which in turn are attached to the robotic cannulas (trocars). The force that the abdominal wall places on each instrument is sustained by the trocar and mechanical robotic arm. The robotic laparoscope is 11 mm in diameter and is also introduced through a trocar, which is docked to the robotic scope arm. In contrast, conventional laparoscopy is performed with 3 or 5 mm instruments that are introduced through smaller trocars.",
"      <br/>",
"      <br/>",
"      Also, robotic instruments have seven degrees of freedom, similar to the human arm and hand, while rigid conventional instruments have four degrees of freedom. While there are newer flexible laparoscopic needle holders which move in seven degrees (eg, Autonomy Laparo-Angle&trade;), movements with these are not intuitive and their use requires additional training [",
"      <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Stabilization of instruments within the surgical field &mdash; In conventional laparoscopy, small movements by the surgeon are amplified (including errors or hand tremor). Robot-assisted surgery minimizes surgeon tremor. &nbsp;",
"     </li>",
"     <li>",
"      Improved ergonomics for the operating surgeon &mdash; The surgeon can be seated with telerobotic systems [",
"      <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. In an observational study, 8 to 12 percent of surgeons reported pain and numbness in their arms, wrists, or shoulders after performing conventional laparoscopic gastrointestinal surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/6\">",
"       6",
"      </a>",
"      ]. Additionally, all surgeons can perform robot-assisted procedures in a seated position, rather than standing at the operating table. This avoidance of long-term standing during surgery may be particularly helpful to surgeons who are pregnant or have orthopedic limitations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Limitations of robotic surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The limitations of robotic technology include [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Additional surgical training",
"     </li>",
"     <li>",
"      Increased costs and operating room time",
"     </li>",
"     <li>",
"      Bulkiness of the devices",
"     </li>",
"     <li>",
"      Instrumentation limitations (eg, lack of a robotic suction and irrigation device, size, cost)",
"     </li>",
"     <li>",
"      Lack of haptics (tactile feedback)",
"     </li>",
"     <li>",
"      Risk of mechanical failure",
"     </li>",
"     <li>",
"      Limited number of energy sources (ie, less than with conventional laparoscopy)",
"     </li>",
"     <li>",
"      Not designed for abdominal surgery involving more than two quadrants (the device needs to be re-docked and repositioned to operate in the quadrants it is not facing)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Robotic surgical systems are designed with features intended to minimize the potential effects of mechanical failures on patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/12\">",
"     12",
"    </a>",
"    ]. Such features include system redundancy, so-called ''graceful'' performance degradation or failure, fault tolerance, just-in-time maintenance, and system alerting. In simplified terms, there are several mechanical checks and balances built into current robotic surgical systems so that the risk of mechanical failure is minimized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ROBOTIC DEVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two active functional robots are used currently: the robotic camera holder (AESOP&reg;) and immersive telerobotic surgical system (da Vinci&reg;). An integrated robotic surgical system (Zeus) which included AESOP&reg; is no longer available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Robotic camera holder",
"    </span>",
"    &nbsp;&mdash;&nbsp;The robotic camera holder (AESOP&reg;) holds and controls the laparoscopic camera. Of note, it is being phased out. AESOP&reg; was initially introduced with surgeon-operated foot switch or hand control [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/17,18\">",
"     17,18",
"    </a>",
"    ] and was later modified to respond to voice commands with a 23-word vocabulary [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    AESOP&reg; provides a steady platform for the camera and eliminates the need for a human camera holder. Thus, the surgeon has an additional free hand to control instruments, making it possible to operate without an assistant",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    to use an additional port site. In a prospective case series of 50 women undergoing routine gynecologic procedures, similar operative times were demonstrated with AESOP&reg; use compared to a surgical assistant holding the laparoscope [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/20\">",
"     20",
"    </a>",
"    ]. The use of AESOP&reg; has decreased significantly since the da Vinci&reg; surgical system has become widely utilized; however, AESOP&reg; is still in use and has been instrumental for some surgeons in single port laparoscopy. There is also the ViKY&reg; system that offers vision control of the laparoscope and eliminates the need for a surgical assistant to position the camera [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Immersive telerobotic surgical system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery using this system is performed by a surgeon seated at a console remote from the operative field.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Surgical equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most widely used system is the da Vinci&reg; system. Equipment for this system includes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/16,21\">",
"     16,21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgeon's console (three-dimensional [3D] immersive video screen, hand and foot controls, and seat) with",
"      <span class=\"nowrap\">",
"       master/slave",
"      </span>",
"      software system whereby the surgeon directs the movement of robotic arms (",
"      <a class=\"graphic graphic_picture graphicRef56565 \" href=\"UTD.htm?17/10/17570\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Surgical cart (three or four robotic arms and seven-degree laparoscopic instruments) (",
"      <a class=\"graphic graphic_picture graphicRef68297 \" href=\"UTD.htm?19/40/20098\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Equipment cart (camera [surgeon views 3D images, other monitors display 2D images], light source, energy devices [eg, electrocautery]) (",
"      <a class=\"graphic graphic_picture graphicRef79637 \" href=\"UTD.htm?34/33/35346\">",
"       picture 3",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, surgical instruments have been developed to use with either the da Vinci&reg; system (VeSPA) or alone (ViKY&reg;) for single port laparoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/5,22\">",
"     5,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9029?source=see_link&amp;anchor=H1115365#H1115365\">",
"     \"Laparoendoscopic single-site (single port) surgery\", section on 'Single-site robotic surgery'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31770?source=see_link\">",
"     \"Abdominal access techniques used in laparoscopic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     OPERATIVE PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initially, the patient is positioned and prepped similarly to conventional laparoscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22903905\">",
"    <span class=\"h2\">",
"     Laparoscopic access",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to docking the robot, it may be appropriate to use a conventional laparoscope to explore the entire abdomen. In some circumstances, conventional laparoscopy can be used to free adhesions, or mobilize bowel, to allow the needed ports for the robot. Simply because a robotic procedure is planned, it does not mean that conventional laparoscopy cannot be used initially, or subsequently. The following incisions are made (",
"    <a class=\"graphic graphic_figure graphicRef77622 \" href=\"UTD.htm?29/55/30579\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef66829 \" href=\"UTD.htm?17/59/18358\">",
"     picture 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      12 mm midline upper abdominal &ndash; laparoscope port; placement is at least 20 cm superior to the pubic symphysis and at least 8 to 10 cm superior to the uterine fundus.",
"     </li>",
"     <li>",
"      8 mm lateral lower abdominal &ndash; robotic accessory ports; two ports placed bilaterally, inferior and 8 to 12 cm lateral to the laparoscope port (ie, midclavicular line, lateral to the rectus muscle, making a 15- to 30-degree angle); if the fourth robotic arm (the third operating arm) is used, then this port is placed 8 to 12 cm lateral (at the same level or cephalad) to the previously placed robotic port (either on the right or left side, depending on the surgeon's needs; this distance between ports is needed to avoid collision of the robotic arms).",
"     </li>",
"     <li>",
"      10 mm lateral upper abdominal &ndash; conventional accessory port (ie, for",
"      <span class=\"nowrap\">",
"       suction/irrigation,",
"      </span>",
"      introduction of sutures, removal of specimens); placed on the left or right side of the patient, superior and medial to the ipsilateral robotic accessory port.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The robotic arms are attached to these ports and, after this point, the operating table is no longer moved. During the surgery, the assistants stand at the patient's side and change the instruments.",
"   </p>",
"   <p>",
"    The robot tower that has the robotic arms has traditionally been placed between the patient&rsquo;s legs (",
"    <a class=\"graphic graphic_figure graphicRef83552 \" href=\"UTD.htm?14/16/14597\">",
"     figure 2",
"    </a>",
"    ). Some robot models can be &ldquo;side docked&rdquo; (",
"    <a class=\"graphic graphic_figure graphicRef83551 \" href=\"UTD.htm?6/41/6805\">",
"     figure 3",
"    </a>",
"    ), allowing free access to the lower abdominal quadrant and pelvic structures (eg, vagina, perineum). Side docking can be performed with the robot tower positioned 45 degrees to the patient&rsquo;s left or right leg stirrup or in parallel to the patient&rsquo;s bed. For gynecologic surgery, side docking has been reported to improve access to the vagina and perineum and reduce assistant fatigue and the potential for injury due to a collision with the robotic arms. In our practice, we perform parallel side docking of the robot tower in the majority of procedures due to improved efficiency and ease and greater access to the vagina and perineum [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H240170\">",
"     'Vaginal access for gynecologic surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The surgeon is seated at a console, views the operative field via a binocular device, and places his or her hands in the \"masters\" hand controls, which translate the movements of the surgeon's hands into an electric signal which travels via a cord to the surgical cart and activates the robotic arms. These \"masters\" can be modified to adjust the ratio of motion of the surgeon's hand to that of the robotic arms (motion scaling). As an example, a 3:1 ratio allows for every 3 cm of movement by the surgeon, only 1 cm movement by the robotic arm. Another &ldquo;masters&rdquo; modification adjusts the speed at which the instruments move. The hand controls also filter hand tremors, resulting in error reduction and more efficient suturing and dissection.",
"   </p>",
"   <p>",
"    The surgeon supinates and pronates his or her hands while stepping on the camera foot pedal to focus the picture. There are buttons on the hand controls to clutch the arms and thus the instruments in order to improve instrument precision. The dual console system improves a surgeon&rsquo;s ability to teach a trainee because both surgeons are able to sit at a console simultaneously, visualize the operative field in 3D, and swap control of various instruments.",
"   </p>",
"   <p>",
"    Foot pedals control the camera, energy devices, and \"masters.\" The pedals act to toggle each of these functions (ie, if you press on the camera foot pedal, the movement of the hand controls moves the camera in the same direction; if you press down on another foot pedal [monopolar or bipolar], you activate an energy source).",
"   </p>",
"   <p>",
"    The robotic arms, located on the surgical cart, are attached to surgical instruments through a robotic instrument adapter. A 12 mm telescope is connected to the central robotic arm and contains two 5 mm telescopes, producing three-dimensional (3D) vision (",
"    <a class=\"graphic graphic_picture graphicRef55100 \" href=\"UTD.htm?41/23/42365\">",
"     picture 5",
"    </a>",
"    ). Each instrument passes through a reusable 8 mm system-specific port [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/2\">",
"     2",
"    </a>",
"    ]. Some robotic ports have valves which allow insufflation through the robotic trocar.",
"   </p>",
"   <p>",
"    Disadvantages of the da Vinci&reg; system are similar to those of other robotic systems, including a lack of tactile feedback and the bulkiness of equipment (restricts placement of accessory ports in small patients and movement of operating room staff), limited instrumentation, and difficulty changing the patient's position. Cost remains a major drawback, which in the current economic environment cannot be underestimated.",
"   </p>",
"   <p>",
"    Two additional systems include the da Vinci-S&reg; (a slimmer version) and the da Vinci-S-HD&reg;, which includes a touch screen monitor, telestration to improve mentoring and surgical team communication, and a multi-input display that integrates additional patient critical information (eg, a view of radiographic images superimposed on the operative field) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H240170\">",
"    <span class=\"h2\">",
"     Vaginal access for gynecologic surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;With use of side docking of the surgical robot, vaginal access is similar to access for conventional laparoscopy with an assistant seated between the patient&rsquo;s legs.",
"   </p>",
"   <p>",
"    There are several available uterine and vaginal manipulators (eg, RUMI&reg;, ZUMI&trade;, KOH Colpotomizer&trade;, VCare&reg;, Valtchev&reg;, Pelosi). Placement of the uterine manipulator is performed during set up of laparoscopic equipment. Some of these can be attached to a device that is placed between the patient&rsquo;s legs, thus replacing the role of a vaginal surgical assistant. As an example, RUMI&reg; instruments are attached to the Uterine Positioning System&trade;. With this system, the device is held in place by one or two stitches in the cervix. The VCare&reg; and Valchev&reg; manipulators do not require stay sutures. Choice of uterine manipulator is a matter of surgeon preference.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     TELEROBOTICS IN EDUCATION AND SIMULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical simulation, telementoring, and telepresence surgery are potential novel benefits of robotic technology. Physical distance between an expert surgeon in a telementoring or telepresence set-up requires safeguards in case of mechanical failure or surgical complication (eg, latency of signal from mentoring to operating surgeon, redundancy of internet lines), although these have not yet been established.",
"   </p>",
"   <p>",
"    Robot workstations can transmit video and audio information to a surgical simulator [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/12,24\">",
"     12,24",
"    </a>",
"    ]. Robotic simulation could allow rehearsal of procedures with the potential for reduction in complication rates and learning curves, and even for the development of new technical approaches. In addition to providing input integration of imaging registered with an interventional robotic platform, robots can capture data regarding how a surgeon performs specific tasks. However, these systems are still under investigation and cost is a significant issue. Various virtual reality teaching programs are in the development and testing phase, but are not in wide use.",
"   </p>",
"   <p>",
"    Telementoring provides the ability for an experienced physician at a remote site to be able to mentor a less experienced surgeon in training or in real time [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. As an example, in one report, transmission or audio and three-dimensional (3D) video with telestration between a group of surgeons in the United States and Italy allowed telementoring of urologic procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/25\">",
"     25",
"    </a>",
"    ]. However, this function was provided only by the Zeus system, which is no longer available. When two consoles are available with the da Vinci&reg; Si system, the surgeon is able to mentor another surgeon by maintaining control of various instruments and swapping instruments. There are no published data yet to support routine use of a dual console system compared to an attending surgeon standing at bedside to assist a training surgeon.",
"   </p>",
"   <p>",
"    Telepresence surgery is another innovation which may be possible with robotic technology. The largest series (n = 21) is from Canada, where a group of general hospital surgeons performed surgery at a distance of 400 km using the Zeus system [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/29\">",
"     29",
"    </a>",
"    ]. There were no conversions to laparotomy, however, a skilled surgeon was present at the remote site to manage complications and complete the surgery conventionally, if necessary. Information was transmitted using commercially available internet lines with a signal latency of 135 to 140 milliseconds, which was easily perceived by the surgeons. The US Food and Drug Administration (FDA) requires that all operations using a telerobotic system are performed in the same room as the patient.",
"   </p>",
"   <p>",
"    The speed of information transmission is a key element in telepresence surgery. Surgeons are able to complete tasks with a delay in operating room to console signal transmission of up to 500 milliseconds [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     ISSUES IN IMPLEMENTING A ROBOTIC SURGERY PROGRAM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major obstacles to the clinical use of robots are cost, training of physicians and nursing teams, and lack of outcome data [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/12\">",
"     12",
"    </a>",
"    ]. There is no doubt that robotic technology is fulfilling its promise to allow both generalists and subspecialists to gain competence in complex laparoscopic procedures. This is particularly the case for surgeons who have not had training or experience in complex conventional laparoscopic procedures that involve laparoscopic suturing, knot-tying, ureterolysis, retroperitoneal dissection, and minimally invasive hysterectomy for the enlarged uterus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19939567\">",
"    <span class=\"h2\">",
"     Is robotic surgery included in surgical training programs?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Training and credentialing standards have not yet been established for robotic surgeons [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/12,14,31\">",
"     12,14,31",
"    </a>",
"    ]. Robotic training programs have become part of many surgical residency programs, but it is not standardized across the board. Currently, there are no guidelines or standard requirements for robot-assisted laparoscopy training in residencies, although a committee has been set up by the device industry to develop criteria for a training curriculum. Some residents and fellows will be trained as part of this curriculum and it is at the discretion of the residency or fellowship director whether the trainee is competent or not. There are no standardized criteria in hospitals across the United States to discern whether a surgeon coming out of training or from another institution should receive robotic privileges. The time is fast approaching that newly introduced procedures in a resident&rsquo;s or fellow&rsquo;s training may be performed using robot-assisted laparoscopy rather than laparotomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19939604\">",
"    <span class=\"h2\">",
"     How should a surgeon in practice learn robotic surgical skills?",
"    </span>",
"    &nbsp;&mdash;&nbsp;A surgeon must set up three robotic cases prior to scheduled training in an animal lab at various robotic-training centers so that he or she immediately implements the training and reinforces what",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    learns in the animate or cadaver lab. The trainee is also required to pass an online training test in order to obtain a certificate that documents",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    training experience. The number of mentored patient procedures leading to independent practice varies from institution to institution and will likely be individualized based on surgical experience and technical ability. Additionally, many institutions are imposing a certain volume of cases so that surgeons maintain a competent skill level, although individual differences in acquiring skills make an arbitrary number of completed cases illogical. Additionally, performance of one type of pelvic surgery does not necessarily mean another type of pelvic procedure can also be performed safely. Credentialing requirements vary among institutions and many institutions are in the process or have recently established criteria for credentialing surgeons to perform procedures on robotic platforms. Finally, in the United States, there is no current residency curriculum requirement established by the Residency Review Committee for robotic-assisted surgery.",
"   </p>",
"   <p>",
"    Surgical learning curves depend on two aspects of surgical volume: total number of procedures performed and the time interval between procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Experience from urologic surgery suggests that acquiring robotic skills is possible with intensive training (eg, a five-day course) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/34-36\">",
"     34-36",
"    </a>",
"    ], but further study is needed for other surgical specialties. Proficiency in a new procedure includes both the procedure itself and the ability to manage complications [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/32\">",
"     32",
"    </a>",
"    ]. In addition, safe surgical practice also depends upon continued surgical volume after training, just as for open procedures. Additionally, most experts agree that a surgeon should be competent in performing a procedure via laparotomy before learning a robotic approach. However, there may come a time in the future that most open surgeries are converted to minimally invasive surgery and thus, trainees will perform a particular procedure solely with robot-assisted or conventional laparoscopy.",
"   </p>",
"   <p>",
"    In studies of robot-assisted laparoscopic hysterectomy, 15 to 70 cases were required to achieve an operating time of approximately two hours [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/7,37,38\">",
"     7,37,38",
"    </a>",
"    ]. Similarly, a case series of 113 robot-assisted procedures performed by two surgeons with advanced laparoscopy skills found that set-up time, operative time, and blood loss improved until approximately 50 cases had been performed, and then stabilized [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Are surgical robots cost-effective?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Robotic surgery is expensive. The da Vinci&reg; system currently costs over $1.75 million and each instrument attached to the robotic arm costs between $2200 and $3200 and requires replacement after 10 uses. For example, in our practice, for a robot-assisted sacral colpopexy, we use several scissors, forceps, and needle drivers, which each cost $220 to $320 per case, for a total procedure cost of $1270.",
"   </p>",
"   <p>",
"    Results of cost-effectiveness analyses vary by whether single-procedure or overall robotic costs are included and by a hospital's surgical volume [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27176/abstract/40\">",
"     40",
"    </a>",
"    ]. Costs incurred by robotic surgery include capital acquisition, limited use instruments, team training expenses, equipment maintenance, equipment repair, and operating room set-up time. As noted above, robot-assisted cases cost approximately $2000 more per case than the same procedure performed by conventional laparoscopy (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Robotic versus other surgical approaches'",
"    </a>",
"    above). In the era of healthcare reform, this elevated cost may be the greatest detriment to continued implementation of robotic surgery. More prospective studies are required to analyze overall costs (direct and indirect) of robot-assisted procedures to health care systems. Further investigation is warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A surgical robot is a computer-controlled device that can be programmed to aid the positioning and manipulation of surgical instruments. The goal of robotic gynecologic surgery is to use a minimally invasive approach to perform procedures which are generally performed by laparotomy or are too complex for conventional laparoscopy or surgeons who are novices in laparoscopic surgery. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Advantages of robotic over conventional laparoscopy include three-dimensional (3D) imaging, mechanical improvement (eg, instruments with seven degrees of freedom), stabilization of instruments within the surgical field, and improved ergonomics. The major advantage to the patient is a potentially shorter hospital stay, and more rapid postoperative recovery and return to full function. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Advantages of robotic surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The limitations of robotic technology include high costs and increased operating room time, lack of tactile feedback, large size of the devices, and risk of mechanical failure. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Limitations of robotic surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two robotic systems are available: the robotic camera holder and immersive telerobotic surgical system. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Robotic devices'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical simulation, telementoring (guidance given to the surgeon by another surgeon who is not in the operating room), and telepresence surgery (surgery performed via a robot by a surgeon who is not in the operating room) are potential novel benefits of robotic technology. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Telerobotics in education and simulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some obstacles to the clinical use of robots are cost, physician and nursing team training, and need for more outcome data. Further evaluation and implementation will determine the role of robot-assisted laparoscopy. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Issues in implementing a robotic surgery program'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/1\">",
"      Kim YT, Kim SW, Jung YW. Robotic surgery in gynecologic field. Yonsei Med J 2008; 49:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/2\">",
"      Dharia SP, Falcone T. Robotics in reproductive medicine. Fertil Steril 2005; 84:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/3\">",
"      Satava RM. Robotic surgery: from past to future--a personal journey. Surg Clin North Am 2003; 83:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/4\">",
"      Falcone T, Goldberg J, Garcia-Ruiz A, et al. Full robotic assistance for laparoscopic tubal anastomosis: a case report. J Laparoendosc Adv Surg Tech A 1999; 9:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/5\">",
"      Hung AJ, Abreu AL, Shoji S, et al. Robotic transrectal ultrasonography during robot-assisted radical prostatectomy. Eur Urol 2012; 62:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/6\">",
"      Berguer R, Forkey DL, Smith WD. Ergonomic problems associated with laparoscopic surgery. Surg Endosc 1999; 13:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/7\">",
"      Kho RM, Hilger WS, Hentz JG, et al. Robotic hysterectomy: technique and initial outcomes. Am J Obstet Gynecol 2007; 197:113.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/8\">",
"      Hur HC, Donnellan N, Mansuria S, et al. Vaginal cuff dehiscence after different modes of hysterectomy. Obstet Gynecol 2011; 118:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/9\">",
"      AAGL Advancing Minimally Invasive Gynecology Worldwide. AAGL position statement: Robotic-assisted laparoscopic surgery in benign gynecology. J Minim Invasive Gynecol 2013; 20:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/10\">",
"      Liu H, Lu D, Wang L, et al. Robotic surgery for benign gynaecological disease. Cochrane Database Syst Rev 2012; 2:CD008978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/11\">",
"      Reza M, Maeso S, Blasco JA, Andradas E. Meta-analysis of observational studies on the safety and effectiveness of robotic gynaecological surgery. Br J Surg 2010; 97:1772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/12\">",
"      Herron DM, Marohn M, SAGES-MIRA Robotic Surgery Consensus Group. A consensus document on robotic surgery. Surg Endosc 2008; 22:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/13\">",
"      Oppenheimer P, Weghorst S, MacFarlane M, Sinanan M. Immersive surgical robotic interfaces. Stud Health Technol Inform 1999; 62:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/14\">",
"      Usui S, Inoue H, Yoshida T, et al. Preliminary report of multi degrees of freedom forceps for endoscopic surgery. Surg Laparosc Endosc Percutan Tech 2004; 14:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/15\">",
"      Stylopoulos N, Rattner D. Robotics and ergonomics. Surg Clin North Am 2003; 83:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/16\">",
"      Sroga J, Patel SD, Falcone T. Robotics in reproductive medicine. Front Biosci 2008; 13:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/17\">",
"      Sackier JM, Wang Y. Robotically assisted laparoscopic surgery. From concept to development. Surg Endosc 1994; 8:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/18\">",
"      Jacobs LK, Shayani V, Sackier JM. Determination of the learning curve of the AESOP robot. Surg Endosc 1997; 11:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/19\">",
"      Ballantyne GH. Robotic surgery, telerobotic surgery, telepresence, and telementoring. Review of early clinical results. Surg Endosc 2002; 16:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/20\">",
"      Mettler L, Ibrahim M, Jonat W. One year of experience working with the aid of a robotic assistant (the voice-controlled optic holder AESOP) in gynaecological endoscopic surgery. Hum Reprod 1998; 13:2748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/21\">",
"      Ballantyne GH, Moll F. The da Vinci telerobotic surgical system: the virtual operative field and telepresence surgery. Surg Clin North Am 2003; 83:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/22\">",
"      Haber GP, White MA, Autorino R, et al. Novel robotic da Vinci instruments for laparoendoscopic single-site surgery. Urology 2010; 76:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/23\">",
"      Einarsson JI, Hibner M, Advincula AP. Side docking: an alternative docking method for gynecologic robotic surgery. Rev Obstet Gynecol 2011; 4:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/24\">",
"      Haluck RS, Krummel TM. Computers and virtual reality for surgical education in the 21st century. Arch Surg 2000; 135:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/25\">",
"      Micali S, Virgili G, Vannozzi E, et al. Feasibility of telementoring between Baltimore (USA) and Rome (Italy): the first five cases. J Endourol 2000; 14:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/26\">",
"      Panait L, Rafiq A, Tomulescu V, et al. Telementoring versus on-site mentoring in virtual reality-based surgical training. Surg Endosc 2006; 20:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/27\">",
"      Sebajang H, Trudeau P, Dougall A, et al. The role of telementoring and telerobotic assistance in the provision of laparoscopic colorectal surgery in rural areas. Surg Endosc 2006; 20:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/28\">",
"      Rashid HH, Leung YY, Rashid MJ, et al. Robotic surgical education: a systematic approach to training urology residents to perform robotic-assisted laparoscopic radical prostatectomy. Urology 2006; 68:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/29\">",
"      Anvari M, McKinley C, Stein H. Establishment of the world's first telerobotic remote surgical service: for provision of advanced laparoscopic surgery in a rural community. Ann Surg 2005; 241:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/30\">",
"      Anvari M, Broderick T, Stein H, et al. The impact of latency on surgical precision and task completion during robotic-assisted remote telepresence surgery. Comput Aided Surg 2005; 10:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/31\">",
"      Robot-assisted surgery. ACOG Technology Assessment in Obstetrics and Gynecology No. 6. American College of Obstetricians and Gynecologists. Obstet Gynecol 2009; 114:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/32\">",
"      Whiteside JL. Robotic gynecologic surgery: a brave new world? Obstet Gynecol 2008; 112:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/33\">",
"      Woelk JL, Casiano ER, Weaver AL, et al. The learning curve of robotic hysterectomy. Obstet Gynecol 2013; 121:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/34\">",
"      Artibani W, Fracalanza S, Cavalleri S, et al. Learning curve and preliminary experience with da Vinci-assisted laparoscopic radical prostatectomy. Urol Int 2008; 80:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/35\">",
"      Vlaovic PD, Sargent ER, Boker JR, et al. Immediate impact of an intensive one-week laparoscopy training program on laparoscopic skills among postgraduate urologists. JSLS 2008; 12:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/36\">",
"      Kaul S, Shah NL, Menon M. Learning curve using robotic surgery. Curr Urol Rep 2006; 7:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/37\">",
"      Payne TN, Dauterive FR. A comparison of total laparoscopic hysterectomy to robotically assisted hysterectomy: surgical outcomes in a community practice. J Minim Invasive Gynecol 2008; 15:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/38\">",
"      Seamon LG, Cohn DE, Richardson DL, et al. Robotic hysterectomy and pelvic-aortic lymphadenectomy for endometrial cancer. Obstet Gynecol 2008; 112:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/39\">",
"      Lenihan JP Jr, Kovanda C, Seshadri-Kreaden U. What is the learning curve for robotic assisted gynecologic surgery? J Minim Invasive Gynecol 2008; 15:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27176/abstract/40\">",
"      Liberman D, Trinh QD, Jeldres C, Zorn KC. Is robotic surgery cost-effective: yes. Curr Opin Urol 2012; 22:61.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3297 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-FA0D210239-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_34_27176=[""].join("\n");
var outline_f26_34_27176=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HISTORY OF SURGICAL ROBOTICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ROBOTIC VERSUS OTHER SURGICAL APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Advantages of robotic surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Limitations of robotic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ROBOTIC DEVICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Robotic camera holder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Immersive telerobotic surgical system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Surgical equipment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      OPERATIVE PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22903905\">",
"      Laparoscopic access",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H240170\">",
"      Vaginal access for gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      TELEROBOTICS IN EDUCATION AND SIMULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      ISSUES IN IMPLEMENTING A ROBOTIC SURGERY PROGRAM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19939567\">",
"      Is robotic surgery included in surgical training programs?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19939604\">",
"      How should a surgeon in practice learn robotic surgical skills?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Are surgical robots cost-effective?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3297\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3297|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/55/30579\" title=\"figure 1\">",
"      Robotic laparoscopy ports",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/16/14597\" title=\"figure 2\">",
"      Surgical Robot Between the Legs Docking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/41/6805\" title=\"figure 3\">",
"      Surgical Robot Side Docking",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3297|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/10/17570\" title=\"picture 1\">",
"      Robotic surg console",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/40/20098\" title=\"picture 2\">",
"      Robotic surg robot arms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/33/35346\" title=\"picture 3\">",
"      Robot surg immersive syst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/59/18358\" title=\"picture 4\">",
"      Robot surg ports",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/23/42365\" title=\"picture 5\">",
"      Robot surg laparoscope",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31770?source=related_link\">",
"      Abdominal access techniques used in laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18810?source=related_link\">",
"      Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9029?source=related_link\">",
"      Laparoendoscopic single-site (single port) surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/22/14698?source=related_link\">",
"      Laparoscopic approach to hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/48/8970?source=related_link\">",
"      Laparoscopic myomectomy and other laparoscopic treatments for uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/39/5749?source=related_link\">",
"      Laparoscopic/robotic-assisted radical cystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12393?source=related_link\">",
"      Oophorectomy and ovarian cystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19001?source=related_link\">",
"      Operative management of achalasia: Laparoscopic and open Heller myotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41990?source=related_link\">",
"      Vaginal cuff dehiscence after hysterectomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_34_27177="Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)";
var content_f26_34_27177=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/34/27177/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/34/27177/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/34/27177/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/34/27177/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/34/27177/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/34/27177/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/34/27177/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/34/27177/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/34/27177/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eosinophilic granulomatosis with polyangiitis (Churg-Strauss), abbreviated EGPA, which was previously called the Churg-Strauss syndrome (CSS) or allergic granulomatosis and angiitis, is a multisystem disorder characterized by chronic rhinosinusitis, asthma, and prominent peripheral blood eosinophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. EGPA is classified as a vasculitis of the small and medium sized arteries, although the vasculitis is often not apparent in the initial phases of the disease.",
"   </p>",
"   <p>",
"    The most commonly involved organ is the lung, followed by the skin. EGPA, however, can affect any organ system, including the cardiovascular, gastrointestinal, renal, and central nervous systems. Vasculitis of extrapulmonary organs is largely responsible for the morbidity and mortality associated with EGPA.",
"   </p>",
"   <p>",
"    The clinical features and diagnosis of EGPA will be reviewed here. The epidemiology, pathogenesis, treatment, and prognosis of this disorder, as well as the approach to patients with vasculitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    eosinophilia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=see_link\">",
"     \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/33/35353?source=see_link\">",
"     \"Treatment and prognosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link\">",
"     \"Classification of and approach to the vasculitides in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24745?source=see_link\">",
"     \"Approach to the patient with eosinophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Phases of disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of EGPA typically develop in several sequential phases, although these phases are not always clearly distinguishable [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prodromal phase &ndash; The prodromal phase occurs among individuals in the second and third decades of life and is characterized by atopic disease, allergic rhinitis, and asthma.",
"     </li>",
"     <li>",
"      Eosinophilic phase &ndash; Features of the eosinophilic phase include peripheral blood eosinophilia and eosinophilic infiltration of multiple organs, especially the lung and gastrointestinal tract. Almost 40 percent of patients with EGPA present with pulmonary opacities, asthma, and peripheral eosinophilia prior to the development of a systemic vasculitis (polyangiitis) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vasculitic phase &ndash; In the third and fourth decades of life, a life-threatening systemic vasculitis of the medium and small vessels frequently occurs, and is often associated with vascular and extravascular granulomatosis [",
"      <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/6\">",
"       6",
"      </a>",
"      ]. The vasculitic phase may be heralded by nonspecific constitutional symptoms and signs, especially fever, weight loss, malaise, and lassitude.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Asthma and lung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asthma is the cardinal clinical feature of EGPA and is present in more than 90 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/10\">",
"     10",
"    </a>",
"    ]. Asthma usually precedes the vasculitic phase by approximately 8 to 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/6,11\">",
"     6,11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Phases of disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    EGPA is typically suspected in patients whose asthma is poorly controlled on moderate doses of inhaled glucocorticoids; many patients diagnosed with EGPA require frequent or long-term courses of systemic glucocorticoids to control their asthma. As the vasculitic phase begins, asthma severity and the number of exacerbations may increase. Rarely, the asthma symptoms lessen in the early stages of the vasculitic phase.",
"   </p>",
"   <p>",
"    Prolonged treatment of asthma with glucocorticoid therapy may partially or totally suppress the usual clinical signs of untreated EGPA. The disease may therefore not become evident until glucocorticoids are reduced or stopped [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other pulmonary findings are reported in 50 to 70 percent and include pulmonary opacities with eosinophilia, pleural effusion (often eosinophilic), nodules that are rarely cavitary, and alveolar hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/3\">",
"     3",
"    </a>",
"    ]. In one series, venous thromboembolic disease was noted in 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Upper airway and ear disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ear, nose, and throat involvement, including serous otitis, allergic rhinitis, nasal obstruction, recurrent sinusitis, and nasal polyposis, is reported in 48 percent of patients with EGPA [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/10,14\">",
"     10,14",
"    </a>",
"    ]. In a series of 29 patients with EGPA, nasal polyposis was detected in 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/15\">",
"     15",
"    </a>",
"    ]. Prior to the onset of eosinophilic infiltration of the lung or other organs, the characteristics of these patients overlap considerably with those associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    -exacerbated respiratory disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\", section on 'CRS with nasal polyposis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39944?source=see_link\">",
"     \"Aspirin exacerbated respiratory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic serous otitis and sensorineural hearing loss are occasionally seen in EGPA and likely reflect the severity of rhinosinusitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Necrotizing lesions of the nasopharynx and upper airway are more characteristic of granulomatosis with polyangiitis (Wegener's), and are unusual in EGPA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin involvement is one of the most common features of the vasculitic phase of EGPA. Half to two-thirds of patients with EGPA have skin lesions, which usually appear as tender subcutaneous nodules on the extensor surfaces of the arm, particularly the elbows, hands, and legs (",
"    <a class=\"graphic graphic_picture graphicRef52628 \" href=\"UTD.htm?10/45/10961\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/3,18\">",
"     3,18",
"    </a>",
"    ]. Biopsy of these lesions usually reveals granulomas. The pathology of cutaneous EGPA is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=see_link&amp;anchor=H11#H11\">",
"     \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\", section on 'Pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Skin lesions can also appear as palpable purpura, a macular or papular erythematous rash, and hemorrhagic lesions, ranging from petechiae to extensive ecchymosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cardiovascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac involvement is one of the more serious manifestations of EGPA, accounting for approximately one-half of deaths attributable to EGPA [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Clinical manifestations include clinical signs of heart failure or pericarditis and cardiac rhythm abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/20,22\">",
"     20,22",
"    </a>",
"    ]. Patients with cardiac involvement typically have a shorter duration of EGPA related symptoms than those without. Cardiac involvement is more frequent in patients with higher eosinophil counts at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/20,23\">",
"     20,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a series of 383 patients with EGPA, 16 percent had a cardiomyopathy and 15 percent had pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/10\">",
"     10",
"    </a>",
"    ]. In a separate series of 22 patients with evidence of cardiac involvement, cardiac abnormalities included an abnormal ECG in all patients; valvular insufficiency, pericardial effusion, and heart failure were noted in 73, 50, and 41 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/20\">",
"     20",
"    </a>",
"    ]. Endomyocardial involvement was found in 12 patients based on cardiac MRI findings of mural thrombus and a positive endomyocardial biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/20\">",
"     20",
"    </a>",
"    ]. The majority of patients improved with treatment, although 2 of the patients with endomyocardial disease died of heart failure. Patients with cardiac involvement were less likely to have a positive ANCA and more likely to have higher peripheral blood eosinophil counts than other EGPA patients.",
"   </p>",
"   <p>",
"    The use of various cardiovascular tests to evaluate myocardial EGPA and the typical biopsy findings seen on endomyocardial biopsy are discussed separately. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Cardiovascular tests'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=see_link&amp;anchor=H11#H11\">",
"     \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\", section on 'Pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H280932879\">",
"    <span class=\"h2\">",
"     Thromboembolic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CSS appear to be at increased risk for venous thromboembolism, similar to that seen in other systemic vasculitides. In a retrospective study of 232 patients with CSS, the risk of VTE was 8 percent and did not differ significantly between those who were ANCA positive or not [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Neurologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;A peripheral neuropathy, usually mononeuritis multiplex, is seen in up to 75 percent of patients with EGPA [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/3,6,25-27\">",
"     3,6,25-27",
"    </a>",
"    ]. Untreated, this may progress to a symmetric or asymmetric polyneuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/28\">",
"     28",
"    </a>",
"    ]. Severe neuropathic pain may accompany the peripheral neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/27\">",
"     27",
"    </a>",
"    ]. A more detailed description of vasculitic neuropathy is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22423?source=see_link\">",
"     \"Clinical manifestations of vasculitic neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, subarachnoid and cerebral hemorrhage, and cerebral infarction are reported, but rare [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/6,29,30\">",
"     6,29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Renal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of renal involvement varies among studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/10,31,32\">",
"     10,31,32",
"    </a>",
"    ]. In the largest series of 383 patients with EGPA, renal involvement was found in 83 patients (22 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/10\">",
"     10",
"    </a>",
"    ]. Similar findings were noted in a series of 116 patients in which one-half had rapidly progressive or acute renal insufficiency (plasma creatinine concentration &gt;1.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [&gt;124",
"    <span class=\"nowrap\">",
"     micromol/L]),",
"    </span>",
"    while the others had isolated proteinuria or microscopic hematuria [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/32\">",
"     32",
"    </a>",
"    ]. Sixteen patients underwent renal biopsy, which demonstrated necrotizing glomerulonephritis in 11 patients. A positive test for antineutrophil cytoplasmic antibodies (ANCA) was found in all patients with glomerulonephritis, compared with 26 percent of patients without renal involvement. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Antineutrophil cytoplasmic antibodies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Systemic hypertension affects approximately 10 to 30 percent of patients with EGPA and may reflect renal involvement with EGPA or be a complication of glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/6,8,29\">",
"     6,8,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Gastrointestinal tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;An eosinophilic gastroenteritis, characterized by abdominal pain (59 percent of patients), diarrhea (33 percent), gastrointestinal bleeding (18 percent), and colitis, may precede or coincide with the vasculitic phase of EGPA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43703?source=see_link\">",
"     \"Eosinophilic gastroenteritis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H3\">",
"     'Phases of disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Musculoskeletal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myalgias, migratory polyarthralgias, and frank arthritis are less common, but may affect 40 to 50 percent of patients in the vasculitic phase of the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Phases of disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Lymphadenopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eosinophilic lymphadenopathy has been noted in 30 to 40 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/13\">",
"     13",
"    </a>",
"    ]. Prominent cervical and axillary lymphadenopathy has been reported with individual lymph nodes up to 3 cm in diameter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Complications in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fetal death rate may be slightly increased among pregnancies occurring in patients with EGPA, although the number of reported pregnancies is low. As an example, one review reported a fetal death rate of approximately 15 percent among 22 pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/3\">",
"     3",
"    </a>",
"    ]. The effect of EGPA on the placenta is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of EGPA is typically suspected based on the clinical findings (ie, eosinophilia",
"    <span class=\"nowrap\">",
"     &ge;1500/microL,",
"    </span>",
"    asthma, allergic rhinitis). However, confirming the diagnosis is often difficult because of the following confounding factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Individual manifestations of the syndrome can occur in isolation.",
"     </li>",
"     <li>",
"      Lung parenchymal involvement is not universal.",
"     </li>",
"     <li>",
"      Some manifestations can exist for many years before additional features become clinically apparent. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Phases of disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although EGPA is classified as a vasculitis, only 40 to 60 percent of patients with EGPA have antineutrophil cytoplasmic antibodies (ANCA). In addition, many biopsies do not show a necrotizing vasculitis or granuloma, but rather an apparently nondestructive infiltration of vessel walls by eosinophils [",
"      <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/33\">",
"       33",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link\">",
"       \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no laboratory tests that are specific for EGPA, although eosinophilia is characteristic. For patients who have suspected EGPA, we typically obtain a complete cell count with differential, a total eosinophil count, and an IgE level. We also usually obtain an ANCA test, although the sensitivity and specificity are low, as noted below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Eosinophilia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral blood eosinophilia (usually 5000 to 9000",
"    <span class=\"nowrap\">",
"     eosinophils/microL)",
"    </span>",
"    is the most characteristic finding, although levels over 1500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    (or greater than 10 percent of the total leukocyte count) should prompt suspicion for EGPA [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/8,34,35\">",
"     8,34,35",
"    </a>",
"    ]. Eosinophilia, however, is occasionally missed because of rapid spontaneous, or glucocorticoid-induced reductions or fluctuations in eosinophil counts. Tissue eosinophilia can still be found in patients in whom peripheral blood eosinophilia is absent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Antineutrophil cytoplasmic antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;ANCA are found in 40 to 60 percent of patients with EGPA [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/11,25,36-38\">",
"     11,25,36-38",
"    </a>",
"    ]. The majority of ANCA-positive EGPA patients (70 to 75 percent) have antibodies directed against myeloperoxidase with a perinuclear staining pattern (called MPO-ANCA or P-ANCA) (",
"    <a class=\"graphic graphic_picture graphicRef78968 \" href=\"UTD.htm?17/6/17518\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    EGPA disease manifestations may differ between ANCA-positive and ANCA-negative patients, although confirmatory data are needed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 383 patients with EGPA, those who were ANCA-positive had clinical vasculitis manifestations, such as peripheral neuropathy or renal involvement, more frequently than ANCA-negative patients, but less frequently had cardiomyopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of 112 patients with newly diagnosed EGPA, a positive ANCA at diagnosis was associated with renal involvement, peripheral neuropathy, and biopsy-proven vasculitis, whereas a negative ANCA was associated with heart disease and fever [",
"      <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Acute phase reactants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tests of inflammation such as the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are nonspecific and do not differentiate between flares of EGPA and infections (eg, sinusitis, pneumonia). Their usefulness in EGPA is unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=see_link&amp;anchor=H8#H8\">",
"     \"Acute phase reactants\", section on 'Clinical relevance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Other laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with strongly suspected or known EGPA, additional tests are performed to assess the extent of disease, including a urinalysis, serum creatinine, and a serum creatine kinase-MB.",
"   </p>",
"   <p>",
"    Nonspecific laboratory abnormalities that may be observed in EGPA include [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Normochromic, normocytic anemia",
"     </li>",
"     <li>",
"      Leukocytosis",
"     </li>",
"     <li>",
"      An elevated IgE level is common, and may vary with the activity of the vasculitic process",
"     </li>",
"     <li>",
"      Hypergammaglobulinemia",
"     </li>",
"     <li>",
"      A positive rheumatoid factor at low titer",
"     </li>",
"     <li>",
"      Normal or elevated complement (C3, C4, CH50) levels",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest radiographs are typically obtained during a flare of asthma or to evaluate peripheral eosinophilia. Chest radiographic abnormalities in patients with EGPA are diverse and include the following (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71677 graphicRef59884 \" href=\"UTD.htm?41/20/42311\">",
"     image 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/42-45\">",
"     42-45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Transient and patchy opacities (75 percent of patients), without lobar or segmental distribution",
"     </li>",
"     <li>",
"      Symmetrical opacities in an axillary and peripheral distribution",
"     </li>",
"     <li>",
"      Opacities radiating from the hilum with hilar adenopathy",
"     </li>",
"     <li>",
"      Diffuse interstitial or miliary opacities",
"     </li>",
"     <li>",
"      Pulmonary hemorrhage causing widespread shadowing",
"     </li>",
"     <li>",
"      Bilateral, nodular disease without cavitation",
"     </li>",
"     <li>",
"      Hilar adenopathy (infrequent)",
"     </li>",
"     <li>",
"      Pleural effusions, which are found in 30 percent of patients, and are usually exudative and eosinophilic [",
"      <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/43\">",
"       43",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    High resolution chest computed tomography (HRCT) is typically obtained to evaluate unexplained dyspnea, an abnormal chest radiograph, or gas transfer abnormalities, such as a low diffusion capacity or low pulse oximetry. Typical HRCT findings in EGPA include peribronchial thickening, areas of septal thickening, and widely scattered patchy, indistinct opacities. One series described parenchymal consolidation or ground glass opacification on the CT scans of 10 of 17 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/45\">",
"     45",
"    </a>",
"    ]. These findings are not specific for EGPA, but may guide choice of a location for bronchoalveolar lavage or lung biopsy and help in the assessment of the extent of disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=see_link\">",
"     \"High resolution computed tomography of the lungs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A less common HRCT feature is a significant enlargement of the peripheral pulmonary arteries (when compared to the corresponding bronchi) in combination with a stellate and irregular configuration of some pulmonary arteries (referred to as the vasculitis sign) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73909 \" href=\"UTD.htm?23/16/23811\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cardiac magnetic resonance imaging is discussed below. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Cardiovascular tests'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pulmonary function tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spirometry typically shows variable airflow limitation (obstruction) consistent with asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/8\">",
"     8",
"    </a>",
"    ]. Some patients may have a component of irreversible airflow limitation noted on spirometry or peak expiratory flow. When lung parenchymal involvement occurs, lung volume measurements (eg, total vital capacity and forced vital capacity) may be decreased. In addition, gas transfer abnormalities may be manifest by a low pulse oximetry at rest or with exertion, or by a decrease in the diffusion capacity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link\">",
"     \"Overview of pulmonary function testing in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22487?source=see_link\">",
"     \"Use of pulmonary function testing in the diagnosis of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Bronchoalveolar lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoalveolar lavage (BAL) is typically performed in patients with interstitial opacities on radiographic imaging to evaluate for eosinophilia, infection, alveolar hemorrhage, or malignancy. In EGPA, BAL typically reveals a high percentage of eosinophils in the lavage fluid (usually greater than 33 percent). However, this finding is not specific for EGPA and would only be present in a patient with active pneumonitis (",
"    <a class=\"graphic graphic_table graphicRef64886 \" href=\"UTD.htm?15/50/16171\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=see_link\">",
"     \"Causes of pulmonary eosinophilia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical lung biopsy, although not always available, is the \"gold standard\" for the diagnosis of EGPA [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/46\">",
"     46",
"    </a>",
"    ]. In contrast, transbronchial lung biopsy is generally not helpful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=see_link\">",
"     \"Role of lung biopsy in the diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When either skin disease or peripheral neuropathy is present, biopsy of one of those sites is less invasive and often preferred to a lung biopsy. In one study, 15 of 28 patients with a peripheral neuropathy and EGPA had evidence of a necrotizing vasculitis on a peripheral nerve biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16215?source=see_link\">",
"     \"Diagnosis and treatment of vasculitic neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The lung biopsy from patients with EGPA may show asthmatic bronchitis, eosinophilic pneumonia, extravascular granulomas, or vasculitis (affecting arteries, veins, or capillaries). The histopathologic findings of EGPA are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=see_link&amp;anchor=H11#H11\">",
"     \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\", section on 'Pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Cardiovascular tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specific indications for obtaining cardiovascular tests such as the electrocardiogram (ECG), echocardiogram, and cardiovascular magnetic resonance imaging (CMR) are unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/22,47,48\">",
"     22,47,48",
"    </a>",
"    ]. We typically obtain an electrocardiogram and an echocardiogram (looking for wall motion abnormalities, mural thrombi, and valvular thrombi) as part of the initial evaluation of a patient with a diagnosis of EGPA even in the absence of symptoms suggesting cardiac disease. Approximately 40 percent of asymptomatic patients with a normal ECG have evidence of cardiac involvement with CSS on echocardiogram [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common echocardiographic finding in CSS is wall motion abnormalities, which were found in 41 percent of patients in one case series [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/22\">",
"     22",
"    </a>",
"    ]. Other findings include valvular abnormalities (eg, mitral or aortic regurgitation), pericardial effusion, mural thrombi, and pulmonary hypertension.",
"   </p>",
"   <p>",
"    If abnormalities are noted on ECG or echocardiogram, we perform CMR with gadolinium enhancement, if renal function is adequate. Gadolinium enhancement on CMR has been reported to correlate with endomyocardial biopsy evidence of eosinophilic infiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/49\">",
"     49",
"    </a>",
"    ]. Assessment of late images may reveal myocardial necrosis or fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/23,50\">",
"     23,50",
"    </a>",
"    ]. Gadolinium should be used with caution in patients with advanced renal insufficiency because of the risk of inducing nephrogenic systemic fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The exact sensitivity and specificity of CMR for myocardial involvement with EGPA is not known. A comparison of echocardiography and CMR in a small group of patients found that echocardiography had a sensitivity and specificity of 83 and 80 percent, respectively, for abnormalities on CMR, while CMR had a sensitivity and specificity of 88 and 72 percent, respectively, for echocardiographic abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fluoro-2-deoxyglucose-positron emission tomography (FDG-PET) has been evaluated as a method to determine whether delayed myocardial enhancement on CMR is due to fibrosis or inflammation. Among 14 patients with EGPA in remission and delayed myocardial enhancement on CMR, FDG-PET uptake was reduced in 10, increased in 2, and normal in 2 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/51\">",
"     51",
"    </a>",
"    ]. FDG-PET uptake was also normal in six patients with normal CMR findings. As this study evaluated a small number of patients and the outcomes of alterations in therapy based on FDG-PET results were not assessed, further study is needed to determine the most appropriate role for FDG-PET in the evaluation of EGPA. &nbsp;",
"   </p>",
"   <p>",
"    An endomyocardial biopsy is usually obtained when EGPA is suspected, the noninvasive testing suggests endomyocarditis, and the documentation of cardiac involvement would affect the decision about whether to initiate immunosuppressive therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7592?source=see_link\">",
"     \"Endomyocardial biopsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=see_link&amp;anchor=H11#H11\">",
"     \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\", section on 'Pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of different sets of criteria for the diagnosis of EGPA have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/8,35,40,52\">",
"     8,35,40,52",
"    </a>",
"    ]. The classifications used most commonly are the American College of Rheumatology (ACR, preferred) and the Lanham criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/8,35\">",
"     8,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ACR has established six criteria for the classification of EGPA in a patient with documented vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/35\">",
"     35",
"    </a>",
"    ]. The presence of four or more of these criteria had a sensitivity of 85 percent and a specificity of 99.7 percent for EGPA:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Asthma (a history of wheezing or the finding of diffuse high pitched wheezes on expiration)",
"     </li>",
"     <li>",
"      Greater than 10 percent eosinophils on the differential leukocyte count",
"     </li>",
"     <li>",
"      Mononeuropathy (including multiplex) or polyneuropathy",
"     </li>",
"     <li>",
"      Migratory or transient pulmonary opacities detected radiographically",
"     </li>",
"     <li>",
"      Paranasal sinus abnormality",
"     </li>",
"     <li>",
"      Biopsy containing a blood vessel showing the accumulation of eosinophils in extravascular areas (",
"      <a class=\"graphic graphic_picture graphicRef57180 graphicRef82366 \" href=\"UTD.htm?19/16/19722\">",
"       picture 3A-B",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Lanham criteria include asthma, peak peripheral blood eosinophilia in excess of 1500",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    and systemic vasculitis involving two or more extra-pulmonary organs [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/8\">",
"     8",
"    </a>",
"    ]. In this classification, all three criteria must be met for a diagnosis of EGPA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main diseases to consider in the differential diagnosis of EGPA are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    -exacerbated respiratory disease, the eosinophilic pneumonias, allergic bronchopulmonary aspergillosis, the hypereosinophilic syndrome, granulomatosis with polyangiitis (Wegener's), and microscopic polyangiitis. The following observations may help to narrow the differential diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      -exacerbated respiratory disease &mdash; Aspirin exacerbated respiratory disease (AERD) refers to the combination of asthma, chronic rhinosinusitis with nasal polyposis, and reactions to aspirin (acetylsalicylic acid, ASA) and other COX-1 inhibiting nonsteroidal antiinflammatory drugs (NSAIDs) characterized by bronchoconstriction, nasal congestion, and rhinorrhea. These patients may also have eosinophilia, but do not have eosinophilic pneumonia or the other organ system involvement seen in EGPA. However, AERD may evolve into EGPA. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39944?source=see_link\">",
"       \"Aspirin exacerbated respiratory disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic eosinophilic pneumonia &mdash; Chronic eosinophilic pneumonia usually lacks granulomas on biopsy and generally does not involve organs other than the lung [",
"      <a class=\"abstract\" href=\"UTD.htm?26/34/27177/abstract/53,54\">",
"       53,54",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Occasionally, an episode of eosinophilic pneumonia may precede the other manifestations of EGPA, making it difficult to differentiate EGPA from chronic eosinophilic pneumonia. These patients are monitored closely for development of evidence of additional organ involvement that would secure the diagnosis of EGPA. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Phases of disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=see_link&amp;anchor=H10#H10\">",
"       \"Causes of pulmonary eosinophilia\", section on 'Chronic eosinophilic pneumonia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Allergic bronchopulmonary aspergillosis &mdash; Allergic bronchopulmonary aspergillosis is another cause of asthma, radiographic pulmonary opacities, and eosinophilia, but does not affect extrapulmonary organs other than the nose and sinuses. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=see_link\">",
"       \"Causes of pulmonary eosinophilia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypereosinophilic syndrome &mdash; While some patients with the hypereosinophilic syndrome (HES) may have a cough, a minority have pulmonary infiltrates, and asthma is rare. When a clear differentiation cannot be made on clinical grounds, molecular testing for the",
"      <span class=\"nowrap\">",
"       FIP1L1/PDGFRalpha",
"      </span>",
"      mutation may be helpful as this is suggestive of HES. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=see_link&amp;anchor=H25#H25\">",
"       \"Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes\", section on 'Hematologic evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other vasculitides &mdash; Granulomatosis with polyangiitis (Wegener's), microscopic polyangiitis, and EGPA can all affect the lung, although the degree of eosinophilia and presence of asthma are typical of EGPA and not usually seen in the other two. The type of ANCA seen in EGPA is more typically anti-myeloperoxidase, whereas in granulomatosis with polyangiitis it is more likely anti-proteinase 3. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link\">",
"       \"Classification of and approach to the vasculitides in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eosinophilic granulomatosis with polyangiitis (Churg-Strauss), abbreviated EGPA, which was formerly called the Churg-Strauss syndrome (CSS) or allergic granulomatosis and angiitis, is a multisystem disorder characterized by chronic rhinosinusitis, asthma, and prominent peripheral blood eosinophilia (&ge; 1500",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      &gt;10 percent eosinophils on differential leukocyte count). The exact etiology of EGPA is unknown. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Asthma is the cardinal feature of EGPA (occurring in more than 95 percent of patients) and usually precedes the vasculitic phase by approximately 8 to 10 years. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Asthma and lung disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two-thirds of EGPA patients have skin involvement ranging from palpable purpura to subcutaneous nodules. Skin biopsy is often helpful for confirming the diagnosis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Skin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiac involvement is one of the more serious manifestations of EGPA, accounting for approximately one-half of deaths attributable to EGPA. It should be suspected in the presence of refractory dyspnea, clinical evidence of heart failure, or cardiac rhythm abnormalities, but can also be asymptomatic. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Cardiovascular'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with EGPA have peripheral blood eosinophilia (typically above",
"      <span class=\"nowrap\">",
"       1500/microL,",
"      </span>",
"      often 5000 to",
"      <span class=\"nowrap\">",
"       9000/microL),",
"      </span>",
"      although this may be obscured by use of systemic glucocorticoids to control asthma. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Eosinophilia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antineutrophil cytoplasmic antibodies (ANCAs) are noted in 40 to 60 percent of EGPA patients. The majority of ANCAs associated with EGPA are directed against myeloperoxidase with a perinuclear staining pattern (called MPO-ANCA or P-ANCA). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Antineutrophil cytoplasmic antibodies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Typical findings on chest high resolution computed tomography (HRCT) include patchy parenchymal consolidation or ground glass opacification; nodules may also be noted. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of EGPA is suggested by the presence of asthma, rhinosinusitis, and eosinophilia and then confirmed by lung biopsy or biopsy of other clinically affected tissues (eg, skin, peripheral nerve). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two sets of diagnostic criteria are commonly used; the American College of Rheumatology (ACR) criteria for the classification of EGPA in a patient with documented vasculitis and the Lanham criteria. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Diagnostic criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main diseases to consider in the differential diagnosis of EGPA are",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      -exacerbated respiratory disease, the eosinophilic pneumonias, allergic bronchopulmonary aspergillosis, the hypereosinophilic syndrome, granulomatosis with polyangiitis (Wegener's), and microscopic polyangiitis. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/1\">",
"      CHURG J, STRAUSS L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol 1951; 27:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/2\">",
"      Churg A. Pulmonary angiitis and granulomatosis revisited. Hum Pathol 1983; 14:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/3\">",
"      Sinico RA, Bottero P. Churg-Strauss angiitis. Best Pract Res Clin Rheumatol 2009; 23:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/4\">",
"      Pagnoux C, Guilpain P, Guillevin L. Churg-Strauss syndrome. Curr Opin Rheumatol 2007; 19:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/5\">",
"      Keogh KA, Specks U. Churg-Strauss syndrome. Semin Respir Crit Care Med 2006; 27:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/6\">",
"      Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999; 78:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/7\">",
"      Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/8\">",
"      Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984; 63:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/9\">",
"      Pagnoux C, Guillevin L. Churg-Strauss syndrome: evidence for disease subtypes? Curr Opin Rheumatol 2010; 22:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/10\">",
"      Comarmond C, Pagnoux C, Khellaf M, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 2013; 65:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/11\">",
"      Cottin V, Khouatra C, Dubost R, et al. Persistent airflow obstruction in asthma of patients with Churg-Strauss syndrome and long-term follow-up. Allergy 2009; 64:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/12\">",
"      Wechsler ME, Garpestad E, Flier SR, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 1998; 279:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/13\">",
"      Churg A, Brallas M, Cronin SR, Churg J. Formes frustes of Churg-Strauss syndrome. Chest 1995; 108:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/14\">",
"      Chumbley LC, Harrison EG Jr, DeRemee RA. Allergic granulomatosis and angiitis (Churg-Strauss syndrome). Report and analysis of 30 cases. Mayo Clin Proc 1977; 52:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/15\">",
"      Bacciu A, Buzio C, Giordano D, et al. Nasal polyposis in Churg-Strauss syndrome. Laryngoscope 2008; 118:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/16\">",
"      Bacciu A, Bacciu S, Mercante G, et al. Ear, nose and throat manifestations of Churg-Strauss syndrome. Acta Otolaryngol 2006; 126:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/17\">",
"      Ishiyama A, Canalis RF. Otological manifestations of Churg-Strauss syndrome. Laryngoscope 2001; 111:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/18\">",
"      Schwartz RA, Churg J. Churg-Strauss syndrome. Br J Dermatol 1992; 127:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/19\">",
"      Kawakami T, Soma Y, Kawasaki K, et al. Initial cutaneous manifestations consistent with mononeuropathy multiplex in Churg-Strauss syndrome. Arch Dermatol 2005; 141:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/20\">",
"      Neumann T, Manger B, Schmid M, et al. Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore) 2009; 88:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/21\">",
"      Corradi D, Maestri R, Facchetti F. Postpartum Churg-Strauss syndrome with severe cardiac involvement: description of a case and review of the literature. Clin Rheumatol 2009; 28:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/22\">",
"      Dennert RM, van Paassen P, Schalla S, et al. Cardiac involvement in Churg-Strauss syndrome. Arthritis Rheum 2010; 62:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/23\">",
"      Szczeklik W, Miszalski-Jamka T, Mastalerz L, et al. Multimodality assessment of cardiac involvement in Churg-Strauss syndrome patients in clinical remission. Circ J 2011; 75:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/24\">",
"      Allenbach Y, Seror R, Pagnoux C, et al. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis 2009; 68:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/25\">",
"      Della Rossa A, Baldini C, Tavoni A, et al. Churg-Strauss syndrome: clinical and serological features of 19 patients from a single Italian centre. Rheumatology (Oxford) 2002; 41:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/26\">",
"      Solans R, Bosch JA, P&eacute;rez-Bocanegra C, et al. Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. Rheumatology (Oxford) 2001; 40:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/27\">",
"      Wolf J, Bergner R, Mutallib S, et al. Neurologic complications of Churg-Strauss syndrome--a prospective monocentric study. Eur J Neurol 2010; 17:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/28\">",
"      Hattori N, Ichimura M, Nagamatsu M, et al. Clinicopathological features of Churg-Strauss syndrome-associated neuropathy. Brain 1999; 122 ( Pt 3):427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/29\">",
"      Liou HH, Liu HM, Chiang IP, et al. Churg-Strauss syndrome presented as multiple intracerebral hemorrhage. Lupus 1997; 6:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/30\">",
"      Sheerin UM, Barreto J, Brown MM, et al. Subarachnoid haemorrhage as the first clinical manifestation of Churg-Strauss syndrome. J Neurol 2008; 255:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/31\">",
"      Clutterbuck EJ, Evans DJ, Pusey CD. Renal involvement in Churg-Strauss syndrome. Nephrol Dial Transplant 1990; 5:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/32\">",
"      Sinico RA, Di Toma L, Maggiore U, et al. Renal involvement in Churg-Strauss syndrome. Am J Kidney Dis 2006; 47:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/33\">",
"      Churg A. Recent advances in the diagnosis of Churg-Strauss syndrome. Mod Pathol 2001; 14:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/34\">",
"      Noth I, Strek ME, Leff AR. Churg-Strauss syndrome. Lancet 2003; 361:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/35\">",
"      Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/36\">",
"      Schmitt WH, Csernok E, Kobayashi S, et al. Churg-Strauss syndrome: serum markers of lymphocyte activation and endothelial damage. Arthritis Rheum 1998; 41:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/37\">",
"      Reid AJ, Harrison BD, Watts RA, et al. Churg-Strauss syndrome in a district hospital. QJM 1998; 91:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/38\">",
"      Sabl&eacute;-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005; 143:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/39\">",
"      Nathani N, Little MA, Kunst H, et al. Churg-Strauss syndrome and leukotriene antagonist use: a respiratory perspective. Thorax 2008; 63:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/40\">",
"      Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 2003; 115:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/41\">",
"      Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005; 52:2926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/42\">",
"      Choi YH, Im JG, Han BK, et al. Thoracic manifestation of Churg-Strauss syndrome: radiologic and clinical findings. Chest 2000; 117:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/43\">",
"      Erzurum SC, Underwood GA, Hamilos DL, Waldron JA. Pleural effusion in Churg-Strauss syndrome. Chest 1989; 95:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/44\">",
"      Buschman DL, Waldron JA Jr, King TE Jr. Churg-Strauss pulmonary vasculitis. High-resolution computed tomography scanning and pathologic findings. Am Rev Respir Dis 1990; 142:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/45\">",
"      Worthy SA, M&uuml;ller NL, Hansell DM, Flower CD. Churg-Strauss syndrome: the spectrum of pulmonary CT findings in 17 patients. AJR Am J Roentgenol 1998; 170:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/46\">",
"      Allen JN, Davis WB. Eosinophilic lung diseases. Am J Respir Crit Care Med 1994; 150:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/47\">",
"      Sauvetre G, Fares J, Caudron J, et al. [Usefulness of magnetic resonance imaging in Churg-Strauss syndrome related cardiac involvement. A case series of three patients and literature review]. Rev Med Interne 2010; 31:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/48\">",
"      Marmursztejn J, Vignaux O, Cohen P, et al. Impact of cardiac magnetic resonance imaging for assessment of Churg-Strauss syndrome: a cross-sectional study in 20 patients. Clin Exp Rheumatol 2009; 27:S70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/49\">",
"      Baccouche H, Yilmaz A, Alscher D, et al. Images in cardiovascular medicine. Magnetic resonance assessment and therapy monitoring of cardiac involvement in Churg-Strauss syndrome. Circulation 2008; 117:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/50\">",
"      Mavrogeni S, Manoussakis MN, Karagiorga TC, et al. Detection of coronary artery lesions and myocardial necrosis by magnetic resonance in systemic necrotizing vasculitides. Arthritis Rheum 2009; 61:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/51\">",
"      Marmursztejn J, Guillevin L, Trebossen R, et al. Churg-Strauss syndrome cardiac involvement evaluated by cardiac magnetic resonance imaging and positron-emission tomography: a prospective study on 20 patients. Rheumatology (Oxford) 2013; 52:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/52\">",
"      Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/53\">",
"      Hueto-Perez-de-Heredia JJ, Dominguez-del-Valle FJ, Garcia E, et al. Chronic eosinophilic pneumonia as a presenting feature of Churg-Strauss syndrome. Eur Respir J 1994; 7:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27177/abstract/54\">",
"      Steinfeld S, Golstein M, De Vuyst P. Chronic eosinophilic pneumonia (CEP) as a presenting feature of Churg-Strauss syndrome (CSS). Eur Respir J 1994; 7:2098.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4347 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-23F828356C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_34_27177=[""].join("\n");
var outline_f26_34_27177=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Phases of disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Asthma and lung disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Upper airway and ear disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cardiovascular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H280932879\">",
"      Thromboembolic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Neurologic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Renal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Musculoskeletal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Complications in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Other laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pulmonary function tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Cardiovascular tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      DIAGNOSTIC CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4347\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4347|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/53/40787\" title=\"diagnostic image 1A\">",
"      Churg Strauss PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/44/25281\" title=\"diagnostic image 1B\">",
"      Churg Strauss lateral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/16/23811\" title=\"diagnostic image 2\">",
"      Churg Strauss CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4347|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/45/10961\" title=\"picture 1\">",
"      Skin ulceration Churg Strauss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/6/17518\" title=\"picture 2\">",
"      P ANCA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/52/38726\" title=\"picture 3A\">",
"      Small vessel vasculitis Churg Strauss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/4/40006\" title=\"picture 3B\">",
"      Lung biopsy Churg Strauss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4347|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/50/16171\" title=\"table 1\">",
"      ILD associated BAL eosinophilia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=related_link\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24745?source=related_link\">",
"      Approach to the patient with eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39944?source=related_link\">",
"      Aspirin exacerbated respiratory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=related_link\">",
"      Causes of pulmonary eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=related_link\">",
"      Classification of and approach to the vasculitides in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22423?source=related_link\">",
"      Clinical manifestations of vasculitic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=related_link\">",
"      Clinical spectrum of antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16215?source=related_link\">",
"      Diagnosis and treatment of vasculitic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7592?source=related_link\">",
"      Endomyocardial biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43703?source=related_link\">",
"      Eosinophilic gastroenteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=related_link\">",
"      Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=related_link\">",
"      High resolution computed tomography of the lungs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=related_link\">",
"      Role of bronchoalveolar lavage in diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=related_link\">",
"      Role of lung biopsy in the diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/33/35353?source=related_link\">",
"      Treatment and prognosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22487?source=related_link\">",
"      Use of pulmonary function testing in the diagnosis of asthma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_34_27178="Treatment of vulvar and vaginal warts";
var content_f26_34_27178=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of vulvar and vaginal warts",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/34/27178/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/34/27178/contributors\">",
"     Daniela A Carusi, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/34/27178/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/34/27178/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/34/27178/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/34/27178/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/34/27178/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vulvar and vaginal warts are one of the clinical manifestations of human papillomavirus (HPV) infection (",
"    <a class=\"graphic graphic_picture graphicRef60946 graphicRef72781 graphicRef51759 \" href=\"UTD.htm?37/50/38698\">",
"     picture 1A-C",
"    </a>",
"    ). Approximately 90 percent of anogenital warts are associated with HPV types 6",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    11, which are of low oncogenic potential [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Additional HPV types (including high oncogenic risk types) may be identified, but usually as co-infections with HPV 6 or 11.",
"   </p>",
"   <p>",
"    For most patients, the presence of genital warts is concerning because of their cosmetic appearance, association with a sexually transmitted disease, bothersome symptoms, absence of a cure, and social stigma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/4\">",
"     4",
"    </a>",
"    ]. Although treatment can eradicate the warts, disease recurrence is common and occurs in 20 to 30 percent of patients overall.",
"   </p>",
"   <p>",
"    This topic will discuss treatment of vulvar and vaginal warts in women. The epidemiology, pathophysiology, clinical manifestations, and diagnosis of anogenital warts, and issues related to men with anogenital infection, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23144?source=see_link\">",
"     \"Condylomata acuminata (anogenital warts)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRETREATMENT COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be given an explanation of their disease and information about the indications for treatment, treatment options, and prognosis. Written material is available from several sources (see",
"    <a class=\"local\" href=\"#H3316296\">",
"     'Information for patients'",
"    </a>",
"    below). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Information about human papillomavirus infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most women want to know how and when they acquired the disease. We tell them that genital human papillomavirus (HPV) is spread by direct physical contact during sex. They may have acquired the infection years prior to diagnosis since the incubation period can last for months and their first recognition of a lesion may represent a relapse rather than a first episode. Therefore, a new diagnosis of genital warts does not mean that the patient or her partner is having sex outside the relationship. We also inform them that condoms provide some protection against HPV transmission, but contact with genital lesions not covered by the condom can result in infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients are also informed that HPV is so widespread that most men and women will have acquired an HPV infection during their lifetime, but are unaware of the infection because it is usually asymptomatic. Acquiring immunity to one type of HPV does not provide immunity against other types, so reinfection can occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21610?source=see_link\">",
"     \"Epidemiology of human papillomavirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15429408\">",
"    <span class=\"h2\">",
"     Indications for treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main indication for treatment of vulvovaginal warts is alleviation of bothersome symptoms (pruritus, bleeding, burning, tenderness, vaginal discharge, pain, obstruction of the vagina, dyspareunia) or psychologic distress [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/4\">",
"     4",
"    </a>",
"    ]. Warts do not pose serious risks to health or fertility; therefore, some symptomatic patients may reasonably choose expectant management to see if the warts spontaneously resolve. In placebo controlled treatment trials, spontaneous regression occurred in up to 40 percent of cases; the remainder remained stable or increased in size or number.",
"   </p>",
"   <p>",
"    There is no medical indication for treatment of asymptomatic warts incidentally noted on physical examination, but patients should be made aware of the presence of these lesions. There is no reason to believe that treating vulvovaginal warts will reduce a woman&rsquo;s future risk of cancer. Similarly, treatment should not be undertaken to protect sexual contacts since there is no evidence that eradication of warts eliminates infectivity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Overview of treatment and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be informed that prolonged treatment with frequent follow-up is often necessary. They should also understand that medical and surgical therapies lead to clearance of warts in 35 to 100 percent of patients in 3 to 16 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/8\">",
"     8",
"    </a>",
"    ], but do not necessarily eradicate all HPV infected cells [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/6,9,10\">",
"     6,9,10",
"    </a>",
"    ]. Because clinically and histologically latent HPV can exist beyond the treatment area, the possibility of clinical recurrence or transmission of HPV to sexual partners remains [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/8\">",
"     8",
"    </a>",
"    ]. The likelihood of recurrence is variable depending on the patient's medical condition and the extent of disease, but 20 to 30 percent of patients have a recurrence (new lesions at previously treated or new sites) within a few months. Nevertheless, most HPV infections associated with genital warts are cleared within two years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both medical and surgical options are available for treatment. Treatment effectiveness studies show highly variable results, possibly reflecting variations in duration of follow-up, drug dosing, criteria for success, severity of disease, patient population, and HPV types. There is no high quality evidence that any treatment is significantly superior to another or appropriate for all patients and all types of warts; therefore, treatment choice is based on the location, number, and size of the warts; patient characteristics (eg, pregnancy, ability to comply with therapy, immunocompromise); availability of resources and clinical expertise; and patient preferences after considering side effects, cost, and convenience (",
"    <a class=\"graphic graphic_table graphicRef58922 \" href=\"UTD.htm?42/33/43547\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/12-26\">",
"     12-26",
"    </a>",
"    ]. Medical therapies are generally tried first; if the patient has not responded to the initial medical therapy after 3 weeks or complete clearance has not occurred by 6 to 12 weeks, a different medical therapy can be administered [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/27\">",
"     27",
"    </a>",
"    ]. Surgical therapy is typically reserved for patients with large",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bulky lesions and those who have failed to respond adequately to medical therapy. Surgery results in high initial clearance rates (90 to 100 percent), but recurrence rates are similar to those with medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15429822\">",
"    <span class=\"h2\">",
"     Side effects and complications of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;All therapies are associated with localized discomfort including itching, burning, erosions, and pain since the epithelium is disrupted [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/8\">",
"     8",
"    </a>",
"    ]. Complications resulting from treatment include hypo- or hyperpigmentation, scarring, and chronic vulvar pain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/6\">",
"     6",
"    </a>",
"    ]. Hypopigmentation is most common in areas where warts were surgically ablated, but has also been described after treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    . Scarring is most common after surgical procedures that destroy subdermal tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15430200\">",
"    <span class=\"h2\">",
"     Management of sex partners",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sex partners can benefit from informational counseling. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Information about human papillomavirus infection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Symptomatic male partners can be referred to their health care provider for evaluation and possible treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23144?source=see_link\">",
"     \"Condylomata acuminata (anogenital warts)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the high prevalence of infection in adults, high frequency of asymptomatic disease, and absence of curative therapy, testing asymptomatic sexual partners for HPV is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/6\">",
"     6",
"    </a>",
"    ]. Screening for other sexually transmitted infections is performed according to standard guidelines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=see_link\">",
"     \"Screening for sexually transmitted infections\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15430387\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determining the human papillomavirus (HPV) type of the warts is unnecessary as this information does not affect clinical management.",
"   </p>",
"   <p>",
"    The presence of genital warts alone is not an indication for screening for additional sexually transmitted diseases, but such screening is indicated in high risk groups such as women with a history of multiple sex partners and women &le;25 years of age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=see_link\">",
"     \"Screening for sexually transmitted infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15428844\">",
"    <span class=\"h2\">",
"     Indications for pretreatment biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsy to rule out underlying intraepithelial neoplasia or cancer is not mandatory before initiating therapy, but is recommended when:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis is uncertain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23144?source=see_link&amp;anchor=H8#H8\">",
"       \"Condylomata acuminata (anogenital warts)\", section on 'Diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23144?source=see_link&amp;anchor=H9#H9\">",
"       \"Condylomata acuminata (anogenital warts)\", section on 'Differential diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The lesion has any suspicious features, such as fixation (dermal infiltration), irregular and unusual pigmentation (red, blue, black, brown), induration, bleeding, ulceration, sudden recent growth, flat.",
"     </li>",
"     <li>",
"      The patient is postmenopausal or immunocompromised. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Postmenopausal women'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H32\">",
"       'HIV infected and immunocompromised women'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The lesion is refractory to medical therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The biopsy should be obtained from the most abnormal area and include the",
"    <span class=\"nowrap\">",
"     base/side",
"    </span>",
"    of the lesion and adjacent tissue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37349?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnostic evaluation of vulvar lesions\", section on 'Biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H377473421\">",
"    <span class=\"h1\">",
"     TREATMENT OPTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two broad categories of medical therapy: those that directly destroy the wart tissue (cyto-destructive therapies) and those that work through the patient's immune system to clear the wart (immune-mediated therapies). Some of these methods can only be applied in the physician's office, while others can be self-administered by the patient at home [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/28\">",
"     28",
"    </a>",
"    ]. All medical therapies are most useful for patients with limited disease (eg, &le;5 small warts [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/27\">",
"     27",
"    </a>",
"    ]). Some key points regarding medical therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Podophyllotoxin (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/34/23074?source=see_link\">",
"       podofilox",
"      </a>",
"      ),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"       imiquimod",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15923?source=see_link\">",
"       sinecatechins",
"      </a>",
"      , and topical interferon can be self-administered.",
"     </li>",
"     <li>",
"      Any of the medical therapies discussed below can be used to treat vulvar warts, but vaginal warts can only be treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7794?source=see_link\">",
"       trichloroacetic acid",
"      </a>",
"      (TCA), bichloroacetic acid (BCA), and interferons.",
"     </li>",
"     <li>",
"      TCA has no systemic absorption and no known fetal effects; therefore, it is the preferred treatment for pregnant women.",
"     </li>",
"     <li>",
"      In general, if the patient has not responded to the initial therapy after about 3 weeks or complete clearance has not occurred by 6 to 12 weeks, it is appropriate to switch to a different treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Cytodestructive therapies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h4\">",
"     Podophyllotoxin (podofilox) and podophyllum resin (podophyllin)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both drugs are avoided in pregnancy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Podophyllotoxin (",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/34/23074?source=see_link\">",
"       podofilox",
"      </a>",
"      <strong>",
"       )",
"      </strong>",
"      &mdash; Podophyllotoxin (podofilox) contains the biologically active compound from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/8/30851?source=see_link\">",
"       podophyllum resin",
"      </a>",
"      . Using a cotton swab, the patient applies a 0.5 percent gel or solution to external genital warts twice daily for three consecutive days [",
"      <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/6,29\">",
"       6,29",
"      </a>",
"      ]. No more than 0.5 mL of podofilox should be applied in one day. She then withholds treatment for four days, and repeats this cycle weekly up to four times. Large areas (10 cm2 or more) should not be treated in a single application because pain is likely when the area becomes necrotic.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/8/30851?source=see_link\">",
"       Podophyllum resin",
"      </a>",
"      &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/8/30851?source=see_link\">",
"       Podophyllum",
"      </a>",
"      resin is a plant-based resin that blocks cell division at metaphase and leads to cell death. The clinician applies a 25 percent solution directly to the warts with a cotton swab (or similar device). No more than 0.5 mL should be applied during each treatment session and large areas (10 cm",
"      <sup>",
"       2",
"      </sup>",
"      or more) should not be treated in a single application because of potential pain when the area becomes necrotic. The area should air-dry before the patient dresses.",
"      <br/>",
"      <br/>",
"      In contrast to podophyllotoxin, systemic absorption and toxicity have been documented. A weaker solution (10 percent) should be used when treating large warts to minimize total systemic absorption, and application to open",
"      <span class=\"nowrap\">",
"       lesions/wounds",
"      </span>",
"      should be avoided.",
"      <br/>",
"      <br/>",
"      We instruct the patient to wash the area one to four hours after application of the drug, otherwise excessive skin irritation and systemic absorption can occur. The treatment is repeated weekly for four to six weeks, or until the lesions have cleared. Adverse effects range from mild skin irritation to ulceration and pain, depending upon the concentration used and the length of time it is left on the skin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Trichloroacetic acid and bichloroacetic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both TCA and BCA are caustic acids that destroy the wart tissue via chemical coagulation of tissue proteins. TCA is used most commonly, and must be applied by a health care provider. It can be used on the cervix and vagina, and during pregnancy.",
"   </p>",
"   <p>",
"    An 80 to 90 percent TCA solution is applied sparingly to the wart tissue with a cotton swab; the wart turns white as the solution dries. Application of an ointment or gel (such as petroleum or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    jelly) to the normal tissue surrounding the wart can help prevent spreading of acid to unaffected areas. Excessive application of 80 to 90 percent TCA can cause extensive chemical burns of the vagina and adjacent healthy tissue. If excess TCA is applied, it can be neutralized by washing with soap or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    solution.",
"   </p>",
"   <p>",
"    The patient should not sit, stand or dress until the treatment area has dried.",
"   </p>",
"   <p>",
"    Repeated weekly application is required for four to six weeks, or until the lesions have cleared. The only trial that evaluated use of TCA in women reported a 70 percent clearance rate [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/30\">",
"     30",
"    </a>",
"    ]. Thick, large lesions may not respond because the acid may not penetrate the entire lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     5-Fluorouracil",
"    </span>",
"    &nbsp;&mdash;&nbsp;5-fluorouracil (5-FU) is a pyrimidine antimetabolite that interferes with DNA synthesis by blocking methylation of deoxyuridylic acid, leading to cell death. In the United States, the Food and Drug Administration (FDA) has not approved any formulation of 5-FU for treatment of anogenital warts and its use is contraindicated in pregnancy. A disadvantage of topical 5-FU is that it is often poorly tolerated because of burning, pain, inflammation, edema, or painful ulcerations. For these reasons, topical 5-FU has a limited role in the primary therapy of vulvar or vaginal warts.",
"   </p>",
"   <p>",
"    A gel consisting of 5-fluorouracil and epinephrine in a purified bovine collagen matrix is under investigation. The gel is injected intradermally directly under the wart to create a wheal encompassing it and 5 mm of surrounding tissue. This provides a high concentration of drug for an extended period of time. Injections are performed once per week for up to six weeks. Clearance rates of 65 percent after a median of four treatments have been reported, but 40 percent of patients with a complete response had a recurrence at 90 days follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/31\">",
"     31",
"    </a>",
"    ]. Side effects include local pain, erosion, ulceration, and urethro-vulvo-vaginitis.",
"   </p>",
"   <p>",
"    Alternatively, a thin layer of 1 or 5 percent cream has been applied to vulvar or vaginal lesions to cause a chemical desquamation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/32-37\">",
"     32-37",
"    </a>",
"    ]. Several dosing protocols have been suggested, ranging from twice daily application to once weekly for several weeks.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/53/15187?source=see_link\">",
"     Zinc oxide",
"    </a>",
"    cream or petroleum jelly can be applied to unaffected areas as a barrier to help protect against ulceration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Immune-mediated therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    and interferon initiate a local immune response at the site of the wart that ultimately may clear the lesions. Imiquimod and topical interferon may be self-administered; injectable interferon is given in the office. Experience with these agents is more limited than for other medical therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h4\">",
"     Imiquimod",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     Imiquimod",
"    </a>",
"    is a toll-like receptor 7 agonist, which acts as a positive immune response modifier, and stimulates local cytokine induction. Topical treatment of warts increases local production of interferon and reduces human papillomavirus (HPV) virus load [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/38\">",
"     38",
"    </a>",
"    ]. Two formulations are available, Aldara (5 percent imiquimod) and Zyclara (3.75 percent imiquimod), for treatment of external genital warts, but the manufacturers recommend against vaginal administration. There is insufficient information regarding the safety of imiquimod in pregnancy; therefore, it is not recommended for pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The choice between the two formulations should be made based on patient preference, cost and convenience. There are no comparative data available between the two dosing regimens.",
"   </p>",
"   <p>",
"    Hand washing before and after cream application is recommended. The patient applies",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    cream directly to the clean dry warty tissue at bedtime, rubbing it in until the cream is no longer visible; this area is washed with mild soap and water 6 to 10 hours later. Sexual contact should be avoided while the cream is on the skin. The cream can weaken condoms and diaphragms.",
"   </p>",
"   <p>",
"    Aldara is applied three days per week (eg, Monday-Wednesday-Friday) for 4 to 16 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/6,39-42\">",
"     6,39-42",
"    </a>",
"    ]. Zyclara is applied daily for up to 8 weeks. A mild, local inflammatory reaction (erythema, induration,",
"    <span class=\"nowrap\">",
"     ulceration/erosion,",
"    </span>",
"    itching, burning, vesicles) should occur, which is a sign the drug is working. It is generally not so severe as to preclude further treatment. If severe inflammation occurs, use of the drug should be stopped until the inflammation clears and then it can be restarted at a lower frequency.",
"   </p>",
"   <p>",
"    Forty to 50 percent of women will have complete clearance of the warts and most of the remainder will have partial clearance, but up to 30 percent will experience a recurrence within 12 weeks. A tube of Aldara 5 percent or Zyclara 3.75 percent costs in the range of USD $800 to $900, but generic formulations are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h4\">",
"     Sinecatechins",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15923?source=see_link\">",
"     Sinecatechins",
"    </a>",
"    (eg, Veregen) is a botanical drug product for self-administered topical treatment of external anogenital warts. The active ingredient is kunecatechins, which are a mixture of catechins and other components of green tea. The exact mechanism of action of catechins is unknown, but they have both antioxidant and immune enhancing activity. A detailed review of the antiviral, antioxidant, and immunostimulatory properties of green tea catechins is available elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 0.5 cm strand of ointment is placed on each wart and a finger is used to cover the wart with a thin layer of the ointment 3 times each day for up to 16 weeks. It should not be used in the vagina or anus and should be washed off of the skin before sexual contact or before inserting a tampon into the vagina. It can weaken the latex in condoms and diaphragms.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15923?source=see_link\">",
"     Sinecatechins",
"    </a>",
"    should be avoided in immunocompromised women and women with active genital herpes lesions because safety and efficacy have not been established. There is minimal information on the risk of use during pregnancy. Of note, Veregen costs about $257 for one 15 gram tube.",
"   </p>",
"   <p>",
"    In two randomized phase III clinical trials, 15 or 10 percent Veregen ointment or placebo was applied to anogenital warts in men and women three times daily until complete clearance of all warts or for up to 16 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. Veregen was more effective than placebo in achieving complete clearance (54 to 57 versus 34 to 35 percent). Fewer than 10 percent of subjects developed new or recurrent warts [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/46\">",
"     46",
"    </a>",
"    ]. Five percent of subjects discontinued the drug due to side effects and almost 90 percent reported local application site reactions, some of which were severe (pruritus, erythema, pain, inflammation, ulceration, edema, burning, induration, vesicular rash).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H378508907\">",
"    <span class=\"h4\">",
"     Interferons",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferons have antiviral, antiproliferative, and immune-stimulating effects, theoretically making them an ideal agent for treatment of anogenital warts. Interferon-alpha and -beta have been administered as a systemic therapy (intramuscular injection), topically, and as a subcutaneous intralesional injection. Placebo controlled randomized trials have generally found intralesional therapy to be most effective [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/48-50\">",
"     48-50",
"    </a>",
"    ], while evidence for the efficacy of systemic and topical therapy has been inconsistent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/51-56\">",
"     51-56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intralesional injection of 0.5 to 1.5 milli-international units is administered two to three times per week for up to nine weeks. Local anesthesia is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/7\">",
"     7",
"    </a>",
"    ]. Patients receiving interferons by any route commonly experience flu-like symptoms, fatigue, anorexia, and local pain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/48,54,56\">",
"     48,54,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the frequency of bothersome side effects, variable rates of effectiveness, and inconvenience of administration, we don&rsquo;t use interferon for primary treatment of anogenital warts. Interferon may be used as adjunctive therapy to surgical and cyto-destructive treatments, especially in patients with refractory lesions.",
"   </p>",
"   <p>",
"    Interferons are contraindicated in pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h4\">",
"     Bacillus Calmette-Guerin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another approach beginning to appear in the literature involves topical administration of bacillus Calmette-Guerin (BCG) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. It has been used primarily for treatment of perianal warts in men and requires further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h4\">",
"     HPV vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;HPV vaccines are effective in the primary prevention of HPV infection. Their use for treatment of anogenital warts or prevention of recurrent disease is investigational and is not recommended at this time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=see_link\">",
"     \"Recommendations for the use of human papillomavirus vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Surgical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical management options consist of ablative and excisional procedures. Not infrequently, and especially in patients with extensive and multifocal disease, both ablative and excisional modalities are used. The choice of method should depend most on the availability of equipment and the surgeon&rsquo;s experience and personal preference. Regardless of the method chosen, the surgeon should maintain control of the depth of tissue destruction since deep destruction of vaginal lesions theoretically could lead to fistula formation.",
"   </p>",
"   <p>",
"    An advantage of surgical management is that fewer visits for treatment are needed compared with medical therapy, although repeated procedures are sometimes necessary, especially with cryotherapy. A disadvantage of ablative therapies is that persistent hypo- or hyperpigmentation is not uncommon. A disadvantage of all surgical therapies (ablative or excisional) is that they generally require anesthesia and often need to be performed in an operating room; however, small lesions can be ablated or excised in the office with only sedation and local infiltration (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    1 percent with or without epinephrine) in some highly motivated patients. Lastly, surgical therapy may result in scarring, especially when the subdermal layer is destroyed.",
"   </p>",
"   <p>",
"    Biopsy is recommended to rule out underlying intraepithelial neoplasia or cancer prior to surgical treatment of lesions that are refractory to medical therapy. (See",
"    <a class=\"local\" href=\"#H15428844\">",
"     'Indications for pretreatment biopsy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    All of the surgical options can be used in pregnant women and on both the vulva and vagina.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Cryoablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryoablation with either liquid nitrogen or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=see_link\">",
"     nitrous oxide",
"    </a>",
"    destroys wart tissue via cell lysis. Although it is an office procedure, cryoablation causes pain during application and variable localized inflammation afterward. Providing local anesthesia for the procedure is especially important when the area undergoing cryotherapy is large.",
"   </p>",
"   <p>",
"    Liquid nitrogen is most commonly used, and is applied directly to the vulvar or vaginal lesion with a cotton swab or a fine spray. The treatment is applied for 30 to 60 seconds, until an ice ball forms and encompasses the lesion and 1 to 2 mm surrounding area [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/60\">",
"     60",
"    </a>",
"    ]. Repeated weekly application is required until the lesions have resolved.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=see_link\">",
"     Nitrous oxide",
"    </a>",
"    is dispensed via a cryoprobe and generally gives a greater depth of freezing; therefore, it is not recommended for use in the vagina because of the risk of vaginal perforation and fistula formation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Side",
"    <span class=\"nowrap\">",
"     effects/adverse",
"    </span>",
"    reactions include skin irritation, edema, blistering, and ulceration. Post-treatment hypopigmentation is also relatively common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Laser ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lasers produce light energy, which is absorbed by water within warty tissues, leading to thermal damage and resultant ablation. Carbon dioxide laser is the most commonly utilized type of laser for treatment of vulvar warts, but requires specific training and specialized equipment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laser ablation is the preferred therapy for large or multifocal lesions. In such cases, surgical excision is undesirable since large areas of vulvar skin would have to be removed. Laser is also useful for treating cervical and vaginal warts when surgical excision is technically challenging or not feasible.",
"   </p>",
"   <p>",
"    A major benefit of using laser rather than the surgical knife on the vulva is that the laser better maintains normal vulvar anatomy. However, up to 28 percent of patients develop some scar formation post-laser surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/61\">",
"     61",
"    </a>",
"    ]. Other risks of laser surgery include pain and hypopigmentation. Rarely, patients may develop chronic pain and vulvodynia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]; patients should be counseled about these risks prior to treatment.",
"   </p>",
"   <p>",
"    Anogenital warts are epithelial in location; therefore, vaporization should only be carried down to the level of the superficial (papillary) dermis, and no deeper. Scar formation can occur when the laser beam penetrates too deeply. In order to best identify tissue planes and achieve the appropriate depth of treatment, we suggest colposcopic guidance be utilized during the laser procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/64\">",
"     64",
"    </a>",
"    ]. For patients with multifocal or refractory disease, a combination of techniques is often effective. As an example, excision is used to \"debulk\" the warty tissue, followed by laser ablation of the base (see",
"    <a class=\"local\" href=\"#H378510146\">",
"     'Recurrent disease'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The surgeon and operating room personnel should wear protective masks when performing laser ablation, as HPV DNA can be dispersed in the laser plume [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following laser treatment, pain management and careful attention to vulvar hygiene are crucial. Patients are instructed to take sitz baths two to three times a day during the initial one to two weeks following the procedure. Antibacterial creams or ointments are suggested to prevent superficial infection, as well as to separate the vulvar folds and prevent agglutination of tissues. For prevention of agglutination, the patient is instructed to gently separate the vulvar folds each day during healing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H378509078\">",
"    <span class=\"h3\">",
"     Electrocautery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrocautery can also be used for ablation of vulvar or vaginal lesions. An advantage of this approach over cryoablation is that a single treatment session is usually adequate for eliminating the warts. A disadvantage is that electrocautery requires administration of anesthesia and use of an operating room. If available, laser ablation is generally preferable to electrocautery because it is associated with less bleeding and discomfort following the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Ultrasonic aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CUSA technique (Cavitron ultrasonic aspirator-CUSA) utilizes ultrasound to fragment and aspirate warty tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/66\">",
"     66",
"    </a>",
"    ]. This allows removal of epithelium without damage to underlying tissue. As with other ablative techniques, exclusion of intraepithelial neoplasia and malignancy is critical prior to treatment by CUSA, since the pathologic specimen obtained is shallow and fragmented and thus may be insufficient to exclude invasion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H378509105\">",
"    <span class=\"h3\">",
"     Excision",
"    </span>",
"    &nbsp;&mdash;&nbsp;If tissue is needed for histological diagnosis, an excisional biopsy can be performed before an ablative procedure or an excisional procedure can be performed.",
"   </p>",
"   <p>",
"    Typically, exophytic lesions are tangentially excised or shaved to the level of normal skin using scissors or a surgical knife, and then the base of the lesion is cauterized [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/22\">",
"     22",
"    </a>",
"    ]. For larger lesions, wide local excision is often required. Adverse sequelae of excisional therapy include pain, dyspareunia, scar formation, and infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Curettage or electrosurgery can also be used for excision of lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     CLINICAL SETTINGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H378509549\">",
"    <span class=\"h2\">",
"     Nonpregnant immunocompetent women",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, if the patient has not responded to the initial therapy after about 3 weeks or complete clearance has not occurred by 6 to 12 weeks, it is appropriate to switch to a different treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H378508410\">",
"    <span class=\"h3\">",
"     Limited vulvar disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of treatment is guided, in part, by insurance coverage, the patient's out-of-pocket costs, and patient preference.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31995372\">",
"    <span class=\"h4\">",
"     Self-administered therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    or podophyllotoxin (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/34/23074?source=see_link\">",
"     podofilox",
"    </a>",
"    ) for initial therapy of women with a small area of external genital warts (eg, &le;5 small warts [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/27\">",
"     27",
"    </a>",
"    ]), as long as the patient can comply with home therapy. We prefer imiquimod because of its immune stimulation and demonstrated effectiveness against dysplasia (in case there is any unrecognized dysplasia in the lesion), but its higher cost is a disadvantage. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Imiquimod'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Podophyllotoxin (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/34/23074?source=see_link\">",
"     podofilox",
"    </a>",
"    ) has negligible systemic",
"    <span class=\"nowrap\">",
"     absorption/toxicity,",
"    </span>",
"    can be self-administered, and is more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/8/30851?source=see_link\">",
"     podophyllum resin",
"    </a>",
"    (podophyllin) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. In a randomized trial comparing podophyllotoxin (podofilox) to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/8/30851?source=see_link\">",
"     podophyllum",
"    </a>",
"    resin for treatment of warts in women, podophyllotoxin (podofilox) resulted in a higher clearance rate, 71 versus 48 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/68\">",
"     68",
"    </a>",
"    ]. Another comparative trial that included both men and women with genital warts also reported podophyllotoxin was more effective than podophyllum resin for clearance of all warts (84 versus 62 percent of patients had clearance of lesions) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Podophyllotoxin (podofilox) and podophyllum resin (podophyllin)'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15923?source=see_link\">",
"     Sinecatechins",
"    </a>",
"    are a reasonable alternative, but the most costly approach. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Sinecatechins'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If the patient has not responded to monotherapy after about 3 weeks or complete clearance has not occurred by 6 to 12 weeks, it is appropriate to switch to a different monotherapy or cryotherapy. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Cryoablation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31995379\">",
"    <span class=\"h4\">",
"     Office based therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7794?source=see_link\">",
"     trichloroacetic acid",
"    </a>",
"    (TCA) or cryotherapy for initial office-based treatment of women who cannot comply with self-administered therapy or as a second-line approach for those who fail home therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/8,69\">",
"     8,69",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Trichloroacetic acid and bichloroacetic acid'",
"    </a>",
"    above.) Because of the side effects associated with cryoablation, we prefer medical therapy. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Cryoablation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients who fail monotherapy or cryotherapy, we suggest using TCA in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H378508495\">",
"    <span class=\"h3\">",
"     Limited vaginal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest TCA for treatment of a small area of vaginal warts (eg, &le;5 small warts [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/27\">",
"     27",
"    </a>",
"    ]). TCA, bichloroacetic acid (BCA), and interferons are the only medications that can be used to treat vaginal warts, but many patients cannot tolerate intralesional interferons. Laser ablation is our preferred surgical approach as it is possible to reach into the vagina and the depth of treatment can be controlled. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Trichloroacetic acid and bichloroacetic acid'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H378508907\">",
"     'Interferons'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H378509610\">",
"    <span class=\"h3\">",
"     Large and/or bulky lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with large (&gt;20 cm",
"    <sup>",
"     2",
"    </sup>",
"    )",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bulky disease, we suggest surgery as initial therapy because medical therapy alone often requires a prolonged course of treatment and is often inadequate and poorly tolerated. Laser ablation is less destructive and less technically challenging than excision, and better tolerated than electrocautery. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Laser ablation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H378510146\">",
"    <span class=\"h3\">",
"     Recurrent disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with recurrent disease, the same treatment that resulted in initial clearance of warts may be used again and is likely to be successful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H411061133\">",
"    <span class=\"h3\">",
"     Refractory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For refractory disease, we suggest a surgical approach or a combination of intralesional interferon and TCA. (See",
"    <a class=\"local\" href=\"#H378508907\">",
"     'Interferons'",
"    </a>",
"    above.) An excisional procedure or biopsy should be performed to exclude intraepithelial neoplasia or cancer by histopathological examination. (See",
"    <a class=\"local\" href=\"#H15428844\">",
"     'Indications for pretreatment biopsy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A number of trials have examined various combinations of cyto-destructive therapies, immune-mediated therapies, and surgical therapies to minimize recurrence rates, or improve cure rates. Theoretically, the immune-mediated therapies may help reduce the viral load, while the cyto-destructive and surgical therapies can debulk and eradicate the wart tissue. However, results of these trials have been discordant [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/20,64,70-75\">",
"     20,64,70-75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Postmenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postmenopausal women who present with warty-appearing lesions should be biopsied before initiation of therapy, as these women have a greater chance of having an underlying vulvar intraepithelial neoplasia or vulvar cancer than younger women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32952?source=see_link\">",
"     \"Vulvar intraepithelial neoplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9303?source=see_link\">",
"     \"Vulvar cancer: Clinical manifestations, diagnosis, and pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Pregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three important issues arise when anogenital warts are encountered in pregnancy:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Worsening of the disease in the pregnant state",
"     </li>",
"     <li>",
"      Choice of safe and effective treatment",
"     </li>",
"     <li>",
"      Potential vertical transmission to the fetus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are multiple anecdotal reports of rapid worsening of anogenital warts in pregnant women; however, there are no studies which have compared occurrence and course of clinical warts in pregnant and nonpregnant patients. Pregnancy is associated with a decrease in cell mediated immunity, which may lead to a worsening of viral infection. The few studies that evaluated human papillomavirus (HPV) detection and shedding in pregnancy generally showed an increase in both [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/76-78\">",
"     76-78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Indications for treatment of anogenital warts in pregnant women are similar to those for nonpregnant women. In addition, lesions that potentially obstruct the birth canal (vagina and perineum) should be treated to avoid complications during vaginal birth. Treatment may not reduce the risk of vertical transmission (see",
"    <a class=\"local\" href=\"#H31\">",
"     'Vertical transmission and mode of delivery'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Treatment options are limited in pregnancy because podophyllin, podophyllotoxin, interferon, and 5-FU are all contraindicated because of potential fetal harm. Little is known about the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15923?source=see_link\">",
"     sinecatechins",
"    </a>",
"    in pregnancy, so use of these drugs is generally not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TCA has no systemic absorption and no known fetal effects; therefore, it is the preferred medical treatment for pregnant women. Clearance rates are highest and recurrence rates lowest when TCA is used in the second half of the pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cryoablation is also considered a safe and effective treatment for use in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. We prefer to begin with TCA treatment because it has fewer side effects than cryoablation. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Cryoablation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A number of case series have described use of laser ablation in pregnancy for large, bulky, obstructive lesions, with success rates of 90 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/82-85\">",
"     82-85",
"    </a>",
"    ]. The risk of wart recurrence appears lowest when the treatment is delayed until the third trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/82,85\">",
"     82,85",
"    </a>",
"    ]. Isolated, but noteworthy, adverse events reported when laser therapy was used in pregnancy include preterm contractions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/83\">",
"     83",
"    </a>",
"    ] and preterm delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/83,84\">",
"     83,84",
"    </a>",
"    ], but a causal association has not been proven.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Vertical transmission and mode of delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;HPV can manifest in young children as mucosal, conjunctival, or laryngeal disease. Juvenile-onset respiratory papillomatosis (JRP) is the most severe outcome, although rare. Children are usually diagnosed with this condition at 2 to 5 years of age, and may require multiple surgical procedures during their lifetime. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44505?source=see_link&amp;anchor=H36#H36\">",
"     \"Etiology and management of hoarseness in children\", section on 'Papillomatosis (HPV)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Epidemiologic studies have linked JRP to a history of maternal anogenital warts. Early case series reviewed medical histories for mothers of JRP-affected children, and found a history of anogenital warts in about 50 percent of these women [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/86-88\">",
"     86-88",
"    </a>",
"    ] and a 1 in 400 risk of JRP in infants of mothers with genital warts at delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/89\">",
"     89",
"    </a>",
"    ]. These studies are limited by availability of complete medical information, possible recall bias, and lack of control groups. A subsequent retrospective cohort study overcame some of these limitations with the use of detailed national Danish registries and appropriate selection of a control group [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/90\">",
"     90",
"    </a>",
"    ]. This study reported the rate of JRP was significantly higher in women with a diagnosis of anogenital warts in pregnancy than in nondiagnosed controls, with an estimated rate of transmission of 7 per 1000 affected women. Furthermore, JRP lesions were most likely to carry HPV types 6 and 11, which are the types commonly found in anogenital warts [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/79\">",
"     79",
"    </a>",
"    ]. This association raises important questions as to whether antenatal therapy or elective cesarean delivery can reduce the incidence of this disease in children.",
"   </p>",
"   <p>",
"    No studies have examined the effect of antenatal treatment of warts on viral transmission to the fetus. Given that treatment of visible lesions is unlikely to eradicate the HPV virus, particularly virus in the upper vagina and endocervical canal, the potential for transmission likely remains even after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early information suggested that neonatal inoculation occurred during passage through the birth canal. DNA analysis of newborn nasopharyngeal aspirates showed a 36 percent detection rate in vaginally delivered infants, with no detection in those delivered by cesarean delivery. However, this study was limited by very low numbers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/92\">",
"     92",
"    </a>",
"    ]. A separate study looked at cesarean delivery rates for births that were later affected by JRP, and found that the actual cesarean delivery rate was much lower than the expected rate [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/93\">",
"     93",
"    </a>",
"    ]. While these studies suggest that cesarean delivery may protect against neonatal infection, other data limit this conclusion. Neonatal infection has been described following cesarean delivery with unruptured membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. Furthermore, one large retrospective cohort study found no protective benefit of cesarean delivery on the rate of neonatal JRP infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In view of these data, as well as the potential morbidity of cesarean delivery, and the fact that elective cesarean delivery has not been proven to prevent transmission of HPV, we suggest not performing cesarean delivery for women with anogenital warts for the sole indication of preventing JRP or vertical transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/6,79,91\">",
"     6,79,91",
"    </a>",
"    ]. Cesarean delivery is indicated if vulvar or vaginal warts obstruct the birth canal, as the lesions may avulse and hemorrhage or cause dystocia during an attempted vaginal delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     HIV infected and immunocompromised women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are immunocompromised are particularly prone to development of condyloma, and often develop extensive and large lesions requiring repetitive treatment. The prevalence of anogenital warts is higher in human immunodeficiency virus (HIV) positive patients, who often have more than one HPV type, as well as higher viral loads of HPV [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/95-99\">",
"     95-99",
"    </a>",
"    ]. In one study, the cumulative incidence of genital warts was 33 percent in HIV-seropositive versus 9 percent in HIV-seronegative women [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vulvar biopsy is indicated when warts are identified in immunocompromised women because high-grade intraepithelial neoplasia is more common in warty lesions in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/100\">",
"     100",
"    </a>",
"    ]. In fact, high-oncogenic risk HPV types are detected in up to 50 percent of genital warts removed from immunocompromised individuals, but only occasionally in immunocompetent individuals. Patients with HIV who are known to carry HPV are also at increased risk of vulvar carcinoma in addition to cervical cancer, and should therefore have a thorough vulvar examination as part of routine gynecologic care [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/101\">",
"     101",
"    </a>",
"    ]. However, the absolute risk of invasive vulvar cancer is low [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following biopsy to rule-out intraepithelial neoplasia, we suggest that immunocompromised women initially self-treat their warts with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    . Topical 5 percent imiquimod is effective in immunocompromised women [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/97\">",
"     97",
"    </a>",
"    ], and may be more effective than traditional medical therapies and surgical treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/102\">",
"     102",
"    </a>",
"    ]. In observational studies, approximately one-third of patients (primarily male) on highly active antiretroviral therapy (HAART) treated with imiquimod achieved total clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/103,104\">",
"     103,104",
"    </a>",
"    ]. Women who cannot adhere to this outpatient therapy and those whose warts do not clear with medical treatment can be treated surgically. We prefer surgical excision to laser therapy, as the former allows pathologic analysis of removed tissue.",
"   </p>",
"   <p>",
"    Complete and permanent remissions of HPV anogenital lesions have been achieved with topical, intralesional, or systemic administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    in a number of case reports; however, no large controlled trials have been performed. Furthermore, it was teratogenic and embryotoxic in animal studies; there are no data from human pregnancies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37620?source=see_link\">",
"     \"Cidofovir: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although most women with HIV will have regression of warts with treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/99\">",
"     99",
"    </a>",
"    ], recurrence is common after all therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/103,105\">",
"     103,105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Involvement of the clitoris",
"    </span>",
"    &nbsp;&mdash;&nbsp;We treat warts on the clitoris with the same therapies used on vulva warts. Surgical procedures on the clitoris should be performed by physicians with experience operating in this sensitive area.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15430057\">",
"    <span class=\"h1\">",
"     POSTTREATMENT ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15429963\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of sitz baths, mild analgesics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ), and loose clothing can relieve discomfort and aid healing. Postoperative pericare is important for prevention of wound infection and breakdown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15430080\">",
"    <span class=\"h2\">",
"     Sexual activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual activity may be resumed when the patient feels comfortable and after any operative sites have healed, but this may take several weeks. There is some indirect evidence that use of condoms may accelerate disease resolution when both partners have type-concordant human papillomavirus (HPV) infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/106-108\">",
"     106-108",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15430087\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no standards for surveillance following treatment for genital warts. Follow-up appointments at least monthly are important for assessing the response to therapy and managing complications [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/27\">",
"     27",
"    </a>",
"    ]. Most patients who develop recurrent or refractory disease are diagnosed within three to six months of therapy. Recurrence is more common in immunocompromised individuals; more frequent follow-up or self-monitoring is reasonable to allow early intervention in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15430122\">",
"    <span class=\"h2\">",
"     Cancer screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with anogenital warts should undergo cervical cancer screening according to standard guidelines. As discussed above, HPV types associated with anogenital warts usually are not the same as those associated with cervical carcinoma, but oncogenic HPV viruses are sometimes involved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link\">",
"     \"Screening for cervical cancer: Rationale and recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If they have no history of vulvar dysplasia, they should be followed with vulvar exams at the time of scheduled cervical cancer screening, and counseled to have new oral, vulvar, or vaginal symptoms evaluated by a medical professional.",
"   </p>",
"   <p>",
"    Women with perianal warts or a history of receptive anal intercourse may be at increased risk of high-grade anal squamous intraepithelial neoplasia, but there is insufficient evidence to recommend screening anal cytology [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/33/1562?source=see_link&amp;anchor=H12#H12\">",
"     \"Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment\", section on 'Who should be screened for AIN?'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A population based study from Denmark including approximately 33,000 women with genital warts reported increased risks of cancer of the head and neck (standardized incidence ratio [SIR] 2.8), vagina (SIR 5.9), anus (SIR 7.8), and vulva (SIR 14.8) during a 10-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/109\">",
"     109",
"    </a>",
"    ]. The increased risk of cancer could be related to HPV or due to differences unrelated to HPV between individuals with warts and the general population. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15430494\">",
"    <span class=\"h1\">",
"     GUIDELINES FROM SELECTED NATIONAL ORGANIZATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://www.bashh.org/documents/86/86.pdf\">",
"       Clinical Effectiveness Group (British Association for Sexual Health andHIV). United Kingdom National Guideline for the Management of AnogenitalWarts, 2007",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://www.cdc.gov/std/treatment/2010/genital-warts.htm\">",
"       Centers for Disease Control and Prevention",
"      </a>",
"      (CDC)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      2012 European guideline for the management of anogenital warts [",
"      <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      American College of Obstetricians and Gynecologists (ACOG) practice bulletin [",
"      <a class=\"abstract\" href=\"UTD.htm?26/34/27178/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/13/16594?source=see_link\">",
"       \"Patient information: Genital warts (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/60/4035?source=see_link\">",
"       \"Patient information: Genital warts in women (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The main indications for treatment of vulvovaginal warts are bothersome symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      psychologic distress. (See",
"      <a class=\"local\" href=\"#H15429408\">",
"       'Indications for treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of genital warts are cleared by a course of medical therapy. No treatment is significantly superior to another or appropriate for all patients and all types of warts. If the patient has not responded to the initial therapy after 3 weeks or complete clearance has not occurred by 6 to 12 weeks, it is appropriate to switch to a different method. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Overview of treatment and prognosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Clinical settings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Biopsy to exclude precancerous or cancerous lesions is not necessary routinely, but is indicated when warts are identified in immunocompromised or postmenopausal women, when the lesions are visually atypical, or when warts fail to respond to standard therapy. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'HIV infected and immunocompromised women'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27\">",
"       'Postmenopausal women'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15428844\">",
"       'Indications for pretreatment biopsy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For nonpregnant women with limited vulvar disease who can comply with self-therapy at home, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"       imiquimod",
"      </a>",
"      over podophyllotoxin as initial medical treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15923?source=see_link\">",
"       Sinecatechins",
"      </a>",
"      are a reasonable alternative. (See",
"      <a class=\"local\" href=\"#H31995372\">",
"       'Self-administered therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For nonpregnant women with limited vulvar disease who cannot comply with self-therapy or fail self-therapy, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7794?source=see_link\">",
"       trichloroacetic acid",
"      </a>",
"      (TCA) rather than cryotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H31995379\">",
"       'Office based therapy'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      For nonpregnant women with limited vulvar disease that does not clear with monotherapy, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"       imiquimod",
"      </a>",
"      in combination with TCA (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H31995379\">",
"       'Office based therapy'",
"      </a>",
"      above.) For nonpregnant women with limited vaginal disease, we suggest TCA for initial medical therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Laser ablation is our preferred surgical approach as it is possible to reach into the vagina and the depth of treatment can be controlled. (See",
"      <a class=\"local\" href=\"#H378508495\">",
"       'Limited vaginal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For pregnant women with bothersome symptoms from vulvar or vaginal warts, we suggest treatment with TCA rather than cryoablation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For treatment of potentially obstructive lesions, we suggest laser therapy rather than excision (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). These therapies have no known fetal effects. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Pregnant women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with large (&gt;20 cm",
"      <sup>",
"       2",
"      </sup>",
"      )",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bulky disease, we suggest surgery as initial therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Laser ablation is less destructive and less technically challenging than excision, and better tolerated than electrocautery. (See",
"      <a class=\"local\" href=\"#H378509610\">",
"       'Large and/or bulky lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with recurrent disease, the same treatment that resulted in initial clearance of warts is repeated and is likely to be successful. For refractory disease, we suggest a surgical approach or a combination of intralesional interferon and TCA (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H378510146\">",
"       'Recurrent disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H411061133\">",
"       'Refractory disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For immunocompromised women without large",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bulky lesions, we suggest self-treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"       imiquimod",
"      </a>",
"      as first-line therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H32\">",
"       'HIV infected and immunocompromised women'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/1\">",
"      Greer CE, Wheeler CM, Ladner MB, et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol 1995; 33:2058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/2\">",
"      Brown DR, Schroeder JM, Bryan JT, et al. Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol 1999; 37:3316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/3\">",
"      Aubin F, Pr&eacute;tet JL, Jacquard AC, et al. Human papillomavirus genotype distribution in external acuminata condylomata: a Large French National Study (EDiTH IV). Clin Infect Dis 2008; 47:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/4\">",
"      Steben M, LaBelle D. Genital warts: Canadians' perception, health-related behaviors, and treatment preferences. J Low Genit Tract Dis 2012; 16:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/5\">",
"      Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis 2002; 29:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/6\">",
"      Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/7\">",
"      Wiley DJ, Douglas J, Beutner K, et al. External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis 2002; 35:S210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/8\">",
"      Lacey CJ, Woodhall SC, Wikstrom A, Ross J. 2012 European guideline for the management of anogenital warts. J Eur Acad Dermatol Venereol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/9\">",
"      Schoenfeld A, Ziv E, Levavi H, et al. Laser versus loop electrosurgical excision in vulvar condyloma for eradication of subclinical reservoir demonstrated by assay for 2'5' oligosynthetase human papillomavirus. Gynecol Obstet Invest 1995; 40:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/10\">",
"      Ferenczy A, Mitao M, Nagai N, et al. Latent papillomavirus and recurring genital warts. N Engl J Med 1985; 313:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/11\">",
"      Sycuro LK, Xi LF, Hughes JP, et al. Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students. J Infect Dis 2008; 198:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/12\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 61, April 2005. Human papillomavirus. Obstet Gynecol 2005; 105:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/13\">",
"      Bashi SA. Cryotherapy versus podophyllin in the treatment of genital warts. Int J Dermatol 1985; 24:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/14\">",
"      A comparison of interferon alfa-2a and podophyllin in the treatment of primary condylomata acuminata. The Condylomata International Collaborative Study Group. Genitourin Med 1991; 67:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/15\">",
"      Jensen SL. Comparison of podophyllin application with simple surgical excision in clearance and recurrence of perianal condylomata acuminata. Lancet 1985; 2:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/16\">",
"      Stone KM, Becker TM, Hadgu A, Kraus SJ. Treatment of external genital warts: a randomised clinical trial comparing podophyllin, cryotherapy, and electrodesiccation. Genitourin Med 1990; 66:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/17\">",
"      Claesson U, Lassus A, Happonen H, et al. Topical treatment of venereal warts: a comparative open study of podophyllotoxin cream versus solution. Int J STD AIDS 1996; 7:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/18\">",
"      Greenberg MD, Rutledge LH, Reid R, et al. A double-blind, randomized trial of 0.5% podofilox and placebo for the treatment of genital warts in women. Obstet Gynecol 1991; 77:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/19\">",
"      Tyring S, Edwards L, Cherry LK, et al. Safety and efficacy of 0.5% podofilox gel in the treatment of anogenital warts. Arch Dermatol 1998; 134:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/20\">",
"      Recurrent condylomata acuminata treated with recombinant interferon alpha-2a. A multicenter double-blind placebo-controlled clinical trial. Condylomata International Collaborative Study Group. Acta Derm Venereol 1993; 73:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/21\">",
"      Yliskoski M, Saarikoski S, Syrj&auml;nen K, et al. Cryotherapy and CO2-laser vaporization in the treatment of cervical and vaginal human papillomavirus (HPV) infections. Acta Obstet Gynecol Scand 1989; 68:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/22\">",
"      Gollock JM, Slatford K, Hunter JM. Scissor excision of anogenital warts. Br J Vener Dis 1982; 58:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/23\">",
"      Khawaja HT. Treatment of condyloma acuminatum. Lancet 1986; 1:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/24\">",
"      Calkins JW, Masterson BJ, Magrina JF, Capen CV. Management of condylomata acuminata with the carbon dioxide laser. Obstet Gynecol 1982; 59:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/25\">",
"      Bellina JH. The use of the carbon dioxide laser in the management of condyloma acuminatum with eight-year follow-up. Am J Obstet Gynecol 1983; 147:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/26\">",
"      Vance JC, Davis D. Interferon alpha-2b injections used as an adjuvant therapy to carbon dioxide laser vaporization of recalcitrant ano-genital condylomata acuminata. J Invest Dermatol 1990; 95:146S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/27\">",
"      Beutner KR, Reitano MV, Richwald GA, Wiley DJ. External genital warts: report of the American Medical Association Consensus Conference. AMA Expert Panel on External Genital Warts. Clin Infect Dis 1998; 27:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/28\">",
"      Gunter J. Genital and perianal warts: new treatment opportunities for human papillomavirus infection. Am J Obstet Gynecol 2003; 189:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/29\">",
"      Bonnez W, Elswick RK Jr, Bailey-Farchione A, et al. Efficacy and safety of 0.5% podofilox solution in the treatment and suppression of anogenital warts. Am J Med 1994; 96:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/30\">",
"      Abdullah AN, Walzman M, Wade A. Treatment of external genital warts comparing cryotherapy (liquid nitrogen) and trichloroacetic acid. Sex Transm Dis 1993; 20:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/31\">",
"      Swinehart JM, Skinner RB, McCarty JM, et al. Development of intralesional therapy with fluorouracil/adrenaline injectable gel for management of condylomata acuminata: two phase II clinical studies. Genitourin Med 1997; 73:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/32\">",
"      Heaton CL. Clinical manifestations and modern management of condylomata acuminata: a dermatologic perspective. Am J Obstet Gynecol 1995; 172:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/33\">",
"      Ferenczy A. Comparison of 5-fluorouracil and CO2 laser for treatment of vaginal condylomata. Obstet Gynecol 1984; 64:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/34\">",
"      Krebs HB. Treatment of extensive vulvar condylomata acuminata with topical 5-fluorouracil. South Med J 1990; 83:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/35\">",
"      Kirwan P, Naftalin NJ. Topical 5-fluorouracil in the treatment of vaginal intraepithelial neoplasia. Br J Obstet Gynaecol 1985; 92:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/36\">",
"      Pride GL. Treatment of large lower genital tract condylomata acuminata with topical 5-fluorouracil. J Reprod Med 1990; 35:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/37\">",
"      Krebs HB. Treatment of genital condylomata with topical 5-fluorouracil. Dermatol Clin 1991; 9:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/38\">",
"      Tyring SK, Arany I, Stanley MA, et al. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J Infect Dis 1998; 178:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/39\">",
"      Gotovtseva EP, Kapadia AS, Smolensky MH, Lairson DR. Optimal frequency of imiquimod (aldara) 5% cream for the treatment of external genital warts in immunocompetent adults: a meta-analysis. Sex Transm Dis 2008; 35:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/40\">",
"      Garland SM, Waddell R, Mindel A, et al. An open-label phase II pilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in women. Int J STD AIDS 2006; 17:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/41\">",
"      Edwards L, Ferenczy A, Eron L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. Arch Dermatol 1998; 134:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/42\">",
"      Beutner KR, Spruance SL, Hougham AJ, et al. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998; 38:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/43\">",
"      Meltzer SM, Monk BJ, Tewari KS. Green tea catechins for treatment of external genital warts. Am J Obstet Gynecol 2009; 200:233.e1.",
"     </a>",
"    </li>",
"    <li>",
"     Drug Information: Veregen (kunecatechins). www.centerwatch.com/patient/drugs/dru938.html (Accessed on November 06, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/45\">",
"      Veregen: a botanical for treatment of genital warts. Med Lett Drugs Ther 2008; 50:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/46\">",
"      Tatti S, Swinehart JM, Thielert C, et al. Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet Gynecol 2008; 111:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/47\">",
"      Stockfleth E, Beti H, Orasan R, et al. Topical Polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial. Br J Dermatol 2008; 158:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/48\">",
"      Eron LJ, Judson F, Tucker S, et al. Interferon therapy for condylomata acuminata. N Engl J Med 1986; 315:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/49\">",
"      Friedman-Kien AE, Eron LJ, Conant M, et al. Natural interferon alfa for treatment of condylomata acuminata. JAMA 1988; 259:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/50\">",
"      Dinsmore W, Jordan J, O'Mahony C, et al. Recombinant human interferon-beta in the treatment of condylomata acuminata. Int J STD AIDS 1997; 8:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/51\">",
"      Recurrent condylomata acuminata treated with recombinant interferon alfa-2a. A multicenter double-blind placebo-controlled clinical trial. Condylomata International Collaborative Study Group. JAMA 1991; 265:2684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/52\">",
"      Reichman RC, Oakes D, Bonnez W, et al. Treatment of condyloma acuminatum with three different interferon-alpha preparations administered parenterally: a double-blind, placebo-controlled trial. J Infect Dis 1990; 162:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/53\">",
"      Olmos L, Vilata J, Rodr&iacute;guez Pichardo A, et al. Double-blind, randomized clinical trial on the effect of interferon-beta in the treatment of condylomata acuminata. Int J STD AIDS 1994; 5:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/54\">",
"      Benedetti Panici P, Scambia G, Baiocchi G, et al. Randomized clinical trial comparing systemic interferon with diathermocoagulation in primary multiple and widespread anogenital condyloma. Obstet Gynecol 1989; 74:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/55\">",
"      Keay S, Teng N, Eisenberg M, et al. Topical interferon for treating condyloma acuminata in women. J Infect Dis 1988; 158:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/56\">",
"      Syed TA, Khayyami M, Kriz D, et al. Management of genital warts in women with human leukocyte interferon-alpha vs. podophyllotoxin in cream: a placebo-controlled, double-blind, comparative study. J Mol Med (Berl) 1995; 73:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/57\">",
"      Cook K, Brownell I. Treatments for genital warts. J Drugs Dermatol 2008; 7:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/58\">",
"      B&ouml;hle A, B&uuml;ttner H, Jocham D. Primary treatment of condylomata acuminata with viable bacillus Calmette-Guerin. J Urol 2001; 165:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/59\">",
"      Metawea B, El-Nashar AR, Kamel I, et al. Application of viable bacille Calmette-Gu&eacute;rin topically as a potential therapeutic modality in condylomata acuminata: a placebo-controlled study. Urology 2005; 65:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/60\">",
"      Ting PT, Dytoc MT. Therapy of external anogenital warts and molluscum contagiosum: a literature review. Dermatol Ther 2004; 17:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/61\">",
"      Baggish MS. Improved laser techniques for the elimination of genital and extragenital warts. Am J Obstet Gynecol 1985; 153:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/62\">",
"      Baggish MS. Carbon dioxide laser treatment for condylomata acuminata venereal infections. Obstet Gynecol 1980; 55:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/63\">",
"      Ferenczy A. Laser therapy of genital condylomata acuminata. Obstet Gynecol 1984; 63:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/64\">",
"      Reid R, Greenberg MD, Pizzuti DJ, et al. Superficial laser vulvectomy. V. Surgical debulking is enhanced by adjuvant systemic interferon. Am J Obstet Gynecol 1992; 166:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/65\">",
"      Ferenczy A, Bergeron C, Richart RM. Carbon dioxide laser energy disperses human papillomavirus deoxyribonucleic acid onto treatment fields. Am J Obstet Gynecol 1990; 163:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/66\">",
"      Rader JS, Leake JF, Dillon MB, Rosenshein NB. Ultrasonic surgical aspiration in the treatment of vulvar disease. Obstet Gynecol 1991; 77:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/67\">",
"      Lacey CJ, Goodall RL, Tennvall GR, et al. Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts. Sex Transm Infect 2003; 79:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/68\">",
"      Hellberg D, Svarrer T, Nilsson S, Valentin J. Self-treatment of female external genital warts with 0.5% podophyllotoxin cream (Condyline) vs weekly applications of 20% podophyllin solution. Int J STD AIDS 1995; 6:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/69\">",
"      Fine P, Ball C, Pelta M, et al. Treatment of external genital warts at Planned Parenthood Federation of America centers. J Reprod Med 2007; 52:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/70\">",
"      Petersen CS, Bjerring P, Larsen J, et al. Systemic interferon alpha-2b increases the cure rate in laser treated patients with multiple persistent genital warts: a placebo-controlled study. Genitourin Med 1991; 67:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/71\">",
"      Fleshner PR, Freilich MI. Adjuvant interferon for anal condyloma. A prospective, randomized trial. Dis Colon Rectum 1994; 37:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/72\">",
"      Armstrong DK, Maw RD, Dinsmore WW, et al. Combined therapy trial with interferon alpha-2a and ablative therapy in the treatment of anogenital warts. Genitourin Med 1996; 72:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/73\">",
"      Douglas JM Jr, Eron LJ, Judson FN, et al. A randomized trial of combination therapy with intralesional interferon alpha 2b and podophyllin versus podophyllin alone for the therapy of anogenital warts. J Infect Dis 1990; 162:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/74\">",
"      Armstrong DK, Maw RD, Dinsmore WW, et al. A randomised, double-blind, parallel group study to compare subcutaneous interferon alpha-2a plus podophyllin with placebo plus podophyllin in the treatment of primary condylomata acuminata. Genitourin Med 1994; 70:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/75\">",
"      Handley JM, Horner T, Maw RD, et al. Subcutaneous interferon alpha 2a combined with cryotherapy vs cryotherapy alone in the treatment of primary anogenital warts: a randomised observer blind placebo controlled study. Genitourin Med 1991; 67:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/76\">",
"      Rando RF, Lindheim S, Hasty L, et al. Increased frequency of detection of human papillomavirus deoxyribonucleic acid in exfoliated cervical cells during pregnancy. Am J Obstet Gynecol 1989; 161:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/77\">",
"      Schneider A, Hotz M, Gissmann L. Increased prevalence of human papillomaviruses in the lower genital tract of pregnant women. Int J Cancer 1987; 40:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/78\">",
"      Kemp EA, Hakenewerth AM, Laurent SL, et al. Human papillomavirus prevalence in pregnancy. Obstet Gynecol 1992; 79:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/79\">",
"      Ferenczy A. HPV-associated lesions in pregnancy and their clinical implications. Clin Obstet Gynecol 1989; 32:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/80\">",
"      Bergman A, Matsunaga J, Bhatia NN. Cervical cryotherapy for condylomata acuminata during pregnancy. Obstet Gynecol 1987; 69:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/81\">",
"      Matsunaga J, Bergman A, Bhatia NN. Genital condylomata acuminata in pregnancy: effectiveness, safety and pregnancy outcome following cryotherapy. Br J Obstet Gynaecol 1987; 94:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/82\">",
"      Ferenczy A. Treating genital condyloma during pregnancy with the carbon dioxide laser. Am J Obstet Gynecol 1984; 148:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/83\">",
"      Schwartz DB, Greenberg MD, Daoud Y, Reid R. Genital condylomas in pregnancy: use of trichloroacetic acid and laser therapy. Am J Obstet Gynecol 1988; 158:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/84\">",
"      Adelson MD, Semo R, Baggish MS, Osborne NG. Laser vaporization of genital condylomata in pregnancy. J Gynecol Surg 1990; 6:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/85\">",
"      Arena S, Marconi M, Frega A, Villani C. Pregnancy and condyloma. Evaluation about therapeutic effectiveness of laser CO2 on 115 pregnant women. Minerva Ginecol 2001; 53:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/86\">",
"      Cook TA, Brunschwig JP, Butel JS, et al. Laryngeal papilloma: etiologic and therapeutic considerations. Ann Otol Rhinol Laryngol 1973; 82:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/87\">",
"      Hallden C, Majmudar B. The relationship between juvenile laryngeal papillomatosis and maternal condylomata acuminata. J Reprod Med 1986; 31:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/88\">",
"      Quick CA, Watts SL, Krzyzek RA, Faras AJ. Relationship between condylomata and laryngeal papillomata. Clinical and molecular virological evidence. Ann Otol Rhinol Laryngol 1980; 89:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/89\">",
"      Kashima HK, Shah K. Recurrent respiratory papillomatosis. Clinical overview and management principles. Obstet Gynecol Clin North Am 1987; 14:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/90\">",
"      Silverberg MJ, Thorsen P, Lindeberg H, et al. Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet Gynecol 2003; 101:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/91\">",
"      Patsner B, Baker DA, Orr JW Jr. Human papillomavirus genital tract infections during pregnancy. Clin Obstet Gynecol 1990; 33:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/92\">",
"      Sedlacek TV, Lindheim S, Eder C, et al. Mechanism for human papillomavirus transmission at birth. Am J Obstet Gynecol 1989; 161:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/93\">",
"      Shah K, Kashima H, Polk BF, et al. Rarity of cesarean delivery in cases of juvenile-onset respiratory papillomatosis. Obstet Gynecol 1986; 68:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/94\">",
"      Rogo KO, Nyansera PN. Congenital condylomata acuminata with meconium staining of amniotic fluid and fetal hydrocephalus: case report. East Afr Med J 1989; 66:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/95\">",
"      Chiasson MA, Ellerbrock TV, Bush TJ, et al. Increased prevalence of vulvovaginal condyloma and vulvar intraepithelial neoplasia in women infected with the human immunodeficiency virus. Obstet Gynecol 1997; 89:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/96\">",
"      Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997; 102:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/97\">",
"      Gilson RJ, Shupack JL, Friedman-Kien AE, et al. A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. Imiquimod Study Group. AIDS 1999; 13:2397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/98\">",
"      De Marco F, Di Carlo A, Poggiali F, et al. Detection of HPV in genital condylomata: correlation between viral load and clinical outcome. J Exp Clin Cancer Res 2001; 20:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/99\">",
"      Massad LS, Xie X, Darragh T, et al. Genital warts and vulvar intraepithelial neoplasia: natural history and effects of treatment and human immunodeficiency virus infection. Obstet Gynecol 2011; 118:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/100\">",
"      Bryan JT, Stoler MH, Tyring SK, et al. High-grade dysplasia in genital warts from two patients infected with the human immunodeficiency virus. J Med Virol 1998; 54:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/101\">",
"      Conley LJ, Ellerbrock TV, Bush TJ, et al. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet 2002; 359:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/102\">",
"      Conant MA. Immunomodulatory therapy in the management of viral infections in patients with HIV infection. J Am Acad Dermatol 2000; 43:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/103\">",
"      Cusini M, Salmaso F, Zerboni R, et al. 5% Imiquimod cream for external anogenital warts in HIV-infected patients under HAART therapy. Int J STD AIDS 2004; 15:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/104\">",
"      Saiag P, Bauhofer A, Bouscarat F, et al. Imiquimod 5% cream for external genital or perianal warts in human immunodeficiency virus-positive patients treated with highly active antiretroviral therapy: an open-label, noncomparative study. Br J Dermatol 2009; 161:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/105\">",
"      Viazis N, Vlachogiannakos J, Vasiliadis K, et al. Earlier eradication of intra-anal warts with argon plasma coagulator combined with imiquimod cream compared with argon plasma coagulator alone: a prospective, randomized trial. Dis Colon Rectum 2007; 50:2173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/106\">",
"      Hogewoning CJ, Bleeker MC, van den Brule AJ, et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer 2003; 107:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/107\">",
"      Bleeker MC, Berkhof J, Hogewoning CJ, et al. HPV type concordance in sexual couples determines the effect of condoms on regression of flat penile lesions. Br J Cancer 2005; 92:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/108\">",
"      Bleeker MC, Hogewoning CJ, Voorhorst FJ, et al. Condom use promotes regression of human papillomavirus-associated penile lesions in male sexual partners of women with cervical intraepithelial neoplasia. Int J Cancer 2003; 107:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/34/27178/abstract/109\">",
"      Blomberg M, Friis S, Munk C, et al. Genital warts and risk of cancer: a Danish study of nearly 50 000 patients with genital warts. J Infect Dis 2012; 205:1544.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5458 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-3C5F28D7A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_34_27178=[""].join("\n");
var outline_f26_34_27178=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRETREATMENT COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Information about human papillomavirus infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15429408\">",
"      Indications for treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Overview of treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15429822\">",
"      Side effects and complications of treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15430200\">",
"      Management of sex partners",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15430387\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15428844\">",
"      Indications for pretreatment biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H377473421\">",
"      TREATMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Cytodestructive therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Podophyllotoxin (podofilox) and podophyllum resin (podophyllin)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Trichloroacetic acid and bichloroacetic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      5-Fluorouracil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Immune-mediated therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Imiquimod",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Sinecatechins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H378508907\">",
"      Interferons",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Bacillus Calmette-Guerin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      HPV vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Surgical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Cryoablation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Laser ablation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H378509078\">",
"      - Electrocautery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Ultrasonic aspiration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H378509105\">",
"      - Excision",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      CLINICAL SETTINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H378509549\">",
"      Nonpregnant immunocompetent women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H378508410\">",
"      - Limited vulvar disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H31995372\">",
"      Self-administered therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H31995379\">",
"      Office based therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H378508495\">",
"      - Limited vaginal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H378509610\">",
"      - Large and/or bulky lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H378510146\">",
"      - Recurrent disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H411061133\">",
"      - Refractory disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Pregnant women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Vertical transmission and mode of delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      HIV infected and immunocompromised women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Involvement of the clitoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15430057\">",
"      POSTTREATMENT ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15429963\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15430080\">",
"      Sexual activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15430087\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15430122\">",
"      Cancer screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15430494\">",
"      GUIDELINES FROM SELECTED NATIONAL ORGANIZATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5458\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5458|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/40/16006\" title=\"picture 1A\">",
"      Condyloma acuminatum1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/53/38741\" title=\"picture 1B\">",
"      Condyloma acuminatum2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/30/19942\" title=\"picture 1C\">",
"      Condyloma acuminatum3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5458|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/33/43547\" title=\"table 1\">",
"      Approach to the treatment of vulvovaginal warts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/33/1562?source=related_link\">",
"      Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37620?source=related_link\">",
"      Cidofovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23144?source=related_link\">",
"      Condylomata acuminata (anogenital warts)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37349?source=related_link\">",
"      Diagnostic evaluation of vulvar lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21610?source=related_link\">",
"      Epidemiology of human papillomavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44505?source=related_link\">",
"      Etiology and management of hoarseness in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/13/16594?source=related_link\">",
"      Patient information: Genital warts (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/60/4035?source=related_link\">",
"      Patient information: Genital warts in women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=related_link\">",
"      Recommendations for the use of human papillomavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=related_link\">",
"      Screening for cervical cancer: Rationale and recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=related_link\">",
"      Screening for sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9303?source=related_link\">",
"      Vulvar cancer: Clinical manifestations, diagnosis, and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32952?source=related_link\">",
"      Vulvar intraepithelial neoplasia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_34_27179="Kurtzke disability status scale";
var content_f26_34_27179=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F76465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F76465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Kurtzke disability status scale",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. No disability and minimal neurologic signs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Minimal disability (eg, slight weakness or stiffness, mild gait or visual disturbance)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Moderate disability (eg, monoparesis, mild hemiparesis, moderate ataxia, disturbing sensory loss, prominent urinary or eye symptom, or combination of lesser dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Relatively severe disability but fully ambulatory without aid, self sufficient and able to be up around 12 hours/day, does not prevent the ability to work or carry on normal living activities, excluding sexual dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Disability is severe enough to preclude working, maximal motor function involves walking unaided up to 500 meters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Needs assistance with walking (eg, cane, crutches, or braces)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Restricted to a wheelchair but able to wheel oneself and enter and leave chair without assistance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. Restricted to bed or chair, retains many self care functions and has effective use of arms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9. Helpless and bedridden",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10. Death due to multiple sclerosis (from respiratory paralysis, coma, following repeated or prolonged epileptic seizures)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_34_27179=[""].join("\n");
var outline_f26_34_27179=null;
var title_f26_34_27180="Testosterone treatment PI";
var content_f26_34_27180=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F86166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F86166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Androgen replacement medicines (testosterone)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Brand name in US",
"       </td>",
"       <td class=\"subtitle1\">",
"        How it's given",
"       </td>",
"       <td class=\"subtitle1\">",
"        How often it's used",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Delatestryl&reg; (testosterone enanthate)",
"        </p>",
"        <p>",
"         Depo&reg;-Testosterone (testosterone cypionate)",
"        </p>",
"       </td>",
"       <td>",
"        Injection (shot)",
"       </td>",
"       <td>",
"        Every 1 to 2 weeks",
"       </td>",
"       <td>",
"        Shot can be given at home. Hormone levels can go up and down between shots.&nbsp; May cost less than other testosterone medicines.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Androderm&reg;",
"       </td>",
"       <td>",
"        Patch worn on arm or upper body",
"       </td>",
"       <td>",
"        Every night",
"       </td>",
"       <td>",
"        Can cause a skin rash in some people.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AndroGel&reg;",
"       </td>",
"       <td>",
"        Gel put on the upper arm, shoulder, or belly (only put 1% strength on belly, not 1.62%)",
"       </td>",
"       <td>",
"        Every morning",
"       </td>",
"       <td>",
"        Comes in different strengths. Pump bottle gives exact dose.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Testim&reg;",
"       </td>",
"       <td>",
"        Gel put on the upper arm or shoulder",
"       </td>",
"       <td>",
"        Every morning",
"       </td>",
"       <td>",
"        Comes in 1-dose tubes. Some people notice a smell.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fortesta&reg;",
"       </td>",
"       <td>",
"        Gel put on thighs",
"       </td>",
"       <td>",
"        Every morning",
"       </td>",
"       <td>",
"        Pump bottle gives exact dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Axiron&reg;",
"       </td>",
"       <td>",
"        Liquid put on armpits",
"       </td>",
"       <td>",
"        Every morning",
"       </td>",
"       <td>",
"        Pump bottle with applicator gives exact dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Striant&reg;",
"       </td>",
"       <td>",
"        Sticky tablet&nbsp;stays on gums for 12 hours",
"       </td>",
"       <td>",
"        Twice a day",
"       </td>",
"       <td>",
"        Molds to the gums. Do not chew or swallow.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Testopel&reg;",
"       </td>",
"       <td>",
"        Tiny pellets given as a shot under skin",
"       </td>",
"       <td>",
"        Every 3 to&nbsp;4 months",
"       </td>",
"       <td>",
"        Area where shot is given can become red and painful.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    A man might need androgen replacement if he has low levels of an androgen called \"testosterone\". There are several different ones, but testosterone is the main androgen. There are different ways to give testosterone to men who need androgen replacement. Each brand is used a different way.&nbsp; Your doctor or nurse can give you the directions for the brand you use.",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_34_27180=[""].join("\n");
var outline_f26_34_27180=null;
var title_f26_34_27181="Risks of malignancy or death from radiation";
var content_f26_34_27181=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimated risks of fatal malignancy or death resulting from radiation exposure and the life-time odds of dying from selected activities of everyday life",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Exposure",
"       </td>",
"       <td class=\"subtitle1\">",
"        Estimated risk of fatal malignancy or lifetime odds of dying per 1000 individuals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Effective radiation dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1 mSv (calcium score/lung screen)",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10 mSv (coronary CTA/abdomen CT, invasive coronary angiography, radionuclide myocardial perfusion study)",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        50 mSv (yearly radiation worker allowance)",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        100 mSv (definition of low exposure)",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Natural fatal cancer",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td>",
"        212",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\">",
"        Passive smoking",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        (Low exposure)",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        (High exposure, married to a smoker)",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\">",
"        Radon in home",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        US average",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        High exposure (1 to 3 percent)",
"       </td>",
"       <td>",
"        21",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\">",
"        Arsenic in drinking water",
"        <sup>",
"         [5,6]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2.5 microg/L (US estimated average)",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        50 microg/L (acceptable limit before 2006)",
"       </td>",
"       <td>",
"        13",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Motor vehicle accidents",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"       <td>",
"        11.9",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Pedestrian accident",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"       <td>",
"        1.6",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Drowning",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"       <td>",
"        0.9",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Bicycling",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Lightning strike",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"       <td>",
"        0.013",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The National Safety Council estimates based on data from National Center for Health Statistics and US Census Bureau. Deaths are classified on the basis of the Tenth Revision of the World Health Organization's \"The International Classification of Diseases\" (ICD). Lifetime odds are approximated by dividing the one-year odds by the life expectancy of a person born in 2004 (77.9 years).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        US Food and Drug Administration. Whole body scanning using computed tomography (CT). Available at: file://www.fda.gov/cdrh/ct/risks.html. Accessed January 1, 2009.",
"       </li>",
"       <li>",
"        Ries LA, Melbert D, Krapcho M, et al (Eds). SEER Cancer Statistics Review, 1975-2004. Bethesda, Md: National Cancer Institute; based on November 2006 SEER data submission, posted to the SEER Web site, 2007. Tables I-14 and I-17: Lifetime risk (percent) of being diagnosed with cancer and lifetime risk (percent) of dying from cancer, by site and race/ethnicity. Available at file://seer.cancer.gov/csr/1975_2005/results_merged/topic_lifetime_risk.pdf. Accessed January 1, 2009.",
"       </li>",
"       <li>",
"        Committee on Passive Smoking, Board on Environmental Studies and Toxicology, National Research Council. Environmental Tobacco Smoke: Measuring Exposures and Assessing Health Effects. Washington, DC: National Academies Press; 1986.",
"       </li>",
"       <li>",
"        Nero, AV, Schwehr, MB, Nazaroff, WW, Revzan, KL. Distribution of airborne radon-222 concentrations in US homes. Science 1986; 234: 992.",
"       </li>",
"       <li>",
"        Subcommittee on Arsenic in Drinking Water, Committee on Toxicology, Board on Environmental Studies and Toxicology, Commission on Life Sciences, National Research Council. Arsenic in Drinking Water. Washington, DC: National Academies Press; 1999.",
"       </li>",
"       <li>",
"        Smith AH, Hopenhayn-Rich C, Bates MN, et al. Cancer risks from arsenic in drinking water. Environ Health Perspect 1992; 97: 259.",
"       </li>",
"       <li>",
"        National Safety Council (NSC). Odds of death due to injury, United States, 2005. Available at: file://www.nsc.org/research/odds.aspx. Accessed January 1, 2009.",
"       </li>",
"      </ol>",
"      <br>",
"       Reproduced with permission from: Gerber, TC, Carr, JJ, Arai, AE, et al. Ionizing Radiation in Cardiac Imaging: A Science Advisory From the American Heart Association Committee on Cardiac Imaging of the Council on Clinical Cardiology and Committee on Cardiovascular Imaging and Intervention of the Council on Cardiovascular Radiology and Intervention. Circulation 2009; 119:1056-1065. Copyright &copy; 2009 American Heart Association, Inc.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_34_27181=[""].join("\n");
var outline_f26_34_27181=null;
var title_f26_34_27182="Neck stiffness in the well-appearing child";
var content_f26_34_27182=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 502px\">",
"   <div class=\"ttl\">",
"    Neck stiffness or torticollis without major trauma, fever, or neurologic abnormality in the well-appearing child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 482px; height: 375px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_34_27182=[""].join("\n");
var outline_f26_34_27182=null;
var title_f26_34_27183="CT versus EUS";
var content_f26_34_27183=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 509px\">",
"   <div class=\"ttl\">",
"    Radial echoendoscope demonstrating a 360-degree image of malignant appearing mediastinal lymph nodes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 489px; height: 189px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Computed tomography (CT) lymph nodes. B) Endoscopic ultrasound (EUS) radial view.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_34_27183=[""].join("\n");
var outline_f26_34_27183=null;
